

Bugs & Drugs
REFERENCES
October 2017

GENERAL

1. Anon. Drugs for bacterial infections. Treatment Guidelines Med Lett 2010;8: 43-52.
2. Blondel-Hill E, Nigrin J. Guide to antimicrobial susceptibility testing & reporting. Dynacare Kasper Medical Laboratories/BC Children's Hospital. 2017.
3. Gattis WA. A selected review of antimicrobial concentrations within tissues of the bone, eye, and lung. Antimicrobics Infect Dis Newslett 1994;13:75-86.
4. Gilbert DN, Moellering RC, Eliopoulos GM, eds. The Sanford guide to antimicrobial therapy 2017. Sperryville, VA: Antimicrobial Therapy, Inc. 2017.
5. Gorbach SL, Mensa J, Gatell JM. 1999 pocket book of antimicrobial therapy & prevention. Baltimore, Maryland: Williams & Wilkins 1999.
6. Lovgren M, Talbot JA. Antimicrobial-resistant *Streptococcus pneumoniae*. Can J Infect Dis 1999;10:27-9A.
7. Mandell GL, Bennett JE, and Dolin R, eds. Mandell, Douglas and Bennett's principles & practice of infectious diseases. 7th ed. New York: Churchill Livingstone Inc. 2009.
8. Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook. 12th ed. 2005-06.
9. Yu VL, Merigan TC, Barriere SL, eds. Antimicrobial therapy and vaccines. Baltimore, Maryland: Williams & Wilkins 1999.

ANTIMICROBIAL SPECTRUM OF ACTIVITY

1. Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/tazobactam: a novel cephalosporin/ β -lactamase inhibitor combination. Pharmacotherapy 2015;35:701-15.
2. Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against *Pseudomonas aeruginosa* and *Enterobacteriaceae*, including strains with extended-spectrum β -lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 2013;57:1577-82.
3. Farrell DJ, Flamm RK, Sader HS, et al. Antimicrobial activity of ceftolozane-tazobactam tested against *Enterobacteriaceae* and *Pseudomonas aeruginosa* with various resistance patterns isolated in

U.S. hospitals (2011-2012). *Antimicrob Agents Chemother* 2013;57:6305-10.

4. Gilbert DN, Moellering RC, Eliopoulos GM, eds. *The Sanford guide to antimicrobial therapy* 2017. Sperryville, VA: Antimicrobial Therapy, Inc. 2017.
5. Grayson ML, Crowe SM, McCarthy JS, et al, eds. *Kucers' the use of antibiotics 6th edition: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs*. 2010 CRC Press, Boca Raton FL.
6. Scott LJ. Ceftolozane/tazobactam: a review in complicated intra-abdominal and urinary tract infections. *Drugs* 2016;76:231-42.
7. Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-clAI). *Clin Infect Dis* 2015;60:1462-71.
8. Sucher AJ, Chahine EB, Cogan P, et al. Ceftolozane/tazobactam: a new cephalosporin and β -lactamase inhibitor combination. *Ann Pharmacother* 2015;49:1046-56.
9. Versalovic J, Carroll KC, Funke G, et al. *Manual of clinical microbiology*, 10th edition, 2011. Washington, DC: ASM Press 2011.
10. Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane/tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). *Lancet* 2015;385:1949-56.
11. Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/ β -lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. *Drugs* 2014;74:31-51.

PHARMACODYNAMICS OF ANTIMICROBIALS

1. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. *Clin Infect Dis* 2007;44:79-86.
2. Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. *Antimicrob Agents Chemother* 2003;47:1179-86.
3. Andes D, vanOgtrop ML, Peng J, et al. In vivo pharmacodynamics of a new oxazolidinone (linezolid). *Antimicrob Agents Chemother* 2002;46:3484-9.
4. Craig WA. Does the dose matter? *Clin Infect Dis* 2001;33(suppl 3):S233-7.

5. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. *Clin Infect Dis* 1998;26:1-12.
6. Crandon JL, Nicolau DP. Pharmacodynamic approaches to optimizing beta-lactam therapy. *Crit Care Clin* 2011;27:77-93.
7. Gilbert DN, Moellering RC, Eliopoulos GM, eds. *The Sanford guide to antimicrobial therapy* 2012. Sperryville, VA: Antimicrobial Therapy, Inc. 2012.
8. Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. *Ann Intensive Care* 2011;1:30-5.
9. Roberts JA, Lipman F. Pharmacokinetic issues for antibiotics in the critically ill patient. *Crit Care Med* 2009;37:840-51.
10. Wispelway B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. *Clin Infect Dis* 2005;40(suppl 7):S439-47.

EXTENDED INTERVAL AMINOGLYCOSIDE DOSING/MONITORING GUIDELINES

1. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. *Clin Infect Dis* 1997;24:796-809.
2. Ariano RE. A critical evaluation of "once daily" aminoglycoside therapy. *Health Sciences Centre Drug Info Bulletin* 1993;15(6).
3. Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. *Clin Infect Dis* 1997;24:786-95.
4. Bates RD, Nahata MC. Once-daily administration of aminoglycosides. *Ann Pharmacother* 1994;28:757-66.
5. Bertino JS, Rotschafer JC. Editorial response: single daily dosing of aminoglycosides-a concept whose time has not yet come. *Clin Infect Dis* 1997;24:820-23.
6. Blaser J, Konig C, Simmen HP, et al. Monitoring serum concentrations for once-daily netilmicin dosing regimens. *J Antimicrob Chemother* 1994;33:341-8.
7. Conly JM, Gold W, Shafran SD. Once-daily aminoglycoside dosing: a new look at an old drug. *Can J Infect Dis* 1994;5:205-6.
8. Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, et al. Extended-interval aminoglycoside administration for children: a meta-analysis. *Pediatrics* 2004;114:e1111-8.

9. Craig WA. Once-daily dosing of aminoglycosides. *Can J Infect Dis* 1994;5:28C-33C.
10. Gilbert DN. Editorial response: meta-analyses are no longer required for determining the efficacy of single daily dosing of aminoglycosides. *Clin Infect Dis* 1997;24:816-19.
11. Gilbert DN. Minireview: once-daily aminoglycoside therapy. *Antimicrob Agents Chemother* 1991;35:399-405.
12. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. *Ann Intern Med* 1996;124:717-25.
13. Hatala R, Dinh TT, Cook DJ. Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review. *Clin Infect Dis* 1997;24:810-15.
14. Hemsworth S, Nunn AJ, Selwood K, et al. Once-daily netilmicin for neutropenic pyrexia in paediatric oncology. *Acta Paediatr* 2005;94:268-74.
15. Hitt CM, Klepser ME, Nightingale CH, et al. Pharmacoeconomic impact of once-daily aminoglycoside administration. *Pharmacotherapy* 1997;17:810-14.
16. Kirkpatrick CMJ, Duffull SB, Begg EJ. Once-daily aminoglycoside therapy: potential ototoxicity. *Antimicrob Agents Chemother* 1997;41:879-80.
17. Knoderer CA, Everett JA, Buss WF. Clinical issues surrounding once-daily aminoglycoside dosing in children. *Pharmacother* 2003;23:44-56.
18. Levison ME. New dosing regimens for aminoglycoside antibiotics. *Ann Intern Med* 1992;117:693-4.
19. Marra F, Partovi N, Jewesson P. Aminoglycoside administration as a single daily dose: an improvement to current practice or a repeat of previous errors? *Drugs* 1996;52:344-70.
20. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. *Antimicrob Agents Chemother* 1995;39:650-5.
21. Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. *Lancet* 1993;341:335-9.
22. Smyth A, Tan KHV, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial. *Lancet* 2005;365:573-8. VandenBussche HL, Klepser MR. Editorial. *Lancet* 2005;365:547-8.

23. Sung L, Dupuis LL, Bliss B, et al. Randomized controlled trial of once-versus thrice-daily tobramycin in febrile neutropenic children undergoing stem cell transplantation. *J Natl Cancer Inst* 2003;95:1869-77.
24. Tomlinson RJ, Ronghe M, Goodbourne C, et al. Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia. *Arch Dis Child* 1999;80:125-31.
25. Zaske DE. Aminoglycosides. In: Evans WE, Schentag JJ, Jusko WJ, eds. *Applied pharmacokinetics: principles of therapeutic drug monitoring*. Vancouver, WA: Therapeutics; 1992;14:1-47.

VANCOMYCIN DOSING/MONITORING GUIDELINES

1. Ariano RE, Fine A, Sitar DS, et al. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis. *Am J Kid Dis* 2005;46:681-7.
2. Bauer LA. *Applied Clinical Pharmacokinetics*. Chapter 5: Vancomycin. McGraw-Hill, 2001.
3. Brown M, Polisetty R, Gracely EJ, et al. Weight based loading of vancomycin in patients on hemodialysis. *Clin Infect Dis* 2011;53:164-6.
4. Edwards D, Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. *Clin Pharm* 1987;6:652-4.
5. Fekety R. Vancomycin and teicoplanin. In: Mandell GL, Bennett JE, Dolin R, eds. *Principles and practice of infectious diseases*. New York, NY: Churchill Livingstone; 1995;346-53.
6. Freeman C, et al. Vancomycin therapeutic drug monitoring: is it necessary? *Ann Pharmacother* 1993;27:594-8.
7. Frymoyer A, Guglielmo BJ, Wilson SD, et al. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations. *Pharmacotherapy* 2011;31:871-6.
8. Frymoyer A, Hersh AL, Benet LZ, et al. Current recommended dosing of vancomycin for children with invasive methicillin-resistant *Staphylococcus aureus* infections is inadequate. *Pediatr Infect Dis J* 2009;28:398-402.
9. Johnson SV, et al. Inappropriate vancomycin prescribing based on criteria from the Centres for Disease Control and Prevention. *Pharmacotherapy* 1995;15:579-85.
10. Pai AB, Pai MP. Vancomycin dosing in high flux hemodialysis: a limited sampling algorithm. *Am J Health Syst Pharm* 2004;61:1812-6.

11. Panais R, Hirsch DJ, Dipchand C, et al. A protocolized approach to vancomycin dosing in conventional hemodialysis. *J Nephrol* 2010;23:569-74.
- Rodvold KA, et al. Routine monitoring of serum vancomycin concentrations: can waiting be justified? *Clin Pharm* 1987;6:655-8.
12. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists (ASHP), the Infectious Diseases Society of America (IDSA), the Society of Infectious Diseases Pharmacists (SIDP). *Am J Health Syst Pharm* 2009;66:82-98.
13. Saunders NJ. Vancomycin administration and monitoring reappraisal. *J Antimicrob Chemother* 1995;36:279-82.
14. Saunders NJ. Why monitor peak vancomycin concentrations? *Lancet* 1994;344:1748-50.
15. Shalansky S. Rationalization of vancomycin serum concentration monitoring. *Can J Hosp Pharm* 1995;48:17-24.
16. Vandecasteele SJ, DeBacquer D, DeVriese AS. Implementation of a dose calculator for vancomycin to achieve target trough levels of 15-20 µg/mL in persons undergoing hemodialysis. *Clin Infect Dis* 2011;53:124-9.
17. Zelenitsky SA, Ariano RE, McCrae ML, et al. An initial vancomycin dosing protocol to achieve therapeutic serum concentrations in hemodialysis patients. *Clin Infect Dis* 2012;55:527-33.
18. Zimmermann AE, et al. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. *Pharmacotherapy* 1995;15:85-91.

ADULT DOSING RECOMMENDATIONS IN RENAL IMPAIRMENT

1. Bains A, Buna D, Hoag NA. A retrospective review assessing the efficacy and safety of nitrofurantoin in renal impairment. *Can Pharm J* 2009;142:248-52.
2. Bartlett JG. 2002 Pocket book of infectious disease therapy. 12th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002.
3. Bennett WM, et al. Drug prescribing in renal failure: Dosing guidelines for adults. 4th ed. Philadelphia, PA: American College of Physicians; 1999.
4. Canadian Thoracic Society (CTS) of the Canadian Lung Association (CLA) and the Public Health Agency of Canada (PHAC). Canadian

Tuberculosis Standards, 7th Edition, 2013.

<http://www.respiratoryguidelines.ca/tb-standards-2013>

5. Geerts AF, Eppenga WL, Heerdink R, et al. Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. *Eur J Clin Pharmacol* 2013;69:1701-7.
6. Gilbert DN, Moellering RC, Eliopoulos GM, eds. *The Sanford guide to antimicrobial therapy 2017*. Sperryville, VA: Antimicrobial Therapy, Inc. 2017.
7. Hoang P, Salbu RL. Updated nitrofurantoin recommendations in the elderly: a closer look at the evidence. *Consult Pharm* 2016;31:381-4.
8. Mandell GL, Bennett JE, and Dolin R, eds. *Mandell, Douglas and Bennett's principles & practice of infectious diseases*. 7th ed. New York: Churchill Livingstone Inc. 2009.
9. Oplinger M, Andrews CO. Nitrofurantoin contraindication in patients with a creatinine clearance below 60 mL/min: looking for the evidence. *Ann Pharmacother* 2013;47:106-11.
10. Product monographs. *Compendium of Pharmaceuticals and Specialties 2005*.
11. Singh N, Gandhi S, McArthur E, et al. Kidney function and the use of nitrofurantoin to treat urinary tract infections in older women. *CMAJ* 2015;187:648-56.

ADULT DOSING RECOMMENDATIONS IN HEPATIC IMPAIRMENT

1. Brown N, Ho DHW, Fong KL, et al. Effects of hepatic function on vancomycin clinical pharmacology. *Antimicrob Agents Chemother* 1983;23:603-9.
2. Drug Evaluation monographs, Micromedex online 1999.
3. Efthymiopoulos C, Bramer SL, Maroli A, et al. Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction. *Clin Pharmacokinet* 1997;33:25-31.
4. Evans WE, Schentag JJ, Jusko WJ, eds. *Applied pharmacokinetics. Principles of therapeutic drug monitoring*. Vancouver, WA: Applied Therapeutics Inc.; 3rd ed. 1992.
5. Hall KW, Nightingale CH, Gibaldi M, et al. Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects. *J Clin Pharmacol* 1982;22:321-5.
6. Hinthorn DR, Baker LH, Romig DA, et al. Use of clindamycin in patients with liver disease. *Antimicrob Agents Chemother* 1976;9:498-501.

7. Tschida SJ, Vance-Bryan K, Zaske DE. Anti-infective agents and hepatic disease. *Med Clin North Am* 1995;79:895-917.
8. Kenyon J (ed). Tailor antibacterial dosages in hepatic impairment. *Drugs Ther Perspect* 1993;l:12-13.
9. Kubisty CA, Arns PA, Wedlund PJ, et al. Pharmacotherapy in liver failure. In: Chernow B. *Pocket Book of Critical Care Pharmacotherapy*. Baltimore; Williams & Wilkins; 1995.
10. Lietman PS. Liver disease, aminoglycoside antibiotics and renal dysfunction (editorial). *Hepatology* 1988;8:966-8.
11. Matzke GR, Kovarik JM. Clinical pharmacokinetics of anti-infectives. In: Koda-Kimble MA, Young LY, eds. *Applied therapeutics: the clinical use of drugs*. 5th ed. Vancouver, WA: Applied Therapeutics Inc. 1992;34:34-8.
12. McCormick PA, Greenslade L, Kibbler CC, et al. Further evidence against the use of aminoglycosides in cirrhotic patients (letter). *Gastroenterology* 1998;114:612-3.
13. Meyer JM, Rodvold KA. Clinical pharmacology of antimicrobial agents in cirrhosis. *Infect Med* 1997;14:541-7.
14. Moore, RD, Smith CR, Lipsky JJ, et al. Risk factors for nephrotoxicity in patients treated with aminoglycosides. *Ann Int Med* 1984;100:352-7.
15. Product monographs. *Compendium of Pharmaceuticals and Specialties*. 40th ed. Toronto: Webcom Limited; 2005.
16. Westphal JF, Brogard JM. Clinical pharmacokinetics of newer antibacterial agents in liver disease. *Clin Pharmacokinet* 1993;24:46-58.
17. Westphal JF, Jehl F, Vetter D. Pharmacological, toxicologic, and microbiological considerations in the choice of initial antibiotic therapy for serious infections in patients with cirrhosis of the liver. *Clin Infect Dis* 1994;18:324-35.
18. Williams RL, Mamelok RD. Hepatic disease and drug pharmacokinetics. *Clin Pharmacokinet* 1980;5:528-47.

CSF PENETRATION OF ANTIMICROBIALS

1. Alffenaar JWC, vanAltena R, Bokkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. *Clin Infect Dis* 2009;49:1080-2.
2. Barling RWA, Selkon JB. The penetration of antibiotics into cerebrospinal fluid and brain tissue. *J Antimicrob Chemother* 1978;4:203-27.

3. Bellmann R. Clinical pharmacokinetics of systemically administered antimycotics. *Curr Clin Pharmacol* 2007;2:37-58.
4. Blumer JL, Reed MD, Knupp C. Review of the pharmacokinetics of cefepime in children. *Pediatr Infect Dis J* 2001;20:337-42.
5. Boak LM, Li J, Spelman D, et al. Successful treatment and cerebrospinal fluid penetration of oral linezolid in a patient with coagulase-negative *Staphylococcus ventriculitis*. *Ann Pharmacother* 2006;40:1451-5.
6. Calcagno A, Baietto L, De Rosa FG, et al. Posaconazole cerebrospinal concentrations in an HIV-infected patient with brain mucormycosis. *J Antimicrob Chemother* 2011;66:224-5.
7. Cascio A, Conti A, Sinardi L, et al. Post-neurosurgical multidrug-resistant *Acinetobacter baumannii* meningitis successfully treated with intrathecal colistin. A new case and a systematic review of the literature. *Int J Infect Dis* 2010;14:e572-9.
8. Chavez-Bueno S, McCracken GH. Bacterial meningitis in children. *Pediatr Clin N Am* 2005;52:795-810.
9. Chen JL, Orsini J, Killu C. Poor central nervous system penetration of tigecycline in a patient with sepsis and ventriculitis caused by multidrug-resistant *Klebsiella pneumoniae*. *J Pharm Technol* 2007;23:344-8.
10. Cottagnoud P, Stucki A, Accosta F, et al. Ceftaroline is superior to cefepime against a *Klebsiella pneumoniae* strain in an experimental rabbit meningitis model. *Clin Microbiol Inf* 2010;16:S456.
11. Cottagnoud P, Tauber MG. Fluoroquinolones in the treatment of meningitis. *Current Infectious Disease Reports* 2003;5:329-36.
12. Cunha BA, ed. *Antibiotic essentials*. Royal Oak, Michigan: Physicians' Press. 2002.
13. Destache CJ, Pakiz CB, Larsen C, et al. Cerebrospinal fluid penetration and pharmacokinetics of levofloxacin in an experimental rabbit meningitis model. *J Antimicrob Chemother* 2001;47:611-15.
14. Ellis JM, Rivera L, Reyes G, et al. Cefepime cerebrospinal fluid concentrations in neonatal bacterial meningitis [2]. *Ann Pharmacother* 2007;41:900-1.
15. Flaherty JF. Central nervous system infections. In: Young LY, Koda-Kimble M, eds. *Applied Therapeutics*. Vancouver, WA: Applied Therapeutics Inc. 1995;56:1-23.
16. Florea NR, Kuti JL, Quintiliani R. Voriconazole: a novel azole antifungal. *Formulary* 2002;37:389-99.

17. Gilbert DN, Moellering RC, Eliopoulos GM, eds. The Sanford guide to antimicrobial therapy 2012. Sperryville, VA: Antimicrobial Therapy, Inc. 2012.
18. Gorbach SL, Mensa J, Gatell JM. 1999 pocket book of antimicrobial therapy & prevention. Baltimore, Maryland: Williams & Wilkins 1999.
19. Groll AH, Gea-Banacloche JC, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. *Infect Dis Clin N Am* 2003;17:159-91.
20. Guardado AR, Blanco A, Asensi V, et al. Multidrug-resistant *Acinetobacter meningitis* in neurosurgical patients with intraventricular catheters: assessment of different treatments. *J Antimicrob Chemother* 2008;61:908-13.
21. Hart D, Weinstein MP. Cross-over assessment of serum bactericidal activity of moxifloxacin and levofloxacin versus penicillin-susceptible and penicillin-resistant *Streptococcus pneumoniae* in healthy volunteers. *Diagn Microbiol Infect Dis* 2007;58:375-8.
22. Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous *Candida meningoenzephalitis*: implications for echinocandin therapy in neonates. *J Infect Dis* 2008;197:163-71.
23. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. *Clin Infect Dis* 2003;36:630-7.
24. Kanellakopoulou K, Pagoulatou A, Stroumpoulis K, et al. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. *J Antimicrob Chemother* 2008;61:1328-31.
25. Kethireddy S, Andes D. CNS pharmacokinetics of antifungal agents. *Expert Opin Drug Metab Toxicol* 2007;3:573-81.
26. Kullar R, Chin JN, Edwards DJ, Parker D, Coplin WM, Rybak MJ. Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. *Antimicrob Agents Chemother* 2011;55:3505-9.
27. Lat A, Thompson III GR, Rinaldi MG, et al. Micafungin concentrations from brain tissue and pancreatic pseudocyst fluid. *Antimicrob Agents Chemother* 2010;54: 943-4.
28. Le J, Bookstaver PB, Rudisill CN, et al. Treatment of meningitis caused by vancomycin-resistant *Enterococcus faecium*: high-dose and combination daptomycin therapy. *Ann Pharmacother* 2010;44:2001-6.

29. Lengerke C, Haap M, Mayer F, et al. Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges. *Antimicrob Agents Chemother* 2011;55:449-50.
30. Lodise TP, Rhoney DH, Tam VH, et al. Pharmacodynamic profiling of cefepime in plasma and cerebrospinal fluid of hospitalized patients with external ventriculostomies. *Diagn Microbiol Infect Dis* 2006;54:223-30.
31. Lorian V. *Antibiotics in laboratory medicine*. 4th ed. Williams and Wilkins 1996.
32. Lutsar I, McCracken GH, Friedland IR. Antibiotic pharmacodynamics in cerebrospinal fluid. *Clin Infect Dis* 1998;27:1117-29.
33. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. *Clin Infect Dis* 2003;37:728-32.
34. Madaras-Kelly KJ, Ostergaard BE, Rotschafer JC. Central nervous system infections. In: DiPiro JT, Talbert RL, Yee GC, et al, eds. *Pharmacotherapy: a pathophysiologic approach*. Stamford, CT: Appleton & Lange 1997:1971-94.
35. Mandell GL, Bennett JE, and Dolin R, eds. *Mandell, Douglas and Bennett's principles & practice of infectious diseases*. 7th ed. New York: Churchill Livingstone Inc. 2009.
36. Margetis K, Dimaraki E, Charkoftaki G, et al. Penetration of intact blood-brain barrier by doripenem. *Antimicrob Agents Chemother* 2011;55:3637-8.
37. Markantonis SL, Markou N, Fousteri M, et al. Penetration of colistin into cerebrospinal fluid. *Antimicrob Agents Chemother* 2009;53:4907-10.
38. Michalopoulos AS, Falagas ME. Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patients. *Ann Intensive Care* 2011;1:30-5.
39. Nau R, Prange HW, Muth P, et al. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. *Antimicrob Agents Chemother* 1993;37:1518-24.
40. Nau R, Sorgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. *Clin Microbiol Rev* 2010;23:858-83.
41. Nau R, Sorgel F, Prange HW. Pharmacokinetic optimization of the treatment of bacterial central nervous system infections. *Clin Pharmacokinet* 1998;35:223-45.

42. Norrby R. A review of the penetration of antibiotics into CSF and its clinical significance. *Scand J Infect Dis* 1978;14:296-309.
43. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. *Ann Pharmacother* 2007;41:296-308.
44. Okugawa S, Ota Y, Tatsuno K, et al. A case of invasive central nervous system aspergillosis treated with micafungin with monitoring of micafungin concentrations in the cerebrospinal fluid. *Scand J Infect Dis* 2007;39:344-6.
45. Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. *J Antimicrob Chemother* 2005;56:745-55.
46. Proia LA, Tenorio AR. Successful use of voriconazole for treatment of *Coccidioides meningitis*. *Antimicrob Agents Chemother* 2004;48:2341.
47. Ray L, Levasseur K, Nicolau DP, et al. Cerebral spinal fluid penetration of tigecycline in a patient with *Acinetobacter baumannii* cerebritis. *Ann Pharmacother* 2010; 44:582-6.
48. Reinwald M, Uharek L, Lampe D, et al. Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis. *Bone Marrow Transplant* 2009;44:269-70.
49. Rhoney DH, Tam VH, Parker J, et al. Disposition of cefepime in the central nervous system of patients with external ventricular drains. *Pharmacotherapy* 2003;23: 310-4.
50. Riser MS, Bland CM, Rudisill CN, et al. Cerebrospinal fluid penetration of high-dose daptomycin in suspected *Staphylococcus aureus* meningitis. *Ann Pharmacother* 2010;44:1832-5.
51. Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. *J Antimicrob Chemother* 2006;58: 1221-9.
52. Ruping MJGT, Albermann N, Ebinger F, et al. Posaconazole concentrations in the central nervous system. *J Antimicrob Chemother* 2008;62:1468-70.
53. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. *Br J Haematol* 1991;97:663-5.
54. Sejvar JJ, Tenover SC, Stephens DS. Management of anthrax meningitis. *Lancet Infect Dis* 2005;5:287-95.
55. Sinner SW, Tunkell AR. Antimicrobial agents in the treatment of bacterial meningitis. *Infect Dis Clin N Am* 2004;18:581-602.

56. Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook. 11th ed. Hudson, Ohio, USA: Lexi- Comp Inc; 2004.
57. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004;39:1267-84.
58. van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. N Engl J Med 2010;362:146-54.
59. Verweij PE, Den Bergh MF, Rath PM, et al. Invasive aspergillosis caused by *Aspergillus ustus*: case report and review. J Clin Microbiol 1999;37:1606-9.
60. Villani P, Regazzi MB, Marubbi F, et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother 2002;46:936-7.
61. Wallace MR, Sander AW, Licitra C, et al. Methicillin-resistant *Staphylococcus aureus* meningitis successfully treated with daptomycin. Infect Dis Clin Pract 2009; 17:69-70.
62. Wang J, Wang Q, Zhao L, et al. Blood-brain barrier penetration of cefepime after neurosurgery. Chin Med J 2007;120:1176-8.
63. Zeana C, Kubin CJ, Della-Latta P, et al. Vancomycin-resistant *Enterococcus faecium* meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 2001;33:477-82.

β-LACTAM ALLERGY

1. Anon. Is it really a penicillin allergy? CDC
2. Anon. Management of penicillin and beta-lactam allergy – executive summary. NB Prov Health Authorities Anti-Infective Stewardship Committee 2016;Feb.
3. Anon. Penicillin allergy. Med Lett Drugs Ther 1988;30:79-80.
4. Atanaskovic-Markovic M, Gaeta F, Medjo B, et al. Tolerability of meropenem in children with IgE-mediated hypersensitivity to penicillins. Allergy 2008;63:237-40.
5. Belga S, Fryters S, Saxinger L. β-lactam allergy. Alberta Health Services Antimicrobial Stewardship Background. 2017;July. <http://www.albertahealthservices.ca/assets/info/hp/as/if-hp-asb-2017-07-issue-14.pdf>
6. Anon. Penicillin allergy. Med Lett Drugs Ther 1988;30:79-80.
7. Atanaskovic-Markovic M, Gaeta F, Medjo B, et al. Tolerability of meropenem in children with IgE-mediated hypersensitivity to penicillins. Allergy 2008;63:237-40.

8. Blanca M, Romano A, Torres MJ, et al. Update on the evaluation of hypersensitivity reactions to betalactams. *Allergy* 2009;64:183-93.
9. Campagna JD, Bond MC, Schabelman E, et al. The use of cephalosporins in penicillin-allergic patients: a literature review. *J Emerg Med* 2012;42:612-20.
10. DePestel DD, Benninger MS, Danzinger L, et al. Cephalosporin use in treatment of patients with penicillin allergies. *J Am Pharm Assoc* 2008;48:530-40.
11. Frumin J, Gallagher JC. Allergic cross-sensitivity between penicillin, carbapenem, and monobactam antibiotics: what are the chances? *Ann Pharmacother* 2009; 43:304-15.
12. Gallelli JF, Calis KA. Penicillin allergy and cephalosporin cross-reactivity. *Hosp Pharm* 1992;27:540-1.
13. Gray LJ. Penicillin allergy and beta lactam cross allergenicity. *Health Sciences Centre Drug Info Newslett* 1995;17:1-3.
14. Gruchalla RS, Pirmohamed M. Antibiotic allergy. *N Engl J Med* 2006;354:601-9.
15. Guill MF. Allergic drug reactions: identification and management. *Hosp Formul* 1991;26:582-9.
16. Hippern LD, Halapy H. Assessing penicillin allergies with a structured assessment form. *Can J Hosp Pharm* 2000;53:184-92.
17. Holowachuk M. Drug allergy. *On Continuing Pract* 1990;17:41-3.
18. Hunter DE, Hunter WJ. Penicillin allergies. *Am J Hosp Pharm* 1994;51:1963-4.
19. Kelkar PS, Li JTC. Cephalosporin allergy. *N Engl J Med* 2001;345:804-9.
20. Kim S, Warrington RJ. Clinical cross-reactivity between penicillins and cephalosporins. *Can J Allergy Clin Immunol* 1998;3:12-15.
21. Knowles S. Drug allergies: a review. *Pharm Pract CE*. April 2005.
22. Kula B, Djordjevic G, Robinson JL. A systematic review: can one prescribe carbapenems to patients with IgE-mediated allergy to penicillins or cephalosporins? *Clin Infect Dis* 2014;59:1113-22.
23. Lagace-Wiens P, Rubinstein E. Adverse reactions to β -lactam antimicrobials. *Expert Opin Drug Saf* 2012;11:381-99.
24. Langley JM, Halperin S. Allergy to antibiotics in children: perception versus reality. *Can J Infect Dis* 2002;13:160-3.
25. Lee CE, Zembower TR, Fotis MA, et al. The incidence of antimicrobial allergies in hospitalized patients. *Arch Intern Med* 2000;160:2819-22.

26. Legendre DP, Muzny CA, Marshall GD, et al. Antibiotic hypersensitivity reactions and approaches to desensitization. *Clin Infect Dis* 2014;58:1140-8.
27. Lin RY. A perspective on penicillin allergy. *Arch Intern Med* 1992;152:930-7.
28. Logan HA, Bayliff CD. Analysis of therapeutic options in patients reporting a penicillin or cephalosporin allergy. *Can J Hosp Pharm* 1997;50:201-7.
29. MacFadden DR, LaDelfa A, Leen J, et al. Impact of reported beta-lactam allergy on inpatient outcomes: a multicenter prospective cohort study. *Clin Infect Dis* 2016;63:904-10.
30. Macy E, Contreras R. Adverse reactions associated with oral and parenteral use of cephalosporins: a retrospective population-based analysis. *J Allergy Clin Immunol* 2015;135:745-52.
31. Macy E, Contreras R. Health care use and serious infection prevalence associated with penicillin "allergy" in hospitalized patients: a cohort study. *J Allergy Clin Immunol* 2014;133:790-6.
32. McConnell SA, Penzak SR, Warmack TS, et al. Incidence of imipenem hypersensitivity reactions in febrile neutropenic bone marrow transplant patients with a history of penicillin allergy. *Clin Infect Dis* 2000;31:1512-4.
33. Pichicheno ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. *Pediatrics* 2005;115:1048-57.
34. Prescott WA, DePestel DD, Ellis JJ, et al. Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy. *Clin Infect Dis* 2004;38:1102-7.
35. Prescott WA, Kusmierski KA. Clinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergy. *Pharmacother* 2007;27:137-42.
36. Preston SL, Briceland LL, Lesar TS. Accuracy of penicillin allergy reporting. *Am J Hosp Pharm* 1994;51:79-84.
37. Romano A, Viola M, Guéant-Rodriguez RM, et al. Brief communication: tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins. *Ann Intern Med* 2007;146:266-9.
38. Romano A, Viola M, Guéant-Rodriguez RM, et al. Imipenem in patients with immediate hypersensitivity to penicillins [letter]. *N Engl J Med* 2006;354:2835-7.

39. Salkind AR, Cuddy PG, Foxworth JW. Is this patient allergic to penicillin? An evidence-based analysis of the likelihood of penicillin allergy. *JAMA* 2001;285:2498-505.
40. Saxon A, Adelman DC, Patel A, et al. Imipenem cross-reactivity with penicillin in humans. *J Allergy Clin Immunol* 1988;82:213-7.
41. Saxon A, Beall GN, Rohr AS, et al. Immediate hypersensitivity reactions to beta-lactam antibiotics. *Ann Intern Med* 1987;107:204-15.
42. Sodhi M, Axtell SS, Callahan J, et al. Is it safe to use carbapenems in patients with a history of allergy to penicillin? *J Antimicrob Chemother* 2004;54:1155-7.
43. Solensky R, Khan DA, eds. Drug allergy: an updated practice parameter. *Ann Allergy Asthm Immunol* 2010;105:273.e1-78.
44. Wendell GD, Stark BJ, Jamison RB, et al. Penicillin allergy and desensitization in serious infections during pregnancy. *N Engl J Med* 1985;312:1229-32.
45. Wong B. An approach to the patient with penicillin allergy. *Respirology & Allergy Rounds* 2005;2(2).
46. Zvonar RK. Cross-allergy among the β -lactam antibiotic agents: a review of the risks. *Can J Hosp Pharm* 2005;58:90-6.

RECOMMENDED EMPIRIC THERAPY OF SELECTED INFECTIONS (Paediatric/Neonatal, Adult)

General

1. Baker CJ, ed. Red Book atlas of pediatric infectious diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2007.
2. Bradley JS, Nelson JD. 2010-11 Nelson's pocket book of pediatric antimicrobial therapy. 18th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2010.
3. Gilbert DN, Moellering RC, Eliopoulos GM, eds. The Sanford guide to antimicrobial therapy 2012. Sperryville, VA: Antimicrobial Therapy, Inc. 2012.
4. Mandell GL, Bennett JE, and Dolin R, eds. Mandell, Douglas and Bennett's principles & practice of infectious diseases. 7th ed. New York: Churchill Livingstone Inc. 2009.
5. Product monographs. Compendium of Pharmaceuticals and Specialties 2011.

Skin and Soft Tissue

1. Aboltins CA, Hutchinson AF, Sinnappu RN, et al. Oral versus parenteral antimicrobials for the treatment of cellulitis: a randomized non-inferiority trial. *J Antimicrob Chemother* 2015;70:581-6.

2. Achong MR. Soft tissue infections: boils, bites and bad bacteria. *Can J Diagn* 1999;93-103.
3. Bader MS, Twells L, Hawboldt J. Risk factors of cellulitis treatment failure with once-daily intravenous cefazolin plus oral probenecid. *Southern Med J* 2011;104:789-93.
4. Bass JW. Treatment of skin and skin structure infections. *Pediatr Infect Dis J* 1992;11:152-5.
5. Bernard P. Management of common bacterial infections of the skin. *Curr Opin Infect Dis* 2008;21:122-8.
6. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. *N Engl J Med* 1996;334:240-5.
7. Bjork R. What's causing your patient's lower-extremity redness? *Wound Care Advisor* 2013;2:16-19,28.
8. Bowler P. The anaerobic and aerobic microbiology of wounds: a review. *Wounds* 1998;10:170-8.
9. Brown G, Chamberlain R, Goulding J, et al. Ceftriaxone versus cefazolin with probenecid for severe skin and soft tissue infections. *J Emerg Med* 1996;14:547-51.
10. Cox VC, Zed PJ. Once-daily cefazolin and probenecid for skin and soft tissue infections. *Ann Pharmacother* 2004;38:458-63.
11. Dryden MS. Complicated skin and soft tissue infection. *J Antimicrob Chemother* 2010;65 suppl 3:iii35-44.
12. Eron LJ. Cellulitis and soft-tissue infections. *Ann Intern Med* 2009;Jan:ITC1-1-16.
13. Failla DM, Parkey GA. Optimum outpatient therapy of skin & skin structure infections. *Drugs* 1994;48:172-8.
14. Falagas ME, Vergidis PI. Narrative review: diseases that masquerade as infectious cellulitis. *Ann Intern Med* 2005;142:47-55.
15. Gabillot-Carre M, Roujeau JC. Acute bacterial skin infections and cellulitis. *Curr Opin Infect Dis* 2007;20:118-23.
16. Graham-Robinson NA. Skin infections & treating the surface - does it work? *Pharm Practice* 1992 (Jun): 23-9.
17. Grayson LM, McDonald M, Gibson K, et al. Once-daily intravenous cefazolin plus oral probenecid is equivalent to once-daily intravenous ceftriaxone plus oral placebo for the treatment of moderate-to-severe cellulitis in adults. *Clin Infect Dis* 2002;34:1440-8.
18. Halilovic J, Heintz BH, Brown J. Risk factors for clinical failure in patients hospitalized with cellulitis and cutaneous abscess. *J Infection* 2012;65:128-34.
19. Hurwitz S. Guide to skin diseases of infants. *Diagnosis* 1985;103-14.

20. Ki V, Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. *Can J Infect Dis Med Microbiol* 2008;19:173-84.
21. Kilburn SA, Featherstone P, Higgins B, et al. Interventions for cellulitis and erysipelas. *Cochrane Database Syst Rev* 2010, Issue 6. Art. No.: CD004299.
22. Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. *JAMA* 1988;260:2682-5.
23. Moon KT. Which antibiotics are best for skin and soft tissue infections? *Am Fam Physician* 2007;76:1034-8.
24. Nahata MC, Durrell DE, Ginn-Pease ME, et al. Pharmacokinetics and tissue concentrations of cefazolin in pediatric patients undergoing gastrointestinal surgery. *Eur J Drug Metab Pharmacokinet* 1991;16:49-52.
25. Peterson D, McLeod S, Woolfrey K, et al. Predictors of failure of empiric outpatient antibiotic therapy in emergency department patients with uncomplicated cellulitis. *Academic Emerg Med* 2014;21:526-31.
26. Phoenix G, Das S, Joshi M. Diagnosis and management of cellulitis. *BMJ* 2012;345:e4955.
27. Piersimoni C, Scarparo C. Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. *Emerg Infect Dis* 2009;15:1351-8.
28. Reagan DR, et al. Elimination of coincident *Staphylococcus aureus* nasal and hand carriage with intranasal application of mupirocin calcium ointment. *Ann Intern Med* 1991;114:101-6.
29. Rice TL. Topical antibacterials. *Hospital Pharmacy* 1992;27:1099-1108.
30. Robinson JL, Wenman WM. Bacterial skin infections in children: what to look for and what to do. *Can J Diagnosis* 1990;76-92.
31. Schachner L, Press S. Vesicular, bullous and pustular disorders in infancy and childhood. *Pediatr Clin North Am* 1983;30:609-29.
32. Semel JD, Goldin H. Association of athlete's foot with cellulitis of the lower extremities: diagnostic value of bacterial cultures of ipsilateral interdigital space samples. *Clin Infect Dis* 1996;23:1162-4.
33. Singer AJ, Talan DA. Management of skin abscesses in the era of methicillin-resistant *Staphylococcus aureus*. *N Engl J Med* 2014;370:1039-47.
34. Spina SP, Dillon Jr EC. Effect of chronic probenecid therapy on cefazolin serum concentrations. *Ann Pharmacother* 2003;37:621-4.

35. Stevens DL. Streptococcal infections of skin and soft tissues. *N Engl J Med* 1996;334:240-5.
36. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2014;59:e10-52.
37. Strauss WG, et al. Bacterial interference treatment of recurrent furunculosis. *JAMA* 1969;208:861-3.
38. Swartz MN. Cellulitis. *N Engl J Med* 2004;350:904-12.
39. Thomas KS, Crook AM, Nunn AJ, et al. Penicillin to prevent recurrent leg cellulitis. *N Engl J Med* 2013;368:1695-703.
40. Tortoli E. Clinical manifestations of nontuberculous mycobacteria infections. *Clin Microbiol Infect* 2009;15:906-10.
41. Wong MSW. A lousy problem – revisiting the age-old concern of head lice. *Pharmacy Practice* 2002;18;47-53.

MRSA

1. Barton M, Hawkes M, Moore D, et al. Guidelines for the prevention and management of community-associated methicillin-resistant *Staphylococcus aureus*: A perspective for Canadian health care practitioners. *Can J Infect Dis Med Microbiol* 2006;17 (suppl C):4C-24C.
2. Canadian Paediatric Society, Infectious Disease Committee (Principal authors Joan L Robinson, Marina I Salvadori), Management of community-associated methicillin-resistant *Staphylococcus aureus* skin abscesses in children. *Paediatr Child Health* 2011;16:115-6.
www.cps.ca/en/documents/position/methicillin-resistant-Staphylococcus-aureus-skin-abscesses (Accessed September 13, 2012).
3. Chen SF. *Staphylococcus aureus* decolonization. *Ped Infect Dis J* 2005;24:79-80.
4. Conly JM, Johnston BL. The emergence of methicillin-resistant *Staphylococcus aureus* as a community-acquired pathogen in Canada. *Can J Infect Dis Med Micro* 2003;14:249-51.
5. Conly JM, Stiver HG, Weiss KA, et al. A retrospective analysis of practice patterns in the treatment of methicillin-resistant *Staphylococcus aureus* skin and soft tissue infections at three Canadian tertiary care centres. *Can J Infect Dis* 2003;14:315-21.

6. David MZ, Daum RS. Community-associated methicillin-resistant *Staphylococcus aureus*: epidemiology and clinical consequences of an emerging epidemic. *Clin Microbiol Rev* 2010;23:616-87.
7. DeLeo FR, Otto M, Kreiswirth BN, et al. Community-associated methicillin-resistant *Staphylococcus aureus*. *Lancet* 2010;375:1557-68.
8. Fung SK, Louie M, Simor AE. Combined topical and oral antimicrobial therapy for the eradication of methicillin-resistant *Staphylococcus aureus* (MRSA) colonization in hospitalized patients. *Can J Infect Dis* 2002;13:287-92.
9. Liu C, Bayer A, Cosgrove S, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis* 2011;52:1-38.
10. Lucet JC, Regnier B. Screening and decolonization: does methicillin-susceptible *Staphylococcus aureus* hold lessons for methicillin-resistant *S. aureus*? *Clin Infect Dis* 2010;51:585-90.
11. Mulvey MR, MacDougall L, Cholin B, et al. Community-associated methicillin-resistant *Staphylococcus aureus*, Canada. *Emerg Infect Dis* 2005;11:844-50.
12. Nichol KA, Adam HJ, Roscoe DL, et al. Changing epidemiology of methicillin-resistant *Staphylococcus aureus* in Canada. *J Antimicrob Chemother* 2013;68(suppl 1):i47-55.
13. Simor AE, Loeb M. The management of infection and colonization due to methicillin-resistant *Staphylococcus aureus*: a CIDS/CAMM position paper. *Can J Infect Dis* 2004;15:39-48.
14. Simor AE, Phillips E, McGeer A, et al. Randomized controlled trial of chlorhexidine gluconate for washing, intranasal mupirocin, and rifampin and doxycycline versus no treatment for the eradication of methicillin-resistant *Staphylococcus aureus* colonization. *Clin Infect Dis* 2007;44:178-85.
15. van Rijen M, Bonten M, Wenzel R, et al. Mupirocin ointment for preventing *Staphylococcus aureus* infections in nasal carriers. *Cochrane Database Syst Rev* 2008, Issue 4. Art. No.: CD006216.
16. Weber JT. Community-associated methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis* 2005;41:S269-72.
17. Wertheim HFL, Melles DC, Vos MC, et al. The role of nasal carriage in *Staphylococcus aureus* infections. *Lancet Infect Dis* 2005;5:751-62.

Impetigo

1. Bowen AC, Tong SYC, Andrews RM. Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomized, controlled, non-inferiority trial. *Lancet* 2014;384:2132-40.
2. Koning S, van Suijlekom-Smit LWA, Nouwen JL, et al. Fusidic acid cream in the treatment of impetigo in general practice: double blind randomised placebo controlled trial. *BMJ* 2002;324:1-5.
3. Koning S, Verhagen AP, van Suijlekom-Smit LWA, et al. Interventions for impetigo. *Cochrane Database Syst Rev* 2003, Issue 2. Art. No.: CD003261.

Vesicular Lesions

1. Alrabiah FA, Sacks SL. New antiherpesvirus agents: their targets and therapeutic potential. *Drugs* 1996;52:17-32.
2. Amir J, Harel L, Smetana Z, et al. Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study. *Br Med J* 1997;314:1800-3.
3. Anon. Drugs for non-HIV viral infections. *Treatment Guidelines Med Let* 2005;3(32):23-32.
4. Boivin G, Jovey R, Elliott CT, et al. Management and prevention of herpes zoster: a Canadian perspective. *Can J Infect Dis Med Microbiol* 2010;21:45-52.
5. Committee on Infectious Diseases. The use of oral acyclovir in otherwise healthy children with varicella. *Pediatr* 1993;91:674-6.
6. Dworkin RH, Boon RJ, Griffin DRG, et al. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. *J Infect Dis* 1998;178:S76-80.
7. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of Herpes zoster. *Clin Infect Dis* 2007;44:1-26.
8. Hardy I, Gershon AA, Steinberg SP, et al. The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. *Varicella Vaccine Collaborative Study Group. New Engl J Med* 1991;325:1545-50.
9. Heininger U, Seward JF. Varicella. *Lancet* 2006;368:1365-76.
10. Klassen TP, Hartling L. Acyclovir for treatng varicella in otherwise healthy children and adolescents. *Cochrane Database Syst Rev* 2005, Issue 4. Art. No.: CD002980.
11. Nikkels AF, Pierard GE. Recognition and treatment of shingles. *Drugs* 1994;48:528-48.

12. Ormrod D, Goa K. Valaciclovir: A review of its use in the management of herpes zoster. *Drugs* 2000;59:1317-40.
13. Perry CM, Wagstaff AJ. Famciclovir: a review of its pharmacological properties and therapeutic efficacy in Herpesvirus infections. *Drugs* 1995;50:396-415.
14. Schmader K. Herpes zoster in older adults. *Clin Infect Dis* 2001;32:1481-6.
15. Spruance SL, Jones TM, Blatter MM, et al. Oral valaciclovir for the treatment of herpes labialis: two trials of early, high-dose, short-course therapy. Abstract
16. Spruance, SL, Nett R, Marbury T, et al. Acyclovir cream for treatment of herpes simplex labialis: results of two randomized, double-blind, vehicle-controlled, multicenter clinical trials. *Antimicrob Agents Chemother* 2002;46:2238-43.
17. Tyring SK, Beutner KR, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. *Arch Fam Med* 2000;9:863-9.
18. Valtrex® product monograph. GlaxoSmithKline Inc. May 7, 2003.
19. Whitley RJ. A 70 year-old woman with shingles. *JAMA* 2009;302:73-80.
20. Wilson JF. Herpes zoster. *Ann Intern Med* 2011;Mar:ITC3-1-16.

Breast Abscess/Mastitis

1. Bing AU, Loh SF, Morris T, et al. *Actinomyces* species isolated from breast infections. *J Clin Microbiol* 2015;53:3247-55.
2. Bundred NJ, Dover MS, Coley S, et al. Breast abscesses and cigarette smoking. *Br J Surg* 1992;79:58-9.
3. Dixon JM, Khan LR. Treatment of breast infection. *BMJ* 2011;342:d396.
4. Dixon JM. Breast infection. *BMJ* 2013;347:f3291.
5. Jahanfar S, Ng CJ, Teng CL. Antibiotics for mastitis in breastfeeding women. *Cochrane Database Syst Rev* 2009, Issue 1. Art. No.: CD005458.
6. Mertz KR, Baddour LM, Bell JL, et al. Breast cellulitis following breast conservation therapy: a novel complication of medical progress. *Clin Infect Dis* 1998;26:481-6.
7. Seng P, Bayle S, Alliez A, et al. The microbial epidemiology of breast implant infections in a regional referral centre for plastic and

reconstructive surgery in the south of France. *International J Infect Dis* 2015;35:62-6.

Bites

1. Abrahamian FM, Goldstein EJC. Microbiology of animal bite wound infections. *Clin Microbiol Rev* 2011;24:231-46.
2. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. *Clin Micro Rev* 2001;14:244-69.
3. Bunzli WF, Wright DH, Hoang AD, et al. Current management of human bites. *Pharmacotherapy* 1998;18:227-34.
4. Cummings P. Antibiotics to prevent infection in patients with dog bite wounds: a meta-analysis of randomized trials. *Ann Emerg Med* 1994;23:535-40.
5. Davies HD. When your best friend bites: a note on dog and cat bites. *Can J Infect Dis* 2000;11:227-9.
6. Failla DM, Parkey GA. Optimum outpatient therapy of skin & skin structure infections. *Drugs* 1994;48:172-8.
7. Fleisher GR. The management of bite wounds. *N Engl J Med* 1999;340:138-40.
8. Goldstein EJC. Bite wounds and infection. *Clin Infect Dis* 1992;14:633-40.
9. Goldstein EJC, Citron DM, Finegold SM. Dog bite wounds and infection: a prospective clinical study. *Ann Emerg Med* 1980;9:508-12.
10. Goldstein EJC, Citron DM, Finegold SM. Role of anaerobic bacteria in bite-wound infections. *Rev Infect Dis* 1984;6:177-83.
11. Goldstein EJC, Citron DM, Wield B, et al. Bacteriology of human and animal bite wounds. *J Clin Microbiol* 1978;8:667-72.
12. Morgan M, Palmer J. Dog bites. *BMJ* 2007;334:413-7.
13. Oehler R, Velez AP, Mizrachi M, et al. Bite-related and septic syndromes caused by cats and dogs. *Lancet Infect Dis* 2009;9:439-47.
14. Stevens DL, Higbee JW, Oberhofer TR, et al. Antibiotic susceptibilities of human isolates of *Pasteurella multocida*. *Antimicrob Agents Chemother* 1979;16:322-4.
15. Talan DA, Abrahamian FM, Moran GJ, et al. Clinical presentation and bacteriologic analysis of infected human bites in patients presenting to emergency departments. *Clin Infect Dis* 2003;37:1481-9.
16. Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. *N Engl J Med* 1999;340:85-92.

17. Taplitz RA. Managing bite wounds. Currently recommended antibiotics for treatment and prophylaxis. *Postgraduate Medicine* 2004;116:49-59.
18. Taylor GA. Management of human bite injuries of the hand. *Can Med Assoc J* 1985;133:191-2.
19. Weber DJ, Hansen AR. Infections resulting from animal bites. *Infect Dis Clin N Am* 1991;5:663-80.

Diabetic Foot

1. Baglioni P, Malik M, Okosieme OE. Acute Charcot foot. *BMJ* 2012;344:e1397.
2. Bamberger DM, Davis GP, Gerding DN. Osteomyelitis in the feet of diabetic patients: long-term results, prognostic factors, and the role of antimicrobial and surgical therapy. *Amer J Med* 1987;83:653-60.
3. Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. *Clin Micro Rev* 2001;14:244-69.
4. Caputo GM, Cavanagh PR, Ulbrecht JS, et al. Assessment and management of foot disease in patients with diabetes. *N Engl J Med* 1994;331:854-60.
5. Cavanagh PR, Lipsky BA, Bradbury AW, et al. Treatment for diabetic foot ulcers. *Lancet* 2005;366:1725-35.
6. Committee on Antimicrobial Agents, Fong IW. Management of diabetic foot infection: a position paper. *Can J Infect Dis* 1996;7:361-5.
7. Gerding DN. Foot infections in diabetic patients: the role of anaerobes. *Clin Infect Dis* 1995;20:283-8.
8. Grayson ML, Gibbons GW, Habershaw GM, et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. *Clin Infect Dis* 1994;18:683-93.
9. Grayson ML. Diabetic foot infections: antimicrobial therapy. *Infect Dis Clin N* 1995;9:146-61.
10. Kertesz D, Chow AW. Infected pressure and diabetic ulcers. *Clin Geriatr Med* 1992; 8:835-52.
11. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. *Clin Infect Dis* 2012;54:132-73.
12. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. *Clin Infect Dis* 2004;39:885-910.

13. Powlson AS, Coll AP. The treatment of diabetic foot infections. *J Antimicrob Chemother* 2010;65(suppl 3):iii3-9.
14. Tan AI, Greenstein A, Jarrett SJ, et al. Acute neuropathic joint disease. *Diabetes Care* 2005;28:2962-4.
15. Tan JS, Friedman NM, Hazelton-Miller C, et al. Can aggressive treatment of diabetic foot infections reduce the need for above-ankle amputation? *Clin Infect Dis* 1996;23:286-91.
16. Wheat LJ, Allen SD, Henry M, et al. Diabetic foot infections: bacteriologic analysis. *Arch Intern Med* 1986;146:1935-40.

Rapidly Progressive Skin & Soft Tissue

1. Anaya DA, Dellinger EP. Necrotizing soft-tissue infection: diagnosis and management. *Clin Infect Dis* 2007;44:705-10.
2. Capital Health Regional Public Health. Public Health follow-up: invasive Group A Strep disease. *Communicable Disease Corner* 1997;7:8.
3. Chen JL, Fullerton KE, Flynn NM. Necrotizing fasciitis associated with injection drug use. *Clin Infect Dis* 2001;33:6-15.
4. Communicable Disease Control, Alberta Health. Alberta guidelines for management of contacts of cases of invasive Group A streptococcal disease, 1996.
5. Darenberg J, Ihendyane N, Sjolín J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. *Clin Infect Dis* 2003;37:333-40.
6. Demers B, Simor AE, Vellend H, et al. Severe invasive group A Streptococcal infections in Ontario, Canada: 1987-1991. *Clin Infect Dis* 1993;16:792-800.
7. Frick S, Cerny A. Necrotizing fasciitis due to *Streptococcus pneumoniae* after intramuscular injection of nonsteroidal anti-inflammatory drugs: report of 2 cases and review. *Clin Infect Dis* 2001;33:740-4.
8. Gardam MA, Low DE, Saginur R, et al. Group B streptococcal necrotizing fasciitis and streptococcal toxic shock-like syndrome in adults. *Arch Intern Med* 1998;158:1704-8.
9. Givner LB, Abramson JS, Wasilauskas B. Apparent increase in the incidence of invasive group A beta-hemolytic streptococcal disease in children. *J Pediatr* 1991;118:341-6.
10. Hasham S, Matteucci P, Stanley PRW, et al. Necrotising fasciitis. *BMJ* 2005;330:830-3.

11. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. *Clin Infect Dis* 1999;28:800-7.
12. Morris SF, Brennan M. Necrotizing infections of the skin and soft tissue. *Can J CME* 1996;Apr:115-27.
13. Norrby-Teglund A, Basma H, Andersson J, et al. Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. *Clin Infect Dis* 1998;26:631-8.
14. Phan HH, Cocanour CS. Necrotizing soft tissue infections in the intensive care unit. *Crit Care Med* 2010;38(suppl.):S460-8.
15. Stevens DL. Rationale for the use of intravenous gamma globulin in the treatment of streptococcal toxic shock syndrome. *Clin Infect Dis* 1998;26:639-41.
16. Stevens DL, Gibbons AE, Bergstrom R, et al. The Eagle effect revisited: efficacy of clindamycin, erythromycin and penicillin in the treatment of streptococcal myositis. *J Infect Dis* 1988;158:23-8.
17. Stevens DL. Invasive group A Streptococcus infections. *Clin Infect Dis* 1992;14:2-13
18. The Streptococcal Study Group, Departments of Infectious Disease and Microbiology. Protocol for the management of Group A Streptococcal toxic shock syndrome, Mount Sinai Hospital. Toronto, Ontario.
19. The Working Group on Prevention of Invasive Group A Streptococcal Infections. Prevention of invasive Group A streptococcal disease among household contacts of case-patients. *JAMA* 1998;279:1206-10.
20. Ustin JS, Malangoni MA. Necrotizing soft-tissue infections. *Crit Care Med* 2011;39:2156-62.
21. Vinh, DC, Embil JM. Rapidly progressive soft tissue infections. *Lancet Infect Dis* 2005;5:501-13.

Lice

1. Canadian Pediatric Society. Head lice infestations: a clinical update. *Paediatr Child Health* 2008;13:692-6.
2. Boivin M, Dion C, Oleksyn C. Managing head lice - in the age of lice resistance to neurotoxic products and new treatment modalities. *rxBriefCase* 2012.

Bone & Joint

1. Bachur R, Pagon Z. Success of short-course parenteral antibiotic therapy for acute osteomyelitis of childhood. *Clin Pediatrics* 2007;46:30-35.
2. Baker DG, Schumacher HR. Acute monoarthritis. *N Engl J Med* 1993;329:1013-20.
3. Black J, Hunt TL, Godley PJ, et al. Oral antimicrobial therapy for adults with osteomyelitis or septic arthritis. *J Infect Dis* 1987;155:968-72.
4. Chadwick PR, Davis N, Clayson AD, et al. Enterococcal joint prosthesis infection. *Clin Microbiol Infect* 1997;3:264-5.
5. Cunha BA. Osteomyelitis in elderly patients. *Clin Infect Dis* 2002;35:287-93.
6. Dickie AS. Current concepts in the management of infections in bones and joints. *Drugs* 1986;32:458-75.
7. Dirschl DR, Almekinders LC. Osteomyelitis: common causes and treatment recommendations. *Drugs* 1993;45:29-43.
8. Espinosa CM, Davis MM, Gilsdorf JR. Anaerobic osteomyelitis in children. *Pediatr Infect Dis J* 2011;30:422-3.
9. Feigin RD, Pickering LK, Anderson D, et al. Clindamycin treatment of osteomyelitis and septic arthritis in children. *Pediatrics* 1975;55:213-22.
10. Fitzgerald RH, Cowan JDE. Puncture wounds of the foot. *Orthop Clin North Am* 1975;6:965-72.
11. Fox L, Sprunt K. Neonatal osteomyelitis. *Pediatrics* 1978;62:535-42.
12. Gardner GC, Weisman MH. Pyarthrosis in patients with rheumatoid arthritis: a report of 13 cases and a review of the literature from the past 40 years. *Am J Med* 1990;88:503-11.
13. Gentry LD. Antibiotic therapy for osteomyelitis. *Infect Dis Clin North Am* 1990;4:485-99.
14. Gentry LO, Rodriguez GG. Oral ciprofloxacin compared with parenteral antibiotics in the treatment of osteomyelitis. *Antimicrob Agents Chemother* 1990;34:40-3.
15. Gentry LO. Oral antimicrobial therapy for osteomyelitis. *Ann Intern Med* 1991;114:986-7.
16. Gillespie WJ. Prevention and management of infection after total joint replacement. *Clin Infect Dis* 1997;25:1310-7.
17. Goldenberg DL, Reed JI. Bacterial arthritis. *N Engl J Med* 1985;312:764-70.

18. Henry SL, Galloway KP. Local antibacterial therapy for the management of orthopaedic infections: pharmacokinetic considerations. *Clin Pharmacokinet* 1995;29:36-45.
19. Jacobs KF, McCarthy RE, Elser JM. Pseudomonas osteochondritic complicating puncture wounds of the foot in children: a 10-year evaluation. *J Infect Dis* 1989;160:657-61.
20. Jacobs RF, Adelman L, Sack CM, et al. Management of Pseudomonas osteochondritis complicating puncture wounds of the foot. *Pediatrics* 1982;69:432-5.
21. Jacobs RF, McCarthy RE, Elser JM. Pseudomonas osteochondritis complicating puncture wounds of the foot in children: a 10-year evaluation. *J Infect Dis* 1989;160:657-61.
22. Kanellakopoulou K, Giamarellos-Bourboulis EJ. Carrier systems for the local delivery of antibiotics in bone infections. *Drugs* 2000;59:1223-32.
23. Kolyvas E, Ahronheim G, Marks MI, et al. Oral antibiotic therapy of skeletal infections in children. *Pediatrics* 1980;65:867-71.
24. Kortekangas P. Bacterial arthritis in the elderly: an overview. *Drugs & Aging* 1999;14:165-71.
25. La Saux N, Howard A, Barrowman N, et al. Shorter courses of parenteral antibiotic therapy do not appear to influence response rates for children with acute hematogenous osteomyelitis: a systematic review. *BMC Infect Dis* 2002;2:16.
26. Landersdorfer CB, Bulitta JB, Kinzig M, et al. Penetration of antibacterials into bone. *Clin Pharmacokinetics* 2009;48:89-124.
27. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? *Int J Infect Dis* 2005;9:127-38.
28. Lew DP, Waldvogel FA. Osteomyelitis. *N Engl J Med* 1997;336:999-1007.
29. Lipsky BA. Osteomyelitis of the foot in diabetic patients. *Clin Infect Dis* 1997;25:1318-26.
30. Meehan AM, Osmon DR, Duffy MCT, et al. Outcome of penicillin-susceptible streptococcal prosthetic joint infection treated with debridement and retention of the prosthesis. *Clin Infect Dis* 2003;36:845-9.
31. Miller EH, Semian DW. Gram-negative osteomyelitis following puncture wounds of the foot. *J Bone Joint Surg (Am)* 1975;57A:535-7.
32. Minnefor AB, Olson MI, Carver DH. Pseudomonas osteomyelitis following puncture wounds of the foot. *Pediatrics* 1971;47:598-60.

33. Nelson JD. Options for outpatient management of serious infections. *Pediatr Infect Dis J* 1992;11:175-8.
34. Norden CW, Bryant R, Palmer D, et al. Chronic osteomyelitis caused by *Staphylococcus aureus*: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy. *South Med J* 1986;79:947-51.
35. Peltola H, Unkila-Kallio L, Kallio MJT, and the Finnish Study Group. Simplified treatment of acute staphylococcal osteomyelitis of childhood. *Pediatrics* 1997;99:846-50.
36. Perlroth J, Kuo M, Tan J, et al. Adjunctive use of rifampin for the treatment of *Staphylococcus aureus* infections. *Arch Intern Med* 2008;168:805-19.
37. Prober CG. Current antibiotic therapy of community-acquired bacterial infections in hospitalized children: bone and joint infections. *Pediatr Infect Dis J* 1992;11:156-9.
38. Proctor RA, Peters G. Small colony variants in staphylococcal infections: diagnostic and therapeutic implications. *Clin Infect Dis* 1998;27:419-23.
39. Raz R, Miron D. Oral ciprofloxacin for treatment of infection following nail puncture wounds of the foot. *Clin Infect Dis* 1995;21:194-5.
40. Ross JJ, Saltzman CL, Carling P, et al. Pneumococcal septic arthritis: review of 190 cases. *Clin Infect Dis* 2003;36:319-27.
41. Segreti J, Nelson JA, Trenholme GM. Prolonged suppressive antibiotic therapy for infected orthopedic prostheses. *Clin Infect Dis* 1998;27:711-3.
42. Shafran SD, et al. Care plans for native and prosthetic joint septic arthritis, and acute hematogenous and chronic osteomyelitis. *Can J Infect Dis* 2000;11(suppl D):34D-40D.
43. Shirtliff ME, Mader JT. Acute septic arthritis. *Clin Microbiol Rev* 2002;15:527-44.
44. Smith JW, Piercy EA. Infectious arthritis. *Clin Infect Dis* 1995;20:225-31.
45. Sperling JW, Cofield RH, Torchia ME, et al. Infection after shoulder instability surgery. *Clin Ortho Related Research* 2003;414:61-4.
46. Stein A, Bataille JF, Drancourt M, et al. Ambulatory treatment of multidrug-resistant staphylococcus infected orthopedic implants with high-dose oral co-trimoxazole (trimethoprim-sulfamethoxazole). *Antimicrob Agents Chemother* 1998;42:3086-91.
47. Stengel D, Bauwens K, Sehoul J, Ekkernkamp A, et al. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. *Lancet Infect Dis* 2001;1:175-88.

48. Sugarman B. Pressure sores and underlying bone infection. *Arch Intern Med* 1987;147:553-5.
49. Syrogiannopoulos GA, Nelson JD. Duration of antimicrobial therapy for acute suppurative osteoarticular infections. *Lancet* 1988;37-40.
50. Widmer AF. New developments in diagnosis and treatment of infection in orthopedic implants. *Clin Infect Dis* 2001;33(suppl 2):S94-106.
51. Weichert S, Sharland M, Clarke NMP, et al. Acute haematogenous osteomyelitis in children: is there any evidence for how long we should treat? *Curr Opin Infect Dis* 2008;21:258-62.
52. Winingar DA, Fass RJ. Antibiotic-impregnated cement and beads for orthopedic infections. *Antimicrob Agents Chemother* 1996;40:2675-9.
53. Wieland BW, Marcantoni JR, Bommarito KM, et al. A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible *Staphylococcus aureus*. *Clin Infect Dis* 2012;54:585-90.
54. Zimmerli W. Vertebral osteomyelitis. *N Engl J Med* 2010;362:1022-9.
55. Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. *N Engl J Med* 2004;351:1645-54.

Septic Arthritis/Bursitis

1. Harwell JI, Fisher D. Pediatric septic bursitis: case report of retocalcaneal infection and review of the literature. *Clin Infect Dis* 2001;32:102-4.
2. Kherani, RB, Shojania K. Septic arthritis in patients with pre-existing inflammatory arthritis. *Can Med Assoc J* 2007;176:1605.
3. Peltola H, Paakkonen M, Kallio P, et al. Prospective, randomized trial of 10 days versus 30 days of antimicrobial treatment, including a short-term course of parenteral therapy, for childhood septic arthritis. *Clin Infect Dis* 2009;48:1201-10.
4. Perez C, Huttner A, Assal M, et al. Infectious olecranon and patellar bursitis: short-course adjuvant antibiotic therapy is not a risk factor for recurrence in adult hospitalized patients. *J Antimicrob Chemother* 2010;65:1008-14.
5. Smith JW, Chalupa P, Hasan MS. Infectious arthritis: clinical features, laboratory findings and treatment. *Clin Microbiol Infect* 2006;12:309-14.

Prosthetic Joint Infections

1. Barberan J. Management of infections of osteoarticular prosthesis. *Clin Microbiol Infect* 2006;12:93-101.
2. Del Pozo JL, Patel R. Infection associated with prosthetic joints. *N Engl J Med* 2009;361:787-94.
3. Douglas RO, Elie FB, Anthony RB, et al. Diagnosis and management of prosthetic joint infection: Clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2013;56(1):e1-25.
4. Gomez J, Canovas E, Banos V, et al. Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant. *Antimicrobial Agents and Chemotherapy* 2011;4308-10.
5. Kanafani ZA, Sexton DJ, Pien BC, et al. Postoperative joint infections due to *Propionibacterium* species: a case-control study. *Clin Infect Dis* 2009;49:1083-5.
6. Laffer RR, Graber P, Ochsner PE, et al. Outcome of prosthetic knee-associated infection: evaluation of 40 consecutive episodes at a single centre. *Clin Microbiol Infect* 2006;12:433-9.
7. Matthews P, Berendt A, McNally M, et al. Diagnosis and management of prosthetic joint infection. *BMJ* 2009;338:1773.
8. Moran E, Byren I, Atkins BL. The diagnosis and management of prosthetic joint infections. *J Antimicrob Chemother* 2010;65:45-54.
9. Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2013;56:e1-25.
10. Parvizi J, Zmistowski B, Berbari EF, et al. New definition for periprosthetic joint infection: from the workgroup of the musculoskeletal infection society. *Clinical Ortho and Related Research* 2011.
11. Qu X, Zhai Z, Wu C, et al. Preoperative aspiration culture for preoperative diagnosis of infection in total hip or knee arthroplasty. *J Clin Microbiol* 2013;51:3830-4.
12. Samuel JR, Gould FK. Prosthetic joint infections: single versus combination therapy. *J Antimicrob Chemother* 2010;65:18-23.
13. Schafer P, Fink B, Sandow D, et al. Prolonged bacterial culture to identify late periprosthetic joint infection: a promising strategy. *Clin Infect Dis* 2008;47:1403-9.
14. Senneville E, Joulie D, Legout L, et al. Outcome and predictors of treatment failure in total hip/knee prosthetic joint infections due to *Staphylococcus aureus*. *Clin Infect Dis* 2011;53:334-40.

15. Trampuz A, Widmer AF. Infections associated with orthopedic implants. *Curr Opin Infect Dis* 2006;19:349-56.
16. Vilchez F, Martinez-Pastor JC, Garcia-Ramiro S, et al. Outcome and predictors of treatment failure in early post-surgical prosthetic joint infections due to *Staphylococcus aureus* treated with debridement. *Clin Microbiol Infect* 2011;17:439-44.

Respiratory

1. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections - full version. *Clin Microbiol Infect* 2011;17(suppl 6):E1-59.
2. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections - summary. *Clin Microbiol Infect* 2011;17(suppl 6):1-24.

Pharyngitis

1. Adam D, Scholz H, Helmerking M. Short-course antibiotic treatment of 4782 culture-proven cases of group A Streptococcal tonsillopharyngitis and incidence of poststreptococcal sequelae. *J Infect Dis* 2000;182:509-16.
2. Bass JW, Person DA, Chan DS. Twice-daily oral penicillin for treatment of streptococcal pharyngitis: less is best. *Pediatrics* 2000;423-4.
3. Bisno AL. Are cephalosporins superior to penicillin for treatment of acute streptococcal pharyngitis? *Clin Infect Dis* 2004;38:1535-7.
4. Bisno AL, Gerber MA, Gwaltney JM, et al. Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis. *Clin Infect Dis* 2002;35:113-25.
5. Bisno AL, Peter GS, Kaplan EL. Diagnosis of strep throat in adults: are clinical criteria really good enough? *Clin Infect Dis* 2002;35:126-9.
6. Brink WR, Rammelkamp CH, Denny FW, et al. Effect of penicillin and aureomycin on the natural course of streptococcal tonsillitis and pharyngitis. *Am J Med* 1951;10:300-8.
7. Brook I. β -lactamase-producing bacteria in mixed infections. *Clin Microbiol Infect* 2004;10:777-84.
8. Casey JR, Pichichero ME. Higher dosages of azithromycin are more effective in treatment of group A streptococcal tonsillopharyngitis. *Clin Infect Dis* 2005;40:1748-55.

9. Casey JR, Pichichero ME. Meta-analysis of cephalosporins versus penicillin for treatment of group A streptococcal tonsillopharyngitis in adults. *Clin Infect Dis* 2004;38:1526-34.
10. Casey JR, Pichichero ME. Meta-analysis of cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis in children. *Pediatrics* 2004;113:866-82.
11. Casey JR, Pichichero ME. Metaanalysis of short course antibiotic treatment for group A streptococcal tonsillopharyngitis. *Ped Infect Dis J* 2005;24:909-17.
12. Catanzaro FJ, Stetson CA, Morris AJ, et al. The role of the streptococcus in the pathogenesis of rheumatic fever. *Am J Med* 1954;17:749-56.
13. Centor RM, Witherspoon JM, Dalton HP, et al. The diagnosis of strep throat in adults in the emergency room. *Med Dec Making* 1981;1:239-46.
14. Choby BA. Diagnosis and treatment of streptococcal pharyngitis. *Am Fam Physician* 2009;79:383-90.
15. Cimolai N, Elford RW, Bryan L, et al. Do the β -haemolytic non-group A Streptococci cause pharyngitis? *Rev Infect Dis* 1988;10:587-601.
16. Clarridge JE. The recognition and significance of *Arcanobacterium haemolyticum*. *Clin Microbiol Newsletter* 1989;11:41-5.
17. Cooper RJ, Hoffman JR, Bartlett JG, et al. Principles of appropriate antibiotic use for acute pharyngitis in adults: background. *Ann Intern Med* 2001;134:509-17.
18. Davies HD, Low DE, Schwartz B, et al. Evaluation of short-course therapy with cefixime or rifampin for eradication of pharyngeally carried group A Streptococci. *Clin Infect Dis* 1995;21:1294-6.
19. Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. *Cochrane Database Syst Rev*, Issue 3, 2004.
20. DKML. Laboratory diagnosis and management of bacterial pharyngitis. 1996;1
21. Ebell MH, Smith MA, Barry HC, et al. Does this patient have strep throat? *JAMA* 2000;284:2912-8.
22. El Daher N, Hijazi S, Rawashdeh N, et al. Immediate vs. delayed treatment of group A beta-hemolytic streptococcal pharyngitis with penicillin V. *Pediatr Infect Dis J* 1991;10:126-30.
23. Feder HM, Gerber MA, Randolph MF, et al. Once-daily therapy for streptococcal pharyngitis with amoxicillin. *Pediatrics* 1999;103:47-51.

24. Fine AM, Nizet V, Mandl KD. Large-scale validation of the Centor and Mclsaac scores to predict group A streptococcal pharyngitis. *Arch Intern Med* 2012;172:847-52.
25. Gerber M, Spadaccini L, Wright L, et al. Twice daily penicillin in the treatment of streptococcal pharyngitis. *Am J Dis Child* 1985;139:1145-8.
26. Gerber MA, Baltimore RS, Eaton CB, et al. Prevention of rheumatic fever and diagnosis and treatment of acute streptococcal pharyngitis. *Circulation* 2009;119:1541-51.
27. Gerber MA, Randolph MF, Martin NJ, et al. Community-wide outbreak of group G Streptococcal pharyngitis. *Pediatrics* 1991;87:598-603.
28. Gillespie SH. Failure of penicillin in Streptococcus pyogenes pharyngeal infection. *Lancet* 1998;352:1954-6.
29. Infectious Diseases and Immunization Committee. Treatment of group A Streptococcal pharyngitis. *Can J Infect Dis* 1997;8:17-18.
30. Jensen JH, Larsen SB. Treatment of recurrent acute tonsillitis with clindamycin: an alternative to tonsillectomy? *Clin Otolaryngol* 1991;16:498-500.
31. Lan AJ, Colford Jr JM. The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: a meta-analysis. *Pediatrics* 2000;105:e19.
32. Kociolek LK, Shulman ST. Pharyngitis. *Ann Intern Med* 2012;ITC3:1-16.
33. Mclsaac WJ, White D, Tannenbaum D, et al. A clinical score to reduce unnecessary antibiotic use in patients with sore throat. *Can Med Assoc J* 1998;158:75-83.
34. Orrling A, Stjernquist-Desatnik A, Schalen C, et al. Clindamycin in persisting streptococcal pharyngotonsillitis after penicillin treatment. *Scand J Infect Dis* 1994;26:535-41.
35. Parsons WD. The diagnosis and treatment of streptococcal pharyngitis. *Can Fam Physician* 1987;33:1445-8.
36. Peter G. Streptococcal pharyngitis: current therapy and criteria for evaluation of new agents. *Clin Infect Dis* 1992;14:S218-23.
37. Pichichero ME. Cephalosporins are superior to penicillin for treatment of streptococcal tonsillopharyngitis: is the difference worth it? *Pediatr Infect Dis J* 1993;12:268-74.
38. Pichichero ME, Margolis PA. A comparison of cephalosporins and penicillins in the treatment of group A beta-haemolytic streptococcal pharyngitis: a meta-analysis supporting the concept of microbial co-pathogenicity. *Pediatr Infect Dis J* 1991;10:275-81.

39. Schwartz B, Marcy SM, Phillips WR, et al. Pharyngitis – principles of judicious use of antimicrobial agents. *Pediatrics* 1998;101:171-3.
40. Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of Group A Streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2012;55:e86-102.
41. Shulman ST, Gerber MA. So what's wrong with penicillin for strep throat? *Pediatrics* 2004;113:1816-9.
42. Shulman ST, Gerber MA, Tanz RR, et al. Streptococcal pharyngitis: the case for penicillin therapy. *Pediatr Infect Dis J* 1994;13:1-7.
43. Snow S, Mottur-Pilson C, Cooper RJ, et al. Principles of appropriate antibiotic use for acute pharyngitis in adults. *Ann Intern Med* 2001;134:506-8.
44. Tan JS. Treatment recommendations for acute pharyngitis. *Curr Treatment Options Infect Dis* 2003;5:143-50.
45. Tanz RR, Poncher JR, Corydon KE, et al. Clindamycin treatment of chronic pharyngeal carriage of group A Streptococci. *J Pediatr* 1991;119:123-8.
46. Tanz RR, Shulman ST, Barthel MJ, et al. Penicillin plus rifampin eradicates pharyngeal carriage of group A streptococci. *J Pediatr* 1985;106:876-80.
47. Tanz RR, Shulman ST, Sroka PA, et al. Lack of influence of beta-lactamase producing flora on recovery of group A streptococci after treatment of acute pharyngitis. *J Pediatr* 1990;117:859-63.
48. Wessels MR. Streptococcal pharyngitis. *N Engl J Med* 2011;364:648-55.

Jugular Vein Septic Phlebitis

1. Riordan T. Human infection with *Fusobacterium necrophorum* (Necrobacillosis), with a focus on Lemierre's Syndrome. *Clin Micro Rev* 2007;20:622-59.

Pertussis (Whooping cough)

1. Aoyama T, Sunakawa K, Iwata S, et al. Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. *J Pediatr* 1996;129:761-4
2. Birkebaek NH, Kristiansen M, Seefeldt T, et al. *Bordetella pertussis* and chronic cough in adults. *Clin Infect Dis* 1999;29:1239-42.
3. Capital Health Regional Public Health. Pertussis. *Communicable Disease Corner* 1998;2:1-2.

4. Health Protection Agency guidelines for the public health management of pertussis 2012.
5. Hewlett EL, Edwards KM. Pertussis – not just for kids. *N Engl J Med* 2005;352:1215-22.
6. Mihaljevic F. Azithromycin in the treatment of pertussis in children: a pilot study. *ICMAS Abstract* 1996; Jan 24-27.
7. Parkins MD, McNeil SA, Laupland KB. Routine immunization of adults in Canada: Review of the epidemiology of vaccine-preventable diseases and current recommendations for primary prevention. *Can J Infect Dis Med Microbiol* 2009;20:e81-90.
8. Senzilet LD, Halperin SA, Spika JS, et al. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. *Clin Infect Dis* 2001;32:1691-7.
9. Singh M, Lingappan K. Whooping cough - the current scene. *Chest* 2006;130:1547-53.
10. Tozzi AE, Celentano LP, Ciofi degli Atti, ML, et al. Diagnosis and management of pertussis. *CMAJ* 2005;172:509-15.
11. Wirsing von Konig CH. Use of antibiotics in the prevention and treatment of pertussis. *Pediatr Infect Dis J* 2005;24:S66-8.

Croup

1. Alberta Medical Association. Guideline for the diagnosis and management of croup. Edmonton (AB): Toward Optimized Practice;2008. Available from: http://www.topalbertadoctors.org/uploads/croup_guideline.pdf
2. Cherry JD. Croup. *N Engl J Med* 2008;358:384-91.

Otitis Media

1. AHRQ. Management of acute otitis media. Summary, Evidence report/technology assessment: number 15, June 2000. Agency for Healthcare Quality and Research (AHRQ), Rockville, MD. <http://www.ahrq.gov/clinic/epcsums/otitisum.htm>
2. American Academy of Family Physicians, American Academy of Otolaryngology-Head and Neck Surgery and American Academy of Pediatrics. Otitis media with effusion. *Pediatrics* 2004;113:1412-29.
3. American Academy of Pediatrics and American Academy of Family Physicians. Clinical practice guideline. Diagnosis and management of acute otitis media. *Pediatrics* 2004;113:1451-65.
4. Anon. Drugs for treatment of acute otitis media in children. *Med Lett Drugs Ther* 1994;36:19-21.

5. Arrieta A, Arguedas A, Fernandez P, et al. High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media. *Antimicrob Agents Chemother* 2003;47:3179-86.
6. Arrieta A, Singh J. Management of recurrent and persistent acute otitis media: new options with familiar antibiotics. *Pediatr Infect Dis J* 2004;23:S115-24.
7. Boucher FD. The new macrolide antibiotics: use them carefully. *Paediatr Child Health* 1997;2:385-6.
8. Casselbrant ML, Kaleida PH, Rockette HE, et al. Efficacy of antimicrobial prophylaxis and of tympanostomy tube insertion for prevention of recurrent acute otitis media: results of a randomized clinical trial. *Pediatr Infect Dis J* 1992;11:278-86.
9. Coker TR, Chan LS, Newberry SJ, et al. Diagnosis, microbial epidemiology, and antibiotic treatment of acute otitis media in children. *JAMA* 2010;304:2161-9.
10. Courter JD, Baker WL, Nowak KS, et al. Increased clinical failures when treating acute otitis media with macrolides: a meta-analysis. *Ann Pharmacother* 2010;44:471-8.
11. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. *Pediatr Infect Dis J* 1996;15:944-8.
12. Dagan R, Abramson O, Leibovitz E, et al. Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. *Ped Infect Dis J* 1996;15:980-5.
13. Dagan R, et al. Bacteriologic and clinical efficacy of amoxicillin-clavulanate vs azithromycin in acute otitis media. *Pediatr Infect Dis J* 2000;19:95-104.
14. Delage G, Dery P, Gold R, et al. Consensus recommendations for the management of otitis media. *Can J Diagn* 1989;6:67-76.
15. Doern GV, Brueggemann A, Holley HP, et al. Antimicrobial resistance of *Streptococcus pneumoniae* recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. *Antimicrob Agents Chemother* 1996;40:1208-13.
16. Dowell SF, Butler JC, Giebink GS, et al. Acute otitis media: management and surveillance in an era of pneumococcal resistance – a report from the Drug-resistant *Streptococcus pneumoniae* Therapeutic Working Group. *Pediatr Infect Dis J* 1999;18:1-9.

17. Dowell SF, Marcy MS, Phillips WR, et al. Otitis media - principles of judicious use of antimicrobial agents. *Pediatrics* 1998;101:165-71.
18. Forgie S, Zhanel G, Robinson J. Management of acute otitis media. *Paediatr Child Health* 2009;14:ID 2009-01.
19. Froom J, Culpepper L, DeMelker RA, et al. Antimicrobials for acute otitis media? A review from the International Primary Care Network. *Brit Med J* 1997;315:98-102.
20. Glasziou PP, Del Mar CB, Sanders SL, et al. Antibiotics for acute otitis media in children (Cochrane Review). In: *The Cochrane Library*, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.
21. Green SM, Rothrock SG. Single-dose intramuscular ceftriaxone for acute otitis media in children. *Pediatrics* 1993;91:23-30.
22. Harrison CJ. Using antibiotic concentrations in middle ear fluid to predict potential clinical efficacy. *Pediatr Infect Dis J* 1997;16:S12-6.
23. Hedrick JA, Sher LD, Schwartz RH, et al. Cefprozil versus high-dose amoxicillin/clavulanate in children with acute otitis media. *Clin Therapeutics* 2001;23:193-204.
24. Hoberman A, Paradise JL, Rockette HE, et al. Shortened antimicrobial treatment for acute otitis media in young children. *N Engl J Med* 2016;375:2446-56.
25. Hoberman A, Paradise JL, Rockette HE, et al. Treatment of acute otitis media in children under 2 years of age. *N Engl J Med* 2011;364:105-15.
26. Kenna MA. Otitis media and the new guidelines. *J Otolaryngology* 2005;34(suppl 1):S24-32.
27. Klein JO. Is acute otitis media a treatable disease? *N Engl J Med* 2011;364:168-9.
28. Klein JO. Microbiologic efficacy of antibacterial drugs for acute otitis media. *Pediatr Infect Dis J* 1998;12:973-5.
29. Le Saux N, Gaboury I, Baird M, et al. A randomized, double-blind, placebo-controlled noninferiority trial of amoxicillin for clinically diagnosed acute otitis media in children 6 months to 5 years of age. *CMAJ* 2005;172:335-41.
30. Leiberman A, Leibovitz E, Piglansky L, et al. Bacteriologic and clinical efficacy of trimethoprim-sulfamethoxazole for treatment of acute otitis media. *Ped Infect Dis J* 2001;20:260-4.
31. Leibovitz E, et al. Bacteriologic efficacy of a three-day intramuscular ceftriaxone regimen in nonresponsive acute otitis media. *Ped Infect Dis J* 1998;17:1126-31.

32. Lieberthal AS, Carroll AE, Chonmaitree T, et al. The diagnosis and management of acute otitis media. *Pediatrics* 2013;131:e964–e99.
33. Little P, Gould C, Moore M, et al. Predictors of poor outcome and benefits from antibiotics in children with acute otitis media: pragmatic randomised trial. *BMJ* 2002;325:22-5.
34. Little P, Gould C, Williamson I, et al. Pragmatic randomized controlled trial of two prescribing strategies for childhood acute otitis media. *BMJ* 2001;322:336-42.
35. Mandel EM, Casselbrant ML. Recent developments in the treatment of otitis media with effusion. *Drugs* 2006;66:1565-76.
36. Marchisio P, Principi N, Sala E, et al. Comparative study of once-weekly azithromycin and once-daily amoxicillin treatments in prevention of recurrent acute otitis media in children. *Antimicrob Agents Chemother* 1996;40:2732-6.
37. Mclsaac WJ, Coyte PC, Croxford R, et al. Otolaryngologists' perceptions of the indications for tympanostomy tube insertion in children. *CMAJ* 2000;162:1285-8.
38. Paradise JL, Feldman HM, Campbell TF, et al. Tympanostomy tubes and developmental outcomes at 9 to 11 years of age. *N Engl J Med* 2007;356:248-61.
39. Schloss MD. Otitis media: to treat or not to treat? *Can Respir J* 1999;6:51-3A.
40. Simor AE, Louie M, The Canadian Bacterial Surveillance Network, and Low DE. Canadian national survey of prevalence of antimicrobial resistance among clinical isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 1996;40:2190-3.
41. Spiro DM, Arnold DH. The concept and practice of a wait-and-see approach to acute otitis media. *Curr Opin Peds* 2008;20:72-8.
42. Tahtinen PA, Laine MK, Huovinen P, et al. A placebo-controlled trial of antimicrobial treatment for acute otitis media. *N Engl J Med* 2011;364:116-26.
43. Trujillo M, Correa N, Olsen K, et al. Cefprozil concentrations in middle ear fluid of children with acute otitis media. *Pediatr Infect Dis J* 2000;19:268-70.
44. Uhari M, Mantysaari K, Niemela M. A meta-analytic review of the risk factors for acute otitis media. *Clin Infect Dis* 1996;22:1079-83.
45. Vouloumanou EK, Karageorgopoulos DE, Kazantzi MS, et al. Antibiotics versus placebo or watchful waiting for acute otitis media: a meta-analysis of randomized controlled trials. *J Antimicrob Chemother* 2009;64:16-24.

46. Wall GM, Stroman DW, Roland PS, et al. Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension for the topical treatment of ear infections. *Ped Infect Dis J* 2009;28:141-4.

Otitis Externa

1. Dohar JE. Evolution of management approaches for otitis externa. *Ped Infect Dis J* 2003;22:299-308.
2. Wooltorton E. Ototoxic effects from gentamicin ear drops. *Can Med Assoc J* 2002;167:56.

Sinusitis

1. Ahovuo-Saloranta A, Borisenko OV, Kovanen N, et al. Antibiotics for acute maxillary sinusitis. *Cochrane Database Syst Rev* 2008;2:CD000243.
2. Alberta Medical Association. Diagnosis and management of acute bacterial sinusitis. Edmonton (AB): Toward Optimized Practice;2008.
3. Bachert C, Fokkens W, Lund V, et al. Medical management of rhinosinusitis. *Respirology & Allergy Scientific Update* 2004;June.
4. Boucher FD. The new macrolide antibiotics: use them carefully. *Paediatr Child Health* 1997;2:385-6.
5. Brook I, Gooch WM, Jenkins SG, et al. Medical management of acute bacterial sinusitis. Recommendations of a clinical advisory committee on pediatric and adult sinusitis. *Ann Otol Rhinol Laryngol* 2000;109:1-20.
6. Chow AW, Benninger MS, Brook I, et al. IDSA clinical practice guidelines for acute bacterial rhinosinusitis in children and adults. *Clin Infect Dis* 2012;54:e72-112.
7. Consensus statement: summary diagnostic and therapeutic recommendations for sinusitis. *Hosp Med Suppl* 1997;33:54-5.
8. de Bock GH, Dekker FW, Stolk J, Springer MP, Kievit J, van Houwelingen JC. Antimicrobial treatment in acute maxillary sinusitis: a meta-analysis. *J Clin Epidemiol* 1997;50:881-90.
9. DeMuri GP, Wald ER. Complications of acute bacterial sinusitis in children. *Ped Infect Dis J* 2011;30:701-2.
10. Desrosiers M, Evans GA, Keith PK, et al. Canadian clinical practice guidelines for acute and chronic rhinosinusitis. *Allergy Asthma Clin Immunol* 2011;7:2.
11. Desrosiers M, Frenkiel S, Hamid QA, et al. Acute bacterial sinusitis in adults: management in the primary care setting. *J Otolaryngol* 2002;31(suppl 2):2S2-14.

12. Dykewicz MS, Hamilos DL. Rhinitis and sinusitis. *J Allergy Clin Immunol* 2010;125:103-15.
13. Evans KL. Recognition and management of sinusitis. *Drugs* 1998;56:59-71.
14. Falagas ME, Giannopoulou KP, Vardakas KZ, et al. Comparison of antibiotics with placebo for treatment of acute sinusitis: a meta-analysis of randomized controlled trials. *Lancet* 2008;8:543-52.
15. Falagas ME, Karageorgopoulos DE, Grammatikou AP, et al. Effectiveness and safety of short vs. long duration of antibiotic therapy for acute bacterial sinusitis: a meta-analysis of randomized trials. *Br J Clin Pharmacol* 2009;67:161-71.
16. Frenkiel S. Diagnosis and management of sinusitis. *Can J Diagn* 1998;Fall:2-7.
17. Garbutt JM, Banister C, Spitznagel E, et al. Amoxicillin for acute rhinosinusitis. *JAMA* 2012;307:685-92.
18. Garbutt JM, Goldstein M, Gellman E, et al. A randomized, placebo-controlled trial of antimicrobial treatment for children with clinically diagnosed acute sinusitis. *Pediatrics* 2001;107:619-25.
19. George DL, Falk PS, Meduri GU, et al. Nosocomial sinusitis in patients in the medical intensive care unit: a prospective epidemiological study. *Clin Infect Dis* 1998;27:463-70.
20. Gwaltney JM. Acute community acquired bacterial sinusitis: to treat or not to treat. *Can Respir J* 1999;6:46-50.
21. Gwaltney JM. Acute community-acquired sinusitis. *Clin Infect Dis* 1996;23:1209-25.
22. Hayward G, Heneghan C, Perera R, et al. Intranasal corticosteroids in management of acute sinusitis: a systematic review and meta-analysis. *Ann Fam Med* 2012;10:241-9.
23. Hickner JM, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for acute rhinosinusitis in adults: background. *Ann Intern Med* 2001;134:498-505.
24. Institute for Clinical Systems Integration. Acute sinusitis in adults. *Postgrad Med* 1998;103:154-68.
25. Ioannidis JPA, Lau J. Technical report: evidence for the diagnosis and treatment of acute uncomplicated sinusitis in children: a systematic overview. *Pediatrics* 2001;108:e57.
26. Karageorgopoulos DE, Giannopoulou KP, Grammatikou AP, et al. Fluoroquinolones compared with β -lactam antibiotics for the treatment of acute bacterial sinusitis: a meta-analysis of randomized controlled trials. *CMAJ* 2008;148:845-54.

27. Khianey R, Oppenheimer J. Is nasal saline irrigation all it is cracked up to be? *Ann Allergy Asthma Immunol* 2012;109:20-8.
28. Lemiengre MB, van Driel ML, Merenstein D, et al. Antibiotics for clinically diagnosed acute rhinosinusitis in adults (review). *Cochrane Database Systematic Reviews* 2012, Issue 10. Art. No.: CD006089. DOI: 10.1002/14651858.CD006089.pub4.
29. Low DE, Desrosiers M, McSherry J, et al. A practical guide for the diagnosis and treatment of acute sinusitis. *Can Med Assoc J* 1997;156:S1-14.
30. Nord CE. The role of anaerobic bacteria in recurrent episodes of sinusitis and tonsillitis. *Clin Infect Dis* 1995;20:1512-24.
31. Noyek A, Brodovsky D, Coyle S, et al. Classification, diagnosis and treatment of sinusitis: evidence-based clinical practice guidelines. *Can J Infect Dis* 1998;9:3B-24B.
32. O'Brien KL, Dowell SF, Schwartz B, et al. Acute sinusitis – principles of judicious use of antimicrobial agents. *Pediatrics* 1998;101:174-7.
33. Orlandi RR, Kingdom TT, Hwang PH. International consensus statement on allergy and rhinology: rhinosinusitis executive summary. *Int Forum Allergy Rhinol* 2016;6:S3-S21.
34. Payne SC, Benninger MS. *Staphylococcus aureus* is a major pathogen in acute bacterial rhinosinusitis: a meta-analysis. *Clin Infect Dis* 2007;45:121-7.
35. Piccirillo JF. Acute bacterial sinusitis. *N Engl J Med* 2004;351:902-10.
36. Piccirillo JF, Mager DE, Frisse ME, et al. Impact of first-line vs. second-line antibiotics for the treatment of acute uncomplicated sinusitis. *JAMA* 2001;286:1849-56.
37. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. *Otolaryngol Head Neck Surg* 2015;152(2S):S1-39.
38. Rosenfeld RM, Singer M, Jones S. Systematic review of antimicrobial therapy in patients with acute rhinosinusitis. *Otolaryngol Head Neck Surg* 2007;137:32-45.
39. Pichichero ME. Short course of antibiotic in acute otitis media and sinusitis infections. *J Int Med Res* 2000;28:25A-36A.
40. Rouby JJ, Laurent P, Gosnach M, et al. Risk factors and clinical relevance of nosocomial maxillary sinusitis in the critically ill. *Am J Resp Crit Care Med* 1994;150:776-83.
41. Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. *Otolaryngol Head Neck Surg* 2000;123:S4-31.

42. Smith MJ. Evidence for the diagnosis and treatment of acute uncomplicated sinusitis in children: a systematic review. *Pediatrics* 2013;132:e284–e96.
43. Snow V, Mottur-Pilson C, Hickner JM. Principles of appropriate antibiotic use for acute sinusitis in adults. *Ann Intern Med* 2001;134:495-7.
44. Stalman W, van Essen GA, van der Graaf Y, et al. The end of antibiotic treatment in adults with acute sinusitis-like complaints in general practice? A placebo-controlled double-blind randomized doxycycline trial. *Br J Gen Pract* 1997;47:794-9.
45. Stein M, Caplan ES. Nosocomial sinusitis: a unique subset of sinusitis. *Curr Opin Infect Dis* 2005;18:147-50.
46. Talmor M, Li P, Barie PS. Acute paranasal sinusitis in critically ill patients: guidelines for prevention, diagnosis, and treatment. *Clin Infect Dis* 1997;25:1441-6.
47. Tan B. Acute sinusitis in children. *Paediatr Child Health* 1997;2:314-6.
48. Taverner D, Latte J. Nasal decongestants for the common cold. *Cochrane Database Syst Rev* 2007;1:CD001953.
49. Van Buchem FL, Knottnerus JA, Schrijnemaekers VJ, et al. Primary-care-based randomised placebo-controlled trial of antibiotic treatment in acute maxillary sinusitis. *Lancet* 1997;349:683-7.
50. Venekamp RP, Bonten MJM, Rovers MM, et al. Systemic corticosteroid monotherapy for clinically diagnosed acute rhinosinusitis: a randomized controlled trial. *CMAJ* 2012;184:e7517.
51. Venekamp RP, Thompson MJ, Hayward G, et al. Systemic corticosteroids for acute sinusitis. *Cochrane Database Systematic Reviews* 2011, Issue 12. Art. No.: CD008115. DOI: 10.1002/14651858.CD008115.pub2.
52. Wald ER, Bordley WC, Darrow DH, et al. American Academy of Pediatrics clinical practice guideline: management of sinusitis. *Pediatrics* 2001;108:798-808.
53. Westergren V, Lundblad L, Hellquist HB, et al. Ventilator-associated sinusitis: a review. *Clin Infect Dis* 1998;27:851-64.
54. Williamson IG, Rumsby K, Benge S, et al. Antibiotics and topical nasal steroid for treatment of acute maxillary sinusitis. *JAMA* 2007;298:2487-96.
55. Williams Jr JW, Aguilar C, Makela M, et al. Antibiotics for acute maxillary sinusitis (Cochrane Review). In: *The Cochrane Library*, Issue 4, 2001. Oxford: Update Software.

56. Wilson JF. Acute sinusitis. *Ann Intern Med* 2010.
57. Young J, De Sutter A, Merenstein D, et al. Antibiotics for adults with clinically diagnosed acute rhinosinusitis: a meta-analysis of individual patient data. *Lancet* 2008;371:908-14.
58. Zalmanovici A, Yaphe J. Intranasal steroids for acute sinusitis. *Cochrane Database Syst Rev* 2009;4:CD005149.
59. Zucher DR, Balk E, Engels E, et al. Agency for Health Care Policy and Research Publication No. 99-E016: Evidence report/technology assessment Number 9. Diagnosis and treatment of acute bacterial rhinosinusitis. www.ahcpr.gov/clinic/sinussum.htm

Parapharyngeal space infections

1. Craig FW, Schunk JE. Retropharyngeal abscess in children: clinical presentation, utility of imaging, and current management. *Pediatrics* 2003;111:1394-8.
2. Gilmore WC, Jacobus NV, Gorbach SL, et al. A prospective double-blind evaluation of penicillin versus clindamycin in the treatment of odontogenic infections. *J Oral Maxillofac Surg* 1988;46:1065-70.
3. Kristensen LH, Prag J. Human necrobacillosis, with emphasis on Lemierre's Syndrome. *Clin Infect Dis* 2000;31:524-32.

Acute Cervical Adenitis

1. Margileth AM. Cervical adenitis. *Pediatr Rev* 1985;7:13-24.

Bronchitis

1. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 1987;106:196-204.
2. Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. *Ann Intern Med* 2001;134:600-20.
3. Ballow CH, Hyatt JM, Peloquin CA, et al. Effectiveness of grepafloxacin vs. clarithromycin for bacterial eradication in chronic bronchitis. Presented at the 36th Annual Meeting of Infectious Diseases Society of America; Denver, CA; Nov. 12-15, 1998. (Abstract 176 Sa)
4. Balter MS, La Forge J, Low DE, et al. Canadian guidelines for the management of acute exacerbations of chronic bronchitis. *Can Respir J* 2003;10(suppl B):3B-32B.

5. Chodosh S. Treatment of acute exacerbations of chronic bronchitis: state of the art. *Am J Med* 1991;91:87-92.
6. Chodosh S. Use of quinolones for the treatment of acute exacerbations of chronic bronchitis. *Am J Med* 1991;91:93-100.
7. Daniels JMA, Snijders D, de Graaff CS, et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2010;181:150-7.
8. Dimopoulos G, Siempos II, Korbila IP, et al. Comparison of first-line with second-line antibiotics for acute exacerbations of chronic bronchitis: A metaanalysis of randomized controlled trials. *Chest* 2007;132:447-55.
9. Falagas ME, Avgeri SG, Matthaïou DK, et al. Short-versus long-duration antimicrobial treatment for exacerbations of chronic bronchitis: a meta-analysis. *J Antimicrob Chemother* 2008;62:442-50.
10. Forward K, Gold R, Gribble M, et al. Consensus recommendations for management of acute exacerbations of chronic bronchitis. *Can J Diagn* 1990;7:129-39.
11. Gonzales R, Bartlett JG, Besser RE, et al. Principles of appropriate antibiotic use for treatment of uncomplicated acute bronchitis: background. *Ann Intern Med* 2001;134:521-9.
12. Gonzales R, Sande MA. Uncomplicated acute bronchitis. *Ann Intern Med* 2000;133:981-91.
13. Grayston JT, Aldous MB, Easton A, et al. Evidence that *Chlamydia pneumoniae* causes pneumonia and bronchitis. *J Infect Dis* 1993;168:1231-5.
14. Grossman R. Respiratory tract infections: therapeutic considerations. *Can J Diagn* 1999;Winter:2-7.
15. Grossman RF. Management of acute exacerbation of chronic bronchitis. *Can Respir J* 1999;6:40-5.
16. Ho PL, Tse WS, Tsang KWT, et al. Risk factors for acquisition of levofloxacin-resistant *Streptococcus pneumoniae*: a case-control study. *Clin Infect Dis* 2001;32:701-7.
17. Ilowite J, Spiegler P, Chawla S. Bronchiectasis: new findings in the pathogenesis and treatment of this disease. *Curr Opin Infect Dis* 2008;21:163-7.
18. Irwin RS, Madison JM. The diagnosis and treatment of cough. *New Engl J Med* 2000;343:1715-21.
19. Madaras-Kelly KJ, Magdanz SB, Johnson CK, et al. Clinical outcome of ambulatory acute exacerbations of chronic bronchitis with older versus newer antimicrobials. *Ann Pharmacother* 2002;36:975-80.

20. O'Brien KL, Dowell SF, Schwartz B, et al. Cough illness/bronchitis – principles of judicious use of antimicrobial agents. *Pediatrics* 1998;178-81.
21. Orr PH, Scherer K, Macdonald A, et al. Randomized placebo-controlled trials of antibiotics for acute bronchitis: a critical review of the literature. *J Fam Pract* 1993;36:507-12.
22. Pauwels RA, Buist AS, Calverley PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2001;163:1256-76.
23. Quon BS, Qi Gan W, Sin DD. Contemporary management of acute exacerbations of COPD: A systematic review and metaanalysis. *Chest* 2008;133:756-66.
24. Rizkallah J, Man SFP, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: A systematic review and metaanalysis. *Chest* 2009;135:786-93.
25. Russo RL, D'Aprile M. Role of antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. *Ann Pharmacother* 2001;35:576-81.
26. Saint S, Bent S, Vittinghoff E, et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. *JAMA* 1995;273:957-60.
27. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. *N Engl J Med* 2008;359:2355-65.
28. Smucny J, Fahey T, Becker L, et al. Antibiotics for acute bronchitis. *Cochrane Database of Systematic Reviews* 200;4:CD000245.
29. Snow V, Lascher S, Mottur-Pilson C. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. *Ann Intern Med* 2001;134:595-9.
30. Snow V, Mottur-Pilson C, Gonzales R. Principles of appropriate antibiotic use for treatment of acute bronchitis in adults. *Ann Intern Med* 2001;134:518-20.
31. Verghese A, Ismail HM. Acute exacerbations of chronic bronchitis. *Postgrad Med* 1994;96:75-89.
32. Wenzel RP, Fowler AA. Acute Bronchitis. *N Eng J Med* 2006;355-:2125-30.

Bronchiolitis

1. Subcommittee on the Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. www.pediatrics.org/cgi/dol/10.1542/peds.2006-2223.
2. Tregoning JS, Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. *Clin Microb Rev* 2010;74-98.
3. Zorc JJ, Hall CB. Bronchiolitis: recent evidence on diagnosis and management. *Pediatrics* 2010;125:342-9.

Pneumocystis Pneumonia

1. Krajcik BJ, Thomas CF, Limper AH. Pneumocystis pneumonia: current concepts in pathogenesis, diagnosis and treatment. *Clin Chest Med* 2009;30;265-78.

Pneumonia

1. Ailani RK, Agastya G, Ailani RK, et al. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. *Arch Intern Med* 1999;159:266-70.
2. Alberta Medical Association. Guideline for the diagnosis and management of community-acquired pneumonia: Adult. Feb 2002.
3. Alberta Medical Association. Guideline for the diagnosis and management of community-acquired pneumonia: Pediatric. Jan 2002.
4. Alberta Medical Association. Guideline for the diagnosis and management of nursing home acquired pneumonia. Sep 2002.
5. American Thoracic Society. Guidelines for the management of adults with community -acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy and prevention. *Am J Respir Crit Care Med* 2001;163:1730-54.
6. Bartlett JG, Mundy LM. Community-acquired pneumonia. *N Engl J Med* 1995;333:1618-24.
7. Baselski VS, Wunderink RG. Bronchoscopic diagnosis of pneumonia. *Clin Microbiol Rev* 1994;7:533-58.
8. Battleman DS, Callahan M, Thaler HT. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia. *Arch Intern Med* 2002;162:682-8.
9. Boucher FD. The new macrolide antibiotics: use them carefully. *Paediatr Child Health* 1997;2:385-6.

10. Bradley JS. Management of community-acquired pediatric pneumonia in an era of increasing antibiotic resistance and conjugate vaccines. *Pediatr Infect Dis J* 2002;21:592-8.
11. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. *Clin Infect Dis* 2011.
12. British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. *Thorax* 2001;56 Suppl 4:IV 1-64.
13. Chiou CC. Does penicillin remain the drug of choice for pneumococcal pneumonia in view of emerging in vitro resistance? *Clin Infect Dis* 2006;42:234-7.
14. Confalonieri M, Urbino R, Potena A, et al. Hydrocortisone infusion for severe community-acquired pneumonia. A preliminary randomized study. *Am J Respir Crit Care Med* 2005;171:242-8.
15. Cunha BA. Doxycycline for community-acquired pneumonia. *Clin Infect Dis* 2003;37:870.
16. Davies HD. Community-acquired pneumonia in children. *Paediatrics & Child Health* 2003;8:616-9.
17. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. *Clin Infect Dis* 2003;37:752-60.
18. El-Solh AA. Nursing home acquired pneumonia: approach to management. *Curr Opin Infect Dis* 2011;24:148-151.
19. El Solh AA, Alhajhusain A. Update on the treatment of *Pseudomonas aeruginosa* pneumonia. *J Antimicrob Chemother* 2009;64:229-38.
20. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. *Medicine* 1990;69:307-16.
21. Finch RG, Woodhead MA. Practical considerations and guidelines for the management of community-acquired pneumonia. *Drugs* 1998;55:31-45.
22. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community acquired pneumonia. *N Engl J Med* 1997;336:243-50.
23. Garau J. Clinical implications of resistance in the management of respiratory tract infections. *Can Respir J* 1999;6:23-6.

24. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for *Pseudomonas aeruginosa* ventilator-associated pneumonia: An observational, multicenter study comparing monotherapy with combination antibiotic therapy. *Crit Care Med* 2007;35:1888-95.
25. Goldstein RA, Rohatgi PK, Bergofsky EH, et al. Clinical role of bronchoalveolar lavage in adults with pulmonary disease. *Am Rev Respir Dis* 1990;142:481-6.
26. Gorman SK, Slavik RS, Marin J. Corticosteroid treatment of severe community-acquired pneumonia. *Ann Pharmacother* 2007;41:1233-7.
27. Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. *J Infect Dis* 1999;179:25-30.
28. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. *Arch Intern Med* 2000;160:1399-1408.
29. High KP, Bradley SF, Gravenstein S, et al. Clinical practice guideline for the evaluation of fever and infection in older adult residents of long-term care facilities: 2008 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009;48:149-71.
30. Hoban DJ, Karlowsky JA, Zhanel GG, et al. Evolving patterns of resistance to respiratory pathogens in Canada. *Can Respir J* 1999;6:27-30.
31. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. *Arch Intern Med* 2004;164:637-44.
32. Jadavji T, Law B, Lebel MH, et al. A practical guide for the diagnosis and treatment of pediatric pneumonia. *Can Med Assoc J* 1997;156:S703-11.
33. Johnson JR. Doxycycline for the treatment of community-acquired pneumonia. *Clin Infect Dis* 2002;35:632.
34. Jones RN, Sader HS, Fritsche TR. Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against *Streptococcus pneumoniae* (1999-2002). *Diagn Microbiol Infect Dis* 2004;49:147-9.
35. Laheij RJ, Sturkenboom MCJM, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. *JAMA* 2004;292:1955-60.

36. Le Saux N, Robinson JL. Pneumonia in healthy Canadian children and youth: Practice points for management. *Paed Child Health* 2011;16:417-20.
37. Le Saux N, Robinson JL. Uncomplicated pneumonia in healthy Canadian children and youth: practice points for management. *Paediatr Child Health* 2015;20:441-5.
38. Lim WS, vander Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax* 2003;58:377-82.
39. Lynch JP, Martinez FJ. Clinical relevance of macrolide-resistant *Streptococcus pneumoniae* for community-acquired pneumonia. *Clin Infect Dis* 2002;34(suppl 1):S27-46.
40. Kollef MH, Morrow LE, Baughman RP, et al. Health care-associated pneumonia (HCAP): a critical appraisal to improve identification, management, and outcomes - proceedings of the HCAP Summit. *Clin Infect Dis* 2008;46:296-334.
41. MacFarlane JT, Colville A, Guion A, et al. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. *Lancet* 1993;341:511-4.
42. Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. *Clin Infect Dis* 2003;37:1405-33.
43. Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. *Clin Infect Dis* 2000;31:383-421.
44. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2007;44:27-72.
45. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. *JAMA* 2000;283:749-55.
46. Marrie TJ. Risks and outcomes in community acquired pneumonia. *Can Respir J* 1999;6:6-9.
47. Marrie TJ. Community-acquired pneumonia in the elderly. *Clin Infect Dis* 2000;31:1066-78.
48. Marrie TJ. Importance of *Streptococcus pneumoniae* in community-acquired pneumonia. *Can J Infect Dis* 1999;10:19-21.

49. Martinez FJ. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients. *Clin Infect Dis* 2004;38(suppl 4):S328-40.
50. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a β -lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. *Clin Infect Dis* 2003;36:389-95.
51. McIntosh K. Community-acquired pneumonia in children. *N Engl J Med* 2002;346:429-37.
52. Meijvis SC, Hardeman H, Remmelts HH, et al. Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial. *Lancet* 2011;377:2023-30.
53. Mills GD, Oehley MR, Arrol B. Effectiveness of β -lactam antibiotics compared with antibiotics active against atypical pathogens in non-severe community acquired pneumonia: meta analysis. *BMJ* 2005;330:456-63.
54. Mylotte JM. Nursing home-acquired pneumonia. *Clin Infect Dis* 2002;35:1205-11.
55. Peterson LR. Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? *Clin Infect Dis* 2006;42:224-33.
56. Rello J, Rodriguez R, Jubert P, et al. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. *Clin Infect Dis* 1996;23:723-8.
57. Restrepo MI, Mortensen EM, Anzueto A. Common medications that increase the risk for developing community-acquired pneumonia. *Curr Opin Infect Dis* 2010;23:145-51.
58. Roord JJ, Wolf BHM, Goossens MMHT, et al. Prospective open randomized study comparing efficacies and safeties of a 3-day course of azithromycin in children with community-acquired acute lower respiratory tract infections. *Antimicrob Agents Chemother* 1996;40:2765-8.
59. Schutze GE, Jacobs RF. Management of community-acquired bacterial pneumonia in hospitalized children. *Pediatr Infect Dis J* 1992;11:160-4.
60. Shulman ST, Bartlett J, Clyde WA, et al. The unusual severity of mycoplasmal pneumonia in children with sickle-cell disease. *N Engl J Med* 1972;287:164-7.
61. Talan DA, Moran GJ. Emergency department management of pneumonia. *Can Respir J* 1999;6:10-14.

62. Tan JS. Role of 'atypical' pneumonia pathogens in respiratory tract infections. *Can Respir J* 1999;6:15-9.
63. Troy CJ, Peeling RW, Ellis AG, et al. Chlamydia pneumoniae as a new source of infectious outbreaks in nursing homes. *JAMA* 1997;277:1214-18.
64. Vergis EN, Indorf A, File TM, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients. *Arch Intern Med* 2000;160:1294-1300.

Aspiration Pneumonia

1. Bartlett JG, Gorbach SL. Treatment of aspiration pneumonia and primary lung abscess. *JAMA* 1975;234:935-7.
2. Finegold SM. Aspiration pneumonia. *Rev Infect Dis* 1991;13:S737-42.
3. Marik PE. Aspiration pneumonitis and aspiration pneumonia. *N Engl J Med* 2001;344:665-71.

Nosocomial Pneumonia

1. Bartlett JG, O'Keefe P, Tally FP, et al. Bacteriology of hospital-acquired pneumonia. *Arch Intern Med* 1986;146:868-71.
2. Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of *Pseudomonas aeruginosa* infections. *Clin Infect Dis* 2005;40:S99-104.
3. Cunha BA. The antibiotic treatment of community-acquired, atypical, and nosocomial pneumonias. *Med Clin North Am* 1995;79:581-97.
4. Ferguson ND, Grossman RF. Hospital-acquired pneumonia: fighting the germs. *Can J Diagnosis* 1997;Feb:95-108.
5. Fiel S. Guidelines and critical pathways for severe hospital-acquired pneumonia. *Chest* 2001;119(2 suppl):412S-18S.
6. Garau J, Bouza E, Chastre J, et al. Management of methicillin-resistant *Staphylococcus aureus* infections. *Clin Microbiol Infect* 2009;15:125-136.
7. Gotfried MH, Danzinger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. *Chest* 2001;119:1114-22.
8. Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant *Staphylococcus aureus* hospital-acquired, ventilator-associated, or health-care-associated pneumonia. *Chest* 2010 138:1356-62.

9. Kalil AC, Murthy MH, Hermsen ED, et al. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. *Crit Care Med* 2010;38;1802-8.
10. Lynch JP. Hospital-acquired pneumonia. Risk factors, microbiology, and treatment. *Chest* 2001;119(2 suppl):373S-84S.
11. Mallow S, Rebuck JA, Osler T, et al. Do proton pump inhibitors increase the incidence of nosocomial pneumonia and related infectious complications when compared with histamine-2 receptor antagonists in critically ill trauma patients? *Curr Surg* 2004;61;452-8.
12. Mandell LA, Marrie TJ, Niederman MS. The Canadian Hospital Acquired Pneumonia Consensus Conference Group. Initial antimicrobial treatment of hospital acquired pneumonia in adults: a conference report. *Can J Infect Dis* 1993;4:317-21.
13. Masterton RG, Galloway A, French G, et al. Guidelines for the management of hospital-acquired pneumonia in the UK: report of the working party on hospital-acquired pneumonia of the British Society for Antimicrobial Chemotherapy. *J Antimicrob Chemo* 2008;62;5-34.
14. Rotstein C, Evans G, Born A, et al. Clinical practice guidelines for hospital-acquired pneumonia and ventilator-associated pneumonia in adults. *Can J Infect Dis Med Microbiol* 2008;19:19-53.
15. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis* 2008;46;378-85.
16. Scheld WM, Mandell GL. Nosocomial pneumonia: pathogenesis and recent advances in diagnosis and therapy. *Rev Infect Dis* 1991;13:S743-51.
17. Tobin MJ, Grenvik A. Nosocomial lung infection and its diagnosis. *Crit Care Med* 1984;12:191-7.
18. Torres A, Rello J. Update in community-acquired and nosocomial pneumonia 2009. *Am J Respir Crit Care Med* 2010;181;782-7.
19. Unertl KE, Lenhart FP, Forst H, et al. Systemic antibiotic treatment of nosocomial pneumonia. *Intensive Care Med* 1992;18:S28-34.
20. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. *Clin Ther* 2003;25:485-506.
21. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant *Staphylococcus aureus* nosocomial pneumonia: a randomized, controlled study. *Clin Infect Dis* 2012

Ventilator-Associated Pneumonia

1. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 2005;171:388-416.
2. Barcenilla F, Gasco E, Rello J, et al. Antibacterial treatment of invasive mechanical ventilation – associated pneumonia. *Drugs & Aging* 2001;18:189-200.
3. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. A randomized trial. *JAMA* 2003;290:2588-98.
4. Koenig SM, Truitt JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. *Clin Microb Rev* 2006;19:637-57.
5. Kollef MH. The prevention of ventilator-associated pneumonia. *N Engl J Med* 1999;340:627-34.
6. Kollef MH. Ventilator-associated pneumonia: the importance of initial empiric antibiotic selection. *Infect Med* 2000;17:265-8, 278-83.
7. McQuillen DP, Duncan RA, Craven DE. Ventilator-associated pneumonia: emerging principles of management. *Infect Med* 2005;22:104-18.
8. Morehead RS, Pinto SJ. Ventilator-associated pneumonia. *Arch Intern Med* 2000;160:1926-36.
9. Muscedere J, Dodek P, Keenan S, et al. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. *J Crit Care* 2008;23:138-47.
10. Muscedere J, Dodek P, Keenan S, et al. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: prevention. *J Crit Care* 2008;23:126-37.
11. Principi N, Esposito S. Ventilator-associated pneumonia (VAP) in pediatric intensive care units. *Pediatr Infect Dis J* 2007;26:841-44.

Cystic fibrosis

1. Burkhardt O, Lehmann C, Madabushi R, et al. Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? *J Antimicrob Chemother* 2006;58:822-9.
2. Coulthard KP, Peckham DG, Conway SP, et al. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis - caution with trough concentrations. *J Cystic Fibrosis* 2007;6:125-30.

3. Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. *J Cystic Fibrosis* 2007;6:327-33.

Influenza

1. Anon. Antiviral agents for the treatment and chemoprophylaxis of influenza. *MMWR* 2011;60.
2. Anon. Antiviral drugs for prophylaxis and treatment of influenza. *Med Lett Drugs Ther* 2005;47:93-5.
3. Anon. Policy statement - recommendations for prevention and control of influenza in children, 2010-2011. *Am Ac Peds*.
4. Aoki FY, Allen DU, Stiver HG, et al. The use of antiviral drugs for influenza: guidance for practitioners, 2010-11.
5. Jefferson T, Jones M, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. *BMJ* 2009;339:1-8.
6. Smith JR, Ariano RE, Toovey S. The use of antiviral agents for the management of severe influenza. *Crit Care Med* 2010;38;43-51.

Lung abscess

1. Bartlett JG. Anaerobic bacterial infections of the lung and pleural space. *Clin Infect Dis* 1993;16:S248-55.
2. Bartlett JG, Gorbach SL. Penicillin or clindamycin for primary lung abscess? *Ann Intern Med* 1983;98:546-8.
3. Bartlett JG, Gorbach SL. Treatment of aspiration pneumonia and primary lung abscess. *JAMA* 1975;234:935-7.
4. Gadkowski LB, Stout JE. Cavitary pulmonary disease. *Clin Microb Rev* 2008;21;305-33.
5. Gudiol F, Manresa F, Pallares R, et al. Clindamycin vs penicillin for anaerobic lung infections: high rate of penicillin failures associated with penicillin-resistant *Bacteroides melaninogenicus*. *Arch Intern Med* 1990;150:2525-9.
6. Levison ME, Mangura CT, Lorber B, et al. Clindamycin compared with penicillin for the treatment of anaerobic lung abscess. *Ann Intern Med* 1983;98:466-71.
7. Marina M, Strong CA, Civen R, et al. Bacteriology of anaerobic pleuropulmonary infections: preliminary report. *Clin Infect Dis* 1993;16:256-62.

8. Perlino CA. Metronidazole vs clindamycin treatment of anaerobic pulmonary infection: failure of metronidazole therapy. *Arch Intern Med* 1981;141:1424-7.
9. Yazbeck MF, Dahdel M, Kalra A, et al. Lung abscess: update on microbiology and management. *Am J Therapeut* 2012.

Empyema

1. Bryant RE, Salmon CJ. Pleural empyema. *Clin Infect Dis* 1996;22:747-64.
2. Heffner J. Multicenter trials of treatment for empyema – after all these years. *New Engl J Med* 2005;352:926-28.
3. Koegelenberg CFN, Diacon AH, Bolliger CT. Parapneumonic pleural effusion and empyema. *Respiration* 2008;75:241-50.
4. Maskell NA, Davies CWH, Nunn AJ, et al. U.K. controlled trial of intrapleural streptokinase for pleural infection. *N Engl J Med* 2005;352:865-74.
5. Misthos P, Sepsas E, Konstantinou M, et al. Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. *Europ J Cardio-Thor Surg* 2005;28:599-603.
6. Rahman NM, Chapman SJ, Davies RJO. The approach to the patient with a parapneumonic effusion. *Clin Chest Med* 2006;27:253-66.
7. Sahn SA. Diagnosis and management of parapneumonic effusions and empyema. *Clin Infect Dis* 2007;45:1480-6.
8. Schiza S, Siafakas NM. Clinical presentation and management of empyema, lung abscess and pleural effusion. *Curr Opin Pulm Med* 2006;12:205-12.

Tuberculosis

1. Anon. Active tuberculosis: diagnosis and management guideline.
2. Anon. Treatment guidelines: drugs for tuberculosis. 2009:7.
3. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. *Am J Respir Crit Care Med* 2003;167:603-62. Reprinted in: *Morb Mortal Weekly Rep* 2003;52(No. RR-11):1-77.
<http://www.cdc.gov/mmwr/PDF/rr/rr5211.pdf>
4. Canadian Thoracic Society (CTS) of the Canadian Lung Association (CLA) and the Public Health Agency of Canada (PHAC). *Canadian Tuberculosis Standards, 7th Edition, 2013.*
<http://www.respiratoryguidelines.ca/tb-standards-2013>

5. Dooley KE, Golub J, Goes FS, et al. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. *Clin Infect Dis* 2002;34:1607-12.
6. Horsburgh Jr CR, Feldman S, Ridzon R. Practice guidelines for the treatment of tuberculosis. *Clin Infect Dis* 2000; 31: 633-9
7. Long R, Ellis E. Introducing the sixth edition of the Canadian Tuberculosis Standards. *Can J Infect Dis Med Microbiol* 2007;18;283.
8. Small PM, Fujiwara PI. Management of tuberculosis in the United States. *N Engl J Med* 2001;345:189-200.
9. Treatment of tuberculosis. National Guideline Clearinghouse 2004.

Gastrointestinal

Gastroenteritis

1. Abbott SL, Janda JM. Bacterial gastroenteritis I: incidence and etiologic agents. *Clin Microbiol Newslett* 1992;14:17-20.
2. Abbott SL, Janda JM. Bacterial gastroenteritis II: pathogenesis and laboratory identification. *Clin Microbiol Newslett* 1992;14:25-8.
3. Alberta Clinical Practice Guidelines Working Group. Laboratory guidelines for ordering stool tests for investigation of suspected infectious diarrhea. 1997;1-6.
4. Bhattacharya SK, Bhattacharya MK, Dutta D, et al. Single-dose ciprofloxacin for shigellosis in adults.
5. Burke V, Gracey M, Robinson J, et al. The microbiology of childhood gastroenteritis: *Aeromonas* species and other infective agents. *J Infect Dis* 1983;148:68-74.
6. Chinh NT, Parry CM, Thi Ly N, et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. *Antimicrob Agents Chemother* 2000;44:1855-9.
7. Dryden MS, Gabb RJE, Wright SK. Empirical treatment of severe acute community-acquired gastroenteritis with ciprofloxacin. *Clin Infect Dis* 1996;22:1019-25.
8. Dryden MS, Keyworlth N, Gabb R, et al. Asymptomatic foodhandlers as the source of nosocomial salmonellosis. *J Hosp Infect* 1994;28:195-208.
9. DuPont HL. Bacterial diarrhea. *N Engl J Med* 2009;361:1560-9.
10. Galanis E. *Campylobacter* and bacterial gastroenteritis. *CMAJ* 2007;177:570-1.

11. Gallagher JC, Du JK, Rose C. Severe pseudomembranous colitis after moxifloxacin use: a case series. *Ann Pharmacother* 2009;43:123-8.
12. Girgis NI, Butler T, Frenck RW, et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. *Antimicrob Agents Chemother* 1999;43:1441-4.
13. Guerrant RL, Bobak DA. Bacterial and protozoal gastroenteritis. *N Engl J Med* 1991;325:327-40.
14. Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. *Clin Infect Dis* 2001;32:331-351.
15. Khan WA, Saha D, Rahman A, et al. Comparison of single-dose azithromycin and 12-dose, 3-day erythromycin for childhood cholera: a randomised, double-blind trial. *Lancet* 2002;360:1722-7.
16. Pennington H. *Escherichia coli* O157. *Lancet* 2010;376:1428-35.
17. Wistrom J, Jertborn M, Ekwall E, et al. Empiric treatment of acute diarrheal disease with norfloxacin: a randomized, placebo-controlled study. *Ann Intern Med* 1992;117:202-8.
18. Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of *Escherichia coli* O157:H7 infections. *N Engl J Med* 2000;342:1930-6.

Travellers' diarrhea

1. Anon. Advice for Travelers. *Med Lett Treatment Guidelines* 2009;7:83-94.
2. Anon. Drugs for travelers' diarrhea. *Med Lett* 2008;50:58-9.
3. Adachi JA, Ostrosky-Zeichner L, DuPont HL, et al. Empirical antimicrobial therapy for traveler's diarrhea. *Clin Infect Dis* 2000;31:1079-83.
4. CATMAT. Statement on travellers' diarrhea. *Can Commun Dis Rep* 1994;20-17:149-56.
5. Committee to Advise on Tropical Medicine and Travel (CATMAT). Statement on travellers' diarrhea. *Canada Communicable Disease Report* 2001;27(ACS-3).
6. Diemert DJ. Prevention and self-treatment of traveler's diarrhea. *Clin Microbiol Rev* 2006;19:583-94.
7. DuPont HL. Therapy for and prevention of traveler's diarrhea. *Clin Infect Dis* 2007;45:S78-84.

8. DuPont HL, Ericsson CD. Prevention and treatment of traveler's diarrhea. *N Engl J Med* 1993;328:1821-7.
9. Ericsson CD, DuPont HL. Traveler's diarrhea: approaches to prevention and treatment. *Clin Infect Dis* 1993;16:616-26.
10. Hill DR, Beeching NJ. Travelers' diarrhea. *Curr Opin Infect Dis* 2010;23:481-7.
11. Mackell S. Traveler's diarrhea in the pediatric population: etiology and impact. *Clin Infect Dis* 2005;41:S547-52.
12. McCarthy AE, Mileno MD. Prevention and treatment of travel-related infections in compromised hosts. *Curr Opin Infect Dis* 2006;19:450-5.
13. Okhuysen PC. Current concepts in travelers' diarrhea: epidemiology, antimicrobial resistance and treatment. *Curr Opin Infect Dis* 2005;18:522-6.
14. Wolfe MS. Protection of travelers. *Clin Infect Dis* 1997;25:177-86.

***Clostridium difficile* infection (CDI)**

1. Al-Nassir WN, Sethi AK, Nerandzic MM, et al. Comparison of clinical and microbiological response to treatment of *Clostridium difficile*-associated disease with metronidazole and vancomycin. *Clin Infect Dis* 2008;47:56-62.
2. Anand A, Bashey B, Mir T, et al. Epidemiology, clinical manifestations, and outcome of *Clostridium difficile* - associated diarrhea. *Am J Gastroenterol* 1994;89:519-23.
3. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe *Clostridium difficile* colitis: case series and review of the literature. *Clin Infect Dis* 2002;35:690-6.
4. Bakken JS, Borody T, Brandt LJ, et al. Treating *clostridium difficile* infection with fecal microbiota transplantation. *Clin Gastro and Hep* 2011;9:1044-9.
5. Bartlett JG. Antibiotic-associated diarrhea. *N Engl J Med* 2002;346:334-9.
6. Bauer, MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for *Clostridium difficile* infection (CDI). *Clin Microbiol Infect Dis* 2009;15:1067-79.
7. Bryant K, McDonald LC. *Clostridium difficile* infections in children. *Pediatr Infect Dis J* 2009;28:145-6.
8. Buggy BP, Fekety R, Silva J Jr. Therapy of relapsing *Clostridium difficile* – associated diarrhea and colitis with the combination of vancomycin and rifampin. *J Clin Gastroenterol* 1987;9:155-9.

9. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). *Infect Control Hosp Epidemiol* 2010;31:431-55.
10. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for *Clostridium difficile* diarrhea. *J Hospital Infection* 2003;54:243-5.
11. Dalton BR, Lye-MacCannell T, Henderson EA, et al. Proton pump inhibitors increase significantly the risk of *Clostridium difficile* infection in a low-endemicity, non-outbreak hospital setting. *Aliment Pharmacol Ther* 2008;29:626-34.
12. Deshpande A, Pant C, Pasupuleti V, et al. Association between proton pump inhibitor therapy and *Clostridium difficile* infection in a meta-analysis. *Clin Gastroenterol Hepatol* 2012;article in press.
13. Dial S, Alrasadi K, Manoukian C, et al. Risk of *Clostridium difficile* diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. *CMAJ* 2004;171:33-8.
14. Dial S, Delaney JAC, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired *Clostridium difficile* disease. *JAMA* 2005;294:2989-95.
15. Dial S, Kezouh A, Dascal A, et al. Patterns of antibiotic use and risk of hospital admission because of *Clostridium difficile* infection. *CMAJ* 2008;179:767-72.
16. Do AN, Fridkin SK, Yechouron A, et al. Risk factors for early recurrent *Clostridium difficile* – associated diarrhea. *Clin Infect Dis* 1998;26:954-9.
17. Drug Safety. Proton pump inhibitors (PPis) - drug safety communication: *Clostridium difficile*-associated diarrhea (CDAD) can be associated with stomach acid drugs. 2012.
18. Fedorko DP. Controversies in *Clostridium difficile* testing. *Clinical Microbiol Newsletter* 2002;24:76-9.
19. Fekety R. Guidelines for the diagnosis and management of *Clostridium difficile*-associated diarrhea and colitis. *Am J Gastroenterol* 1997;92:739-50.
20. Gerding DN, Johnson S, Peterson LR, et al. *Clostridium difficile*-associated diarrhea and colitis. *Infect Control Hosp Epidemiol* 1995;16:459-77.

21. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent *Clostridium difficile* infection. *Clin Infect Dis* 2011;53:994-1002.
22. Health Canada. Proton pump inhibitors (antacids): possible risk of *Clostridium difficile*-associated diarrhea. 2012.
23. Hogenauer C, Hammer HF, Krejs GJ, et al. Mechanisms and management of antibiotic-associated diarrhea. *Clin Infect Dis* 1998;27:702-10.
24. Hurley, BW, Nguyen CC. The spectrum of pseudomembranous enterocolitis and antibiotic-associated diarrhea. *Arch Intern Med* 2002;162:2177-84.
25. Johnson S, Gerding DN. *Clostridium difficile* – associated diarrhea. *Clin Infect Dis* 1998;26:1027-36.
26. Kamboj M, Khosa P, Kaltsas A, et al. Relapse versus reinfection: surveillance of *Clostridium difficile* infection. *Clin Infect Dis* 2011;53:1003-6.
27. Kelly CP, LaMont JT. *Clostridium difficile* - more difficult than ever. *N Engl J Med* 2008;359:1932-40.
28. Knop FC, Owens M, Crocker IC. *Clostridium difficile*: clinical disease and diagnosis. *Clin Microbiol Rev* 1993;6:251-65.
29. Letter to the Editor. Control of *Clostridium difficile*-associated diarrhea by antibiotic stewardship in a small community hospital. *Can J Infect Dis Med Microbiol* 2012:23
30. Linsky A, Gupta K, Lawler EV, et al. Proton pump inhibitors and risk for recurrent *Clostridium difficile* infection. *Arch Intern Med* 2010;170:772-8.
31. Louie TJ, Meddings J. *Clostridium difficile* infection in hospitals: risk factors and responses. *CMAJ* 2004;171:45-6.
32. Malnick SDH, Zimhony O. Treatment of *Clostridium difficile*-associated diarrhea. *Ann Pharmacother* 2002;36:1767-75.
33. Mylonakis E, Ryan ET, Calderwood SB. *Clostridium difficile*-associated diarrhea. *Arch Intern Med* 2001;161:525-33.
34. Owens RC Jr., Donskey CJ, Gaynes RP, et al. Antimicrobial-associated risk factors for *Clostridium difficile* infection. *Clin Infect Dis* 2008;46:S19-31.
35. Pasic M, Jost R, Carrel T, et al. Intracolonic vancomycin for pseudomembranous colitis. *N Engl J Med* 1993;329:583.
36. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for *Clostridium difficile*

- associated diarrhea: a cohort study during an epidemic in Quebec. *Clin Infect Dis* 2005;41:1254-60.
37. Pothoulakis C, Castagliuolo I, Kelly CP, et al. Clostridium difficile - associated diarrhea and colitis: pathogenesis and therapy. *Internat J Antimicrob Agents* 1993;3:17-32.
 38. Poutanen SM, Simor AE. *Clostridium difficile*-associated diarrhea in adults. *CMAJ* 2004;171:51-8.
 39. Reinke CM. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. *Am J Health-Syst Pharm* 1998;55:1407-11.
 40. Riley TV, Cooper M, Bell B, et al. Community-acquired Clostridium difficile - associated diarrhea. *Clin Infect Dis* 1995;20:263-5.
 41. Stevens V, Dumyati G, Fine LS, et al. Cumulative antibiotic exposures over time and the risk of *Clostridium difficile* infection. *Clin Infect Dis* 2011;53:42-8.
 42. Rokas KEE, Johnson JW, Beardsley JR, et al. The addition of intravenous metronidazole to oral vancomycin is associated with improved mortality in critically ill patients with *Clostridium difficile* infection. *Clin Infect Dis* 2015;61:934-41.
 43. Trexler Hessen M. *Clostridium difficile* infection. *Ann Intern Med* 2010;Oct:ITC4-1-16.
 44. Wensch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile – associated diarrhea. *Clin Infect Dis* 1996;22:813-8.
 45. Wensch JM, Schmid D, Kuo HW. Prospective observational study comparing three different treatment regimes in patients with clostridium difficile infection. *Antimicrob Agents & Chemother* 2012:1974-8.
 46. Woelfel JA. Proton pump inhibitors associated with increased risk of *Clostridium difficile* diarrhea. *Pharmacist's Letter* 2004;20:200804.
 47. Zar FA, Bakkanagari SR, Moorthi KMLST, et al. A comparison of vancomycin and metronidazole for the treatment of *Clostridium difficile* -associated diarrhea, stratified by disease severity. *Clin Infect Dis* 2007;45:302-7.

Necrotizing Enterocolitis

1. Lin Pw, Stoll BJ. Necrotising enterocolitis. *Lancet* 2006;368:1271-83.
2. Neu J, Walker WA. Necrotizing enterocolitis. *N Engl J Med* 2011;364:255-64.

H. pylori

1. Alberta Medical Association. Guideline for treatment of *Helicobacter pylori* infection in adults. Jul 2000. Revised Jan 2005.
2. Bardhan KD, Dallaire C, Eisold H, et al. Ranitidine bismuth citrate with clarithromycin for the treatment of duodenal ulcer. *Gut* 1997;41:181-6.
3. Blaser MJ. *Helicobacter pylori*: its role in disease. *Clin Infect Dis* 1992;15:386-93.
4. Bonagura AF, Dabezies MA. *Helicobacter pylori* infection. *Postgrad Med* 1996;100:115-29.
5. Chey WD, Wong BCY. American College of Gastroenterology guideline on the management of *Helicobacter pylori* infection. *Am J Gastroenterol* 2007;102:1808-25.
6. Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of *Helicobacter pylori* infection in adults. *Gastroenterology* 2016;151:51-69.
7. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for *Helicobacter pylori*. *Aliment Pharmacol Ther* 2007;26:343-57.
8. Fuccio L, Laterza L, Zagari RM, et al. Treatment of *Helicobacter pylori* infection. *BMJ* 2008;337:746-7.
9. Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton-pump inhibitor-based triple therapy for *Helicobacter pylori* eradication. *Ann Intern Med* 2007;147:553-62.
10. Gatta L, Vakil N, Leandro G, et al. Sequential therapy or triple therapy for *Helicobacter pylori* infection: systematic review and meta-analysis of randomized controlled trials in adults and children. *Am J Gastroenterol* 2009;104:3069-79.
11. Gatta L, Vakil N, Vaira D, et al. Global eradication rates for *Helicobacter pylori* infection: systematic review and meta-analysis of sequential therapy. *BMJ* 2013;347:f4587.
12. Graham DY, Fischbach L. *Helicobacter pylori* treatment in the era of increasing antibiotic resistance. *Gut* 2010;59:1143-53.
13. Graham DY, Lew GM, Evans DG, et al. Effect of triple therapy (antibiotics plus bismuth) and duodenal ulcer healing: a randomized controlled trial. *Ann Intern Med* 1991;115:266-9.
14. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of *Helicobacter pylori* infection on the long-term recurrence of gastric or duodenal ulcer. *Ann Intern Med* 1992;116:705-8.

15. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of *Helicobacter pylori* and the recurrence of duodenal ulcer. *N Engl J Med* 1993;328:308-50.
16. Hunt R, Thomson ABR. Canadian *Helicobacter pylori* consensus conference. *Can J Gastroenterol* 1998;12:31-41.
17. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for *Helicobacter pylori* infection in patients naïve to treatment. *Ann Intern Med* 2008;148:923-31.
18. Leal-Herrera Y, Torres J, Monath T, et al. High rates of recurrence and of transient reinfections of *Helicobacter pylori* in a population with high prevalence of infection. *Am J Gastroenterol* 2003;98:2395-2402.
19. Luther J, Higgins PDR, Schoenfeld PS, et al. Empiric quadruple vs. triple therapy for primary treatment of *Helicobacter pylori* infection: systematic review and meta-analysis of efficacy and tolerability. *Am J Gastroenterol* 2010;105:65-73.
20. McColl KEL. *Helicobacter pylori* infection. *N Engl J Med* 2010;362:1597-604.
21. Morse AL, Goodman KJ, Munday R, et al. A randomized controlled trial comparing sequential with triple therapy for *Helicobacter pylori* in an Aboriginal community in the Canadian North. *Can J Gastroenterol* 2013;27:701-6.
22. NIH. *Helicobacter pylori* in peptic ulcer disease. *JAMA* 1994;272:65-9.
23. Passaro DJ, Chosy EJ, Parsonnet J. *Helicobacter pylori*: consensus and controversy. *Clin Infect Dis* 2002;35:298-304.
24. Pinchbeck et al. *Can Assoc Gastroenterol* 2012. (abstract) a145.
25. Shah R. Dyspepsia and *Helicobacter pylori*. *BMJ* 2007;334:41-3.
26. Spee LAA, Madderom MB, Pijpers M, et al. Association between *Helicobacter pylori* and gastrointestinal symptoms in children. *Pediatrics* 2010;125:e651-69.
27. Sung JJY, Chung SCS, Ling TKW, et al. Antibacterial treatment of gastric ulcers associated with *Helicobacter pylori*. *N Engl J Med* 1995;332:139-42.
28. Toward Optimized Practice (TOP) Working Group for *H. pylori*. 2016 June. Diagnosis and treatment of *Helicobacter pylori*: clinical practice guideline. Edmonton, AB: Toward Optimized Practice, Available from <http://www.topalbertadoctors.org>

29. Veldhuyzen van Zanten SJO, Sherman PM, Hunt RH. Helicobacter pylori: new developments and treatments. Can Med Assoc J 1997;156:1565-74.
30. Veldhuyzen van Zanten SJO, Bradette M, Chiba N, et al. Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Can J Gastroenterol 2005;19:285-303
31. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995;333:984-91.

Cholecystitis/Cholangitis

1. Anon. Antibiotics for cholangitis. Lancet 1989.
2. Strasberg SM. Acute calculous cholecystitis. N Engl J Med 2008;358:2804-11.
3. van den Hazel SJ, Speelman P, Tytgat GNJ, et al. Role of antibiotics in the treatment and prevention of acute and recurrent cholangitis. Clin Infect Dis 1994;19:279-86.
4. Westphal JF, Brogard JM. Biliary tract infections. A guide to drug treatment. Drugs 1999;57:81-91.

Diverticulitis

1. Chabok A, Pahlman L, Hjern F, et al. Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. British J Surg 2012;99:532-9.
2. de Korte N, Unlu C, Boermeester MA, et al. Use of antibiotics in uncomplicated diverticulitis. British J Surg 2011;98:761-7.
3. Ferzoco LB, Raptopoulos V, Silen W. Acute diverticulitis. N Engl J Med 1998;338:1521-6.
4. Hjern F, Josephson T, Altman D, et al. Conservative treatment of acute colonic diverticulitis: are antibiotics always mandatory? Scand J Gastroenterol 2007;42:41-7.
5. Jacobs DO. Diverticulitis. N Engl J Med 2007;357:2057-66.

Spontaneous Bacterial Peritonitis

1. Bhuvra M, Ganger D, Jensen D. Spontaneous bacterial peritonitis: an update on evaluation, management, and prevention. Am J Med 1994;97:169-75.

2. Centers for Disease Control and Prevention. Ceftriaxone-associated biliary complications of treatment of suspected disseminated Lyme disease - New Jersey, 1990-1992. *Morb Mortal Weekly Rep* 1993;42:39-42.
3. Dupeyron C, Mangeney N, Sedrati L, et al. Rapid emergence of quinolone resistance in cirrhotic patients treated with norfloxacin to prevent spontaneous bacterial peritonitis. *Antimicrob Agents Chemother* 1994;38:340-4.
4. Frazee LA, Marinos AE, Rybarczyk AM, et al. Long-term prophylaxis of spontaneous bacterial peritonitis in patients with cirrhosis. *Ann Pharmacother* 2005;39:908-12.
5. Gilbert J, Kamath P. Spontaneous bacterial peritonitis: an update. *Mayo Clin Proc* 1995;70:365-70.
6. Gines P, Rimola A, Planas R, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. *Hepatology* 1990;12:716-24.
7. Hoefs J. Spontaneous bacterial peritonitis: prevention and therapy. *Hepatology* 1990;2:776-81.
8. Levy MJ, DiPalma JA. New options for spontaneous bacterial prophylaxis: costly or cost effective? *Gastroenterol* 1996;91:1050-1.
9. Mihas AA, Toussaint J, Sh Hsu H, et al. Spontaneous bacterial peritonitis in cirrhosis: clinical and laboratory features, survival and prognostic indicators. *Hepato-Gastroenterol* 1992;39:520-2.
10. Rimola L, Bory F, Teres J, et al. Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. *Hepatology* 1985;5:463-7.
11. Rolachon A, Cordier L, Bacq Y, et al. Ciprofloxacin and long-term prevention of spontaneous bacterial peritonitis: results of a prospective controlled trial. *Hepatology* 1995;22:1171-4.
12. Runyon BA. Management of adult patients with ascites due to cirrhosis. *Hepatology* 2004;39:1-16.
13. Runyon BA. Management of adult patients with ascites due to cirrhosis: an update. *Hepatology* 2009;49:2087-107.
14. Schaad VB, Wedgwood J. Ceftriaxone versus cefuroxime for meningitis in children. *N Engl J Med* 1990;322:1821.
15. Schubert M, Sanyal A, Wong E. Antibiotic prophylaxis for prevention of spontaneous bacterial peritonitis? *Gastroenterol* 1991;101:550-7.
16. Segarra-Newnham M, Henneman A. Antibiotic prophylaxis for prevention of spontaneous bacterial peritonitis in patients without gastrointestinal bleeding. *Ann Pharmacother* 2010:44.

17. Singh N, Gayowski T, Yu VL, et al. Trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in cirrhosis: a randomized trial. *Ann Intern Med* 1995;122:595-8.
18. Soriano G, Guarner C, Teixido M, et al. Selective intestinal decontamination prevents spontaneous bacterial peritonitis. *Gastroenterol* 1991;100:477-81.
19. Soriano G, Guarner C, Tomas A, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. *Gastroenterol* 1992;103:1267-72.
20. Such J, Runyon BA. Spontaneous bacterial peritonitis. *Clin Infect Dis* 1998;27:669-76.
21. Toledo C, Salmeron JM, Rimola A, et al. Spontaneous bacterial peritonitis in cirrhosis: predictive factors of infection resolution and survival in patients treated with cefotaxime. *Hepatology* 1993;17:251-7.
22. Trikudanathan G, Isreal J, Cappa J, et al. Association between proton pump inhibitors and spontaneous bacterial peritonitis in cirrhotic patients - a systematic review and meta-analysis. *Int J Clin Pract* 2011;65:674-8.

Peritonitis

1. Ball CG, Hansen G, Harding GKM, et al. Canadian practice guidelines for surgical intra-abdominal infections. *Can J Infect Dis Med Microbiol* 2010;21;11-37.
2. Fitzmaurice GJ, McWilliams B, Hurreiz H, et al. Antibiotics versus appendectomy in the management of acute appendicitis: a review of the current evidence. *Can J Surg* 2011.
3. Laterre PF. Progress in medical management of intra-abdominal infection. *Curr Opin Infect Dis* 2008;21;393-8.
4. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. *Clin Infect Dis* 2010;50;133-64.

2º/3º Peritonitis

1. Bartlett JG. Intra-abdominal sepsis. *Med Clin N Amer* 1995;79:599-617.

2. Bennion RS, Thompson JE, Baron EJ, et al. Gangrenous and perforated appendicitis with peritonitis: treatment and bacteriology. *Clin Ther* 1990;12:31-44.
3. Bohnen JMA, Solomkin JS, Dellinger EP, et al. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A surgical infection society policy statement. *Arch Surg* 1992;127:83-9.
4. DiPiro JT. Considerations for therapy of mixed infections: focus on intraabdominal infection. *Pharmacother* 1995;15:15-21S.
5. Gorbach SL. Intraabdominal infections. *Clin Infect Dis* 1993;17:961-7.
6. Johnson CC, Baldessarre J, Levison ME. Peritonitis: update on pathophysiology, clinical manifestations, and management. *Clin Infect Dis* 1997;24:1035-47.
7. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. *Surgical Infections* 2002;161-73.
8. McClean KL, Sheehan GJ, Harding GKM. Intraabdominal infection: a review. *Clin Infect Dis* 1994;19:100-16.
9. Nathens AB, Rotstein OD. Therapeutic options in peritonitis. *Surg Clin N Amer* 1994;74:677-92.
10. Nichols RL, et al. Wound and intraabdominal infections: microbiological considerations and approaches to treatment. *Clin Infect Dis* 1993;16:266-72.
11. Podnos YD, Jimenez JC, Wilson SE. Intra-abdominal sepsis in elderly persons. *Clin Infect Dis* 2002;35:62-8.
12. Rotstein OD, Pruett TL, Simmons RL. Mechanisms of microbial synergy in polymicrobial surgical infections. *Rev Infect Dis* 1985;7:151-70.
13. Sawyer MD, Dunn DL. Antimicrobial therapy of intra-abdominal sepsis. *Infect Dis Clin N Amer* 1992;6:545-70.
14. Solomkin JS, Dellinger EP, Christou NV, et al. Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. *Ann Surg* 1990;212:581-91.
15. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. *Clin Infect Dis* 2003;37:997-1005.

PD Peritonitis

1. Anwar N, Merchant M, Were T, et al. A prospective, randomized study of the comparative safety and efficacy of intraperitoneal imipenem

- versus vancomycin and netilmicin in the treatment of peritonitis on CAPD. *Perit Dial Int* 1995;15:167–71.
2. Baker RJ, Senior H, Clemenger M, et al. Empirical aminoglycosides for peritonitis do not affect residual renal function. *Am J Kid Dis* 2003;41:670-5.
 3. Bailie GR. Therapeutic dilemmas in the management of peritonitis. *Perit Dial Int* 2005;25:152-6.
 4. Burkart JM, Bleyer A. Tunnel and peritoneal catheter exit site infections in continuous peritoneal dialysis. UpToDate May 2017.
 5. Dasgupta MK. CAPD peritonitis protocol update:1997.
 6. deFreitas DG, Gokal R. Sterile peritonitis in the peritoneal dialysis patient. *Perit Dial Int* 2005;25:146-51.
 7. Horton MW, Deeter RG, Sherman RA. Treatment of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. *Clin Pharm* 1990;9:102-18.
 8. Keane WF, Bailie GR, Boeschoten E. et al. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. www.ispd.org/2000_treatment_recommendations.html
 9. Kam-Tao P, Szeto CC, Piraino B, et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. *Perit Dial Int* 2016;36:481-508.
 10. Li PKT, Szeto CC, Piraino B, et al. Peritoneal dialysis-related infections recommendations: 2010 update. *Perit Dial Int* 2010;30:393-423.
 11. Millikin SP, Matzke GR, Keane WF. Antimicrobial treatment of peritonitis associated with continuous ambulatory peritoneal dialysis. *Perit Dialysis Internat* 1991;11:252-60.
 12. O'Brien MA, Mason NA. Systemic absorption of intraperitoneal antimicrobials in continuous ambulatory peritoneal dialysis. *Clin Pharm* 1992;11:246-54.
 13. Peterson PK, Matzke G, Keane WF. Current concepts in the management of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. *Rev Infect Dis* 1987;9:604-12.
 14. Piraino B, Bailie GR, Bernardini J, et al. ISPD guidelines/recommendations. Peritoneal dialysis-related infections recommendations: 2005 update. *Perit Dial Int* 2005;25:107-131.
 15. Prowant B, Nolph K, Ryan L, et al. Peritonitis in continuous ambulatory peritoneal dialysis: analysis of an 8-year experience. *Nephron* 1986;43:105-9.

16. Prophylaxis for exit site/tunnel infections using mupirocin. *Nephrology* 2004;9:S86-90.
17. Saklayen MG. CAPD peritonitis: incidence, pathogens, diagnosis, and management. *Med Clin N Amer* 1990;74:997-1010.
18. Salzer W. Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them. *Perit Dial Int* 2005;25:313-9.
19. Shemin D, Maaz D, St. Pierre D, et al. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. *Am J Kidney Dis* 1999;34:14-20.
20. Silva MM, Pecoits-Filho R, Rocha CS, et al. The recommendations from the International Society for Peritoneal Dialysis for Peritonitis Treatment: a single-center historical comparison. *Adv Perit Dial* 2004;20:74-7.
21. Uttley L, Vardhan A, Mahajan S, et al. Decrease in infections with the introduction of mupirocin cream at the peritoneal dialysis catheter exit site. *J Nephrol* 2004;17:242-5.
22. von Graevenitz A, Amsterdam D. Microbiological aspects of peritonitis associated with continuous ambulatory peritoneal dialysis. *Clin Microbiol Rev* 1992;5:36-48.
23. Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. *Perit Dial Int* 2012;32:29-86.
24. Warady BA, Schaefer F, Holloway M, et al. Consensus guidelines for the treatment of peritonitis in pediatric patients receiving peritoneal dialysis. *Perit Dial Int* 2000;20:610-24.
25. Yeung SM, Walker SE, Taylor SA, et al. Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis. *Perit Dial Int* 2004;24:447-53.
26. Zelenitsky S, Ariano R, Harding G. A reevaluation of empiric therapy for peritoneal dialysis-related peritonitis. *Am J Kidney Dis* 2004;44:559-61.

Pancreatitis

1. Baron TH, Morgan DE. Acute necrotizing pancreatitis. *N Engl J Med* 1999;340:1412-7.
2. Buchler MW, Gloor B, Muller CA, et al. Acute necrotizing pancreatitis: treatment strategy according to the status of infection. *Ann Surg* 2000;232:619-26.

3. Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. *Lancet* 2008;371:143-52.
4. Gloor B, Muller CA, Worni M, et al. Pancreatic infection in severe pancreatitis. The role of fungus and multiresistant organisms. *Arch Surg* 2001;136:592-6.
5. Greer SE, Burchard KW. Acute pancreatitis and critical illness. A pancreatic tale of hypoperfusion and inflammation. *Chest* 2009;136:1413-9.
6. Gupta K, Wu B. Acute pancreatitis. *Ann Intern Med* 2010;Nov:ITC5-1-16.
7. Kingsnorth A, O'Reilly D. Acute pancreatitis. *BMJ* 2006;332:1072-6.
8. Marshall JB. Acute pancreatitis: a review with an emphasis on new developments. *Arch Intern Med* 1993;153:1185-98.
9. Segarra-Newnham M, Hough A. Antibiotic prophylaxis in acute necrotizing pancreatitis revisited. *Ann Pharmacother* 2009;43:1486-95.
10. Whitcomb DC. Acute pancreatitis. *N Engl J Med* 2006;354:2142-50.

Liver abscess

1. Branum GD, Tyson GS, Branum MA, et al. Hepatic abscess: changes in etiology, diagnosis, and management. *Ann Surg* 1990;212:655-62.
2. Decre D, Verdet C, Emirian A, et al. Emerging severe and fatal infections due to *Klebsiella pneumoniae* in two university hospitals in France. *J Clin Microbiol* 2011;49:3012-4.
3. Fang CT, Lai SY, Yi WC, et al. *Klebsiella pneumoniae* genotype K1: an emerging pathogen that causes septic ocular or central nervous system complications from pyogenic liver abscess. *Clin Infect Dis* 2007;45:284-93.
4. Lee SSJ, Chen YS, Tsai HC, et al. Predictors of septic metastatic infection and mortality among patients with *Klebsiella pneumoniae* liver abscess. *Clin Infect Dis* 2008;47:642-50.

Genital

1. Alberta Health and Wellness. Alberta Treatment Guidelines. Sexually transmitted infections in adolescents and adults 2003.
2. Allen LV. Boric acid suppositories. Boric acid vaginal suppositories are useful for treating chronic mycotic vulvovaginitis. *US Pharmacist* 1996; 1: 92-3.

3. Allen VG, Farrell DJ, Rebbapragada A, et al. Molecular analysis of antimicrobial resistance mechanisms in *Neisseria gonorrhoeae* isolates from Ontario, Canada. *Antimicrob Agents Chemother* 2011;55:703-12.
4. Alrabiah FA, Sacks SL. New antiherpesvirus agents: their targets and therapeutic potential. *Drugs* 1996;52:17-32.
5. Anon. Boric acid 600-mg vaginal suppository. *Int J Pharm Compounding* 2004;8:52.
6. Anon. Drugs for sexually transmitted infections. *Treatment Guidelines Med Lett* 2010;8:53-60.
7. Aoki FY, Tyring S, Diaz-Mitoma F, et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: A randomized, double-blind, placebo-controlled trial. *Clin Infect Dis* 2006;42:8-13.
8. Arredondo JL, Diaz V, Gaitan H, et al. Oral clindamycin and ciprofloxacin versus intramuscular ceftriaxone and oral doxycycline in the treatment of mild-to-moderate pelvic inflammatory disease in outpatients. *Clin Infect Dis* 1997;24:170-8.
9. Augenbraun MH, Rolfs R. Treatment of syphilis, 1998: nonpregnant adults. *Clin Infect Dis* 1999;28:S21-8.
10. Banerji A. Canadian Paediatric Society First Nations, Inuit and Metis Health Committee. Scabies. *Paediatr Child Health* 2015;20:395-8.
11. Beutner KR, Reitano MV, Richwald GA, et al. External genital warts: report of the American Medical Association consensus conference. *Clin Infect Dis* 1998;27:796-806.
12. Beutner KR, Wiley DJ, Douglas JM, et al. Genital warts and their treatment. *Clin Infect Dis* 1999;28:S37-56.
13. Boehm FH, Estes W, Wright PF, et al. Management of genital herpes simplex virus infection occurring during pregnancy. *Am J Obstet Gynecol* 1981;141:735-40.
14. Bras APM, Sitar DS, Aoki FY. Comparative bioavailability of acyclovir from oral valacyclovir and acyclovir in patients treated for recurrent genital herpes simplex virus infection. *Can J Clin Pharmacol* 2001;8:207-11.
15. Brunham RC, Paavonen J, Stevens CE, et al. Mucopurulent cervicitis - the ignored counterpart in women of urethritis in men. *N Engl J Med* 1984;311:1-6.
16. Burstein GR, Zenilman JM. Nongonococcal urethritis – a new paradigm. *Clin Infect Dis* 1999;28:S66-73.

17. Carey JC, Klebanoff MA, Hauth JC. et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. *N Engl J Med* 2000;342:534-40.
18. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2010. *Morb Mortal Weekly Rep* 2010;59(RR-12):1-80. <http://www.cdc.gov/std/treatment/2010/STD-Treatment-2010-RR5912.pdf>
19. Centers for Disease Control and Prevention. Update to CDC's *Sexually Transmitted Diseases Treatment Guidelines, 2010*: Oral cephalosporins no longer a recommended treatment for gonococcal infections. *Morb Mortal Weekly Rep* 2012;61(No 31):590-4. <http://www.cdc.gov/mmwr/pdf/wk/mm6131.pdf>
20. Cook AM, Romanelli F. Ivermectin for the treatment of resistant scabies. *Ann Pharmacother* 2003;37:279-81.
21. Corey L, Adams HG, Brown ZA, et al. Genital herpes simplex virus infections: clinical manifestations, course, and complications. *Ann Intern Med* 1983;98:958-72.
22. Corey L, Holmes KK. Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention. *Ann Intern Med* 1983;98:973-83.
23. Diaz-Mitoma F, Sibbald RG, Shafran SD, et al. Oral famciclovir for the suppression of recurrent genital herpes: a randomized controlled trial. *JAMA* 1998;280:887-92.
24. Eckert LO. Clinical practice. Acute vulvovaginitis. *N Engl J Med* 2006;355 :1244-52.
25. Eschenbach DA. Bacterial vaginosis and anaerobes in obstetric-gynecologic infection. *Clin Infect Dis* 1993;16:282-7.
26. Fife KH, Barbarash RA, Rudolph T, et al. Valaciclovir versus acyclovir in the treatment of first-episode genital herpes infection. *Sex Transm Dis* 1997;24:481-6.
27. Forbes AJ, Berkahn C, eds. Topical imiquimod: first of its kind for genital warts. *Drugs & Ther Perspectives* 1999;14:1-5.
28. Gratrix J, Bergman J, Egan C, et al. Retrospective review of pharyngeal gonorrhoea treatment failures in Alberta, Canada. *Sexually Transmitted Dis* 2013;40:877-9.
29. Greaves WL, Chungafung J, Morris B, et al. Clindamycin versus metronidazole in the treatment of bacterial vaginosis. *Obstet Gynecol* 1988;72:799-802.
30. Gupta R, Warren T, Wald A. Genital herpes. *Lancet* 2007;370:2127-37.

31. Hooton TM, Wong ES, Barnes RC, et al. Erythromycin for persistent or recurrent nongonococcal urethritis: a randomized, placebo-controlled trial. *Ann Intern Med* 1990;113:21-6.
32. Infectious Diseases and Immunization Committee, CPS. Toward the rational management of herpes infection in pregnant women and their newborn infants. *Can Med Assoc J* 1992;146:1557-9.
33. Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. *Clin Infect Dis* 1999;28:S57-65.
34. Kaplowitz LG, Baker D, Gelb L, et al. Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection. *JAMA* 1991;265:747-51.
35. Kent ME, Romanelli F. Reexamining syphilis: an update on epidemiology, clinical manifestations, and management. *Ann Pharmacother* 2008;42:226-36.
36. Kropp RY, Wong T, on behalf of the Canadian LGV Working Group. Emergence of lymphogranuloma venereum in Canada. *CMAJ* 2005;172:1674-6.
37. Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment. *Clin Infect Dis* 2002;34:958-62.
38. Leung DT, Sacks SL. Current recommendations for the treatment of genital herpes. *Drugs* 2000;60:1329-52.
39. Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. *Clin Infect Dis* 2010;50:1641-52.
40. Mann J, Kropp R, Wong T, et al. Gonorrhoea treatment guidelines in Canada: 2004 update. *CMAJ* 2004;171:1345-6.
41. Marrazzo JM, Martin DH. Management of women with cervicitis. *Clin Infect Dis* 2007;44(suppl 3):S102-10.
42. Martin I, Jayaraman G, Wong T, et al. Trends in antimicrobial resistance in *Neisseria gonorrhoeae* isolated in Canada: 2000-2009. *Sexually Transmitted Diseases* 2011;38:892-8.
43. Meltzer MC, Schwebke JR. Lactational amenorrhoea as a risk factor for Group A streptococcal vaginitis. *Clin Infect Dis* 2008;46:e112-5.
44. Nygren P, Fu R, Freeman M, et al. Evidence on the benefits and harms of screening and treating pregnant women who are asymptomatic for bacterial vaginosis: an update review for the U.S. Preventative Services Task Force. *Ann Intern Med* 2008;148:220-33.
45. Perry CM, Lamb HM. Topical imiquimod: a review of its use in genital warts. *Drugs* 1999;58:375-90.

46. Perry CM, Wagstaff AJ. Famciclovir: a review of its pharmacological properties and therapeutic efficacy in Herpesvirus infections. *Drugs* 1995;50:396-415.
47. Peterson HB, Galaid EI, Zenilman JM. Pelvic inflammatory disease: review of treatment options. *Rev Infect Dis* 1990;12:656-64.
48. Public Health Agency of Canada. Canadian guidelines on sexually transmitted infections: treatment of *N. gonorrhoeae* in response to the discontinuation of spectinomycin: alternative treatment guidance statement. 2017;May.
49. Public Health Agency of Canada Expert Working Group on the Canadian guidelines on sexually transmitted infections. Canadian guidelines on sexually transmitted infections. Ottawa, ON: Public Health Agency of Canada. Available at: <http://www.phac-aspc.gc.ca/std-mts/sti-its/guide-lignesdir-eng.php>. Accessed Feb 2012.
50. Public Health Agency of Canada Expert Working Group on the Canadian guidelines on sexually transmitted infections. Canadian guidelines on sexually transmitted infections. Gonococcal Infections Chapter Revised 2013. Ottawa, ON: Public Health Agency of Canada. Available at: <http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/section-5-6-eng.php>. Accessed October 2013.
51. Prober CG, Corey L, Brown ZA, et al. The management of pregnancies complicated by genital infections with Herpes simplex virus. *Clin Infect Dis* 1992;15:1031-8.
52. Rein MF, Holmes KK. "Nonspecific vaginitis" vulvovaginal candidiasis, and trichomoniasis: clinical features, diagnosis, and management. *Curr Clin Topics Infect Dis* 1983;4:281-315.
53. Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. *J Infect Dis* 1998;178:603-10.
54. Roett MA, Mayor MT, Uduhiri KA. Diagnosis and management of genital ulcers. *Am Fam Physician* 2012;85:254-62.
55. Rompalo AM. Diagnosis and treatment of sexually acquired proctitis and proctocolitis: an update. *Clin Infect Dis* 1999;28:S84-90.
56. Roos TC, Alam M, Roos S, et al. Pharmacotherapy of ectoparasitic infections. *Drugs* 2001;61:1067-88.
57. Schacker T, Hu H, Koelle DM, et al. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons: a double-blind, placebo-controlled trial. *Ann Intern Med* 1998;128:21-8.

58. Schaeffer AJ. Chronic prostatitis and the chronic pelvic pain syndrome. *N Engl J Med* 2006;355:1690-8.
59. Schmid GP. Treatment of chancroid, 1997. *Clin Infect Dis* 1999;28:S14-20.
60. Sen P, Barton SE. Genital herpes and its management. *BMJ* 2007;334:1048-52.
61. Sheffield JS, Hollier LM, Hill JB, et al. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. *Obstet Gynecol* 2003;102:1396-403.
62. Sobel JD. Vaginitis. *N Engl J Med* 1997;337:1896-1903.
63. Sobel JD. Vulvovaginal candidosis. *Lancet* 2007;369:1961-71.
64. Sobel JD, Chaim W. Treatment of *Torulopsis glabrata* vaginitis: retrospective review of boric acid therapy. *Clin Infect Dis* 1997;24:649-52.
65. Spruance SL, Tyring SK, DeGregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent Herpes genitalis. *Arch Intern Med* 1996;156:1729-35.
66. Stoner BP. Current controversies in the management of adult syphilis. *Clin Infect Dis* 2007;44(suppl 3):130-46.
67. Sweet RL. New approaches for the treatment of bacterial vaginosis. *Am J Obstet Gynecol* 1993;169:479-82.
68. Tan HH, Goh CL. Parasitic skin infections in the elderly. *Drugs & Aging* 2001;18:165-76.
69. Trees DL, Morse SA. Chancroid and *Haemophilus ducreyi*: an update. *Clin Microbiol Rev* 1995;8:357-75.
70. Tsang RSW, Radons SM, Morshed M. Laboratory diagnosis of syphilis: a survey to examine the range of tests used in Canada. *Can J Infect Dis Med Microbiol* 2011;22:83-7.
71. U.S. Preventive Services Task Force. Screening for bacterial vaginosis in pregnancy to prevent preterm delivery: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2008;148:214-9.
72. Wagenlehner FME, Naber KG. Current challenges in the treatment of complicated urinary tract infections and prostatitis. *Clin Microbiol Infect* 2006;12(suppl 3):67-80.
73. Wald A. New therapies and prevention strategies for genital herpes. *Clin Infect Dis* 1999;28:S4-13.

74. Walker CK, Kahn JG, Washington AE, et al. Pelvic inflammatory disease: metaanalysis of antimicrobial regimen efficacy. *J Infect Dis* 1993;168:969-78.
75. Walker CK, Workowski KA, Washington AE, et al. Anaerobes in pelvic inflammatory disease: implications for the Centers for Disease Control and Prevention's guidelines for treatment of sexually transmitted diseases. *Clin Infect Dis* 1999;28:S29-36.
76. Warkentin DI, Epstein JB, Campbell LM, et al. Valacyclovir versus acyclovir for HSV prophylaxis in neutropenic patients. *Ann Pharmacother* 2002;36:1525-31.
77. Wendel KA, Workowski KA. Trichomoniasis: challenges to appropriate management. *Clin Infect Dis* 2007;44:S123-9.
78. Wohrl S, Geusau A. Clinical update: syphilis in adults. *Lancet* 2007;369:1912-4.

Urinary Tract

1. Abbo LM, Hooton TM. Antimicrobial stewardship and urinary tract infections. *Antibiotics* 2014;3:174-92.
2. Allais JM, Preheim LC, Cuevas TA, et al. Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections. *Antimicrob Agents Chemother* 1988;32:1327-30.
3. Allen VM, Yudin MH. Management of group B streptococcal bacteriuria in pregnancy. *J Obstet Gynaecol Can* 2012;34:482-6.
4. Alliance for the Prudent Use of Antibiotics. UTI treatment at a turning point: Improving antimicrobial prescribing for uncomplicated UTIs in an era of increasing antibiotic resistance. Summary of proceedings June 10, 2003 roundtable.
5. American Academy of Pediatrics Committee on Infectious Diseases. The use of systemic fluoroquinolones. *Pediatrics* 2006;118:1287-92.
6. American Academy of Pediatrics Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management. Urinary tract infection: clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. *Pediatrics* 2011;128:595-610.
7. Aydin A, Ahmed K, Zaman I, et al. Recurrent urinary tract infections in women. *Int Urogynecol J* 2015;26:795-804.
8. Barry AL. Nitrofurantoin susceptibility test criteria. *J Antimicrob Chemother* 1990;25:711-13.

9. Barbosa-Cesnik C, Brown MB, Buxton M, et al. Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. *Clin Infect Dis* 2011;52:23-30.
10. Beerepoot MAJ, Geerlings SE, van Haarst EP, et al. Nonantibiotic prophylaxis for recurrent urinary tract infections: a systematic review and meta-analysis of randomized controlled trials. *J Urology* 2013;190:1981-9.
11. Boscia JA, Abrutyn E, Kaye D. Asymptomatic bacteriuria in elderly persons: treat or do not treat? *Ann Intern Med* 1987;106:764-6.
12. Bouvet C, Lubbeke A, Bandi C, et al. Is there any benefit in pre-operative urinary analysis before elective total joint replacement? *Bone Joint J* 2014;96-B:390-4.
13. Cai T, Mazzoli S, Mondaini N, et al. The role of asymptomatic bacteriuria in young women with recurrent urinary tract infections: to treat or not to treat? *Clin Infect Dis* 2012;55:771-7.
14. Car J. Urinary tract infections in women: diagnosis and management in primary care. *BMJ* 2006;332:94-7.
15. Committee on Quality Improvement, Subcommittee on Urinary Tract Infection. Practice parameter: the diagnosis, treatment, and evaluation of the initial urinary tract infection in febrile infants and young children. *Pediatrics* 1999;103:843-52.
16. Conway PH, Cnaan A, Zaoutis T, et al. Recurrent urinary tract infections in children - risk factors and association with prophylactic antimicrobials. *JAMA* 2007;298:179-86.
17. Cordero-Ampuero J, Gonzalez-Fernandez E, Martinez-Velez D, et al. Are antibiotics necessary in hip arthroplasty with asymptomatic bacteriuria? Seeding risk with/without treatment. *Clin Orthop Relat Res* 2013;471:3822-9.
18. Craig JC, Simpson JM, Williams GJ, et al. Antibiotic prophylaxis and recurrent urinary tract infection in children. *N Engl J Med* 2009;361:1748-59.
19. Dai B, Liu Y, Jia J, et al. Long-term antibiotics for the prevention of recurrent urinary tract infection in children: a systematic review and meta-analysis. *Arch Dis Child* 2010;95:499-508.
20. Dick PT, Feldman W. Routine diagnostic imaging for childhood urinary tract infections: a systematic overview. *J Pediatr* 1996;128:15-22.
21. Delzell JE Jr, Lefevre ML. Urinary tract infections during pregnancy. *Am Fam Physician* 2000;61:713-21.

22. Drekonja DM, Rector TS, Cutting A, et al. Urinary tract infection in male veterans. *JAMA Intern Med* 2013;173:62-8.
23. Echols RM, Tosiello RL, Haverstock DC, et al. Demographic, clinical, and treatment parameters influencing the outcome of acute cystitis. *Clin Infect Dis* 1999;29:113-9.
24. Eichenwald HF. Some aspects of the diagnosis and management of urinary tract infection in children and adolescents. *Pediatr Infect Dis* 1986;5:760-5.
25. Epp A, Larochele A. Recurrent urinary tract infection. *JOGC* 2010;250:1082-90.
26. Falagas ME, Vouloumanou EK, Trogias AG, et al. Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials. *J Antimicrob Chemother* 2010;65:1862-77.
27. Falagas ME, Kastoris AC, Kapaskelis AM, et al. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β -lactamase producing, Enterobacteriaceae infections: a systematic review. *Lancet Infect Dis* 2010;10:43-50.
28. Finnell SME, Carroll AE, Downs SM, et al. Technical Report - Diagnosis and management of an initial UTI in febrile infants and young children. *Pediatrics* 2011;128:e749-70.
29. Gagyor I, Bleidorn J, Kochen MM, et al. Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial. *BMJ* 2015;351:h6544.
30. Garau J. Other antimicrobials of interest in the era of extended-spectrum β -lactamases: fosfomycin, nitrofurantoin and tigecycline. *Clin Microbiol Infect* 2008;14(suppl 1):198-202.
31. Geerlings SE, Beerepoot MAJ, Prins JM. Prevention of recurrent urinary tract infections in women. *Antimicrobial and nonantimicrobial strategies*. *Infect Dis Clin N Am* 2014;28:135-47.
32. Gilstrap LC, Ramin SM. Urinary tract infections during pregnancy. *Obstet Gynecol Clin North Am* 2001;28:581-91.
33. Gleckman RA. Treatment duration for urinary tract infections in adults. *Antimicrob Agents Chemother* 1987;31:1-5.
34. Gross PA, Patel B. Reducing antibiotic overuse: a call for a national performance measure for not treating asymptomatic bacteriuria. *Clin Infect Dis* 2007;45:1335-7.
35. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases

- Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis* 2011;52:e103-20.
36. Gupta K, Hooton TM, Stamm WE. Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. *Ann Intern Med* 2001;135:41-50.
 37. Gupta K, Hooton TM, Roberts PL, et al. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. *Arch Intern Med* 2007;167:2207-12.
 38. Gupta K, Scholes D, Stamm WE. Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women. *JAMA* 1999;281:736-8.
 39. Harding G, et al. The antibiotic puzzle: guidelines for the family physician. *Can J Infect Dis* 1997;8:1-16.
 40. Harding GKM, Ronald AR, Nicolle LE, et al. Long-term antimicrobial prophylaxis for recurrent urinary tract infection in women. *Rev Infect Dis* 1982;4:438-43.
 41. Harding GKM, Zhanel GG, Nicolle LE, et al. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. *N Engl J Med* 2002;347:1576-83.
 42. Hatton J, Hughes M, Raymond CH. Management of bacterial urinary tract infections in adults. *Ann Pharmacother* 1994;28:1264-72.
 43. Holland NH, Kazee M, Duff D, et al. Antimicrobial prophylaxis in children with urinary tract infection and vesicoureteral reflux. *Rev Infect Dis* 1982;4:467-74.
 44. Hooton TM. Uncomplicated urinary tract infection. *N Engl J Med* 2012;366:1028-37.
 45. Hooton TM, Besser R, Foxman B, et al. Acute uncomplicated cystitis in an era of increasing antibiotic resistance: a proposed approach to empirical therapy. *Clin Infect Dis* 2004;39:75-80.
 46. Hooton TM, Roberts PL, Cox ME, et al. Voided midstream urine culture and acute cystitis in premenopausal women. *N Engl J Med* 2013;369:1883-91.
 47. Hom J. Are oral antibiotics equivalent to intravenous antibiotics for the initial management of pyelonephritis in children? *Paediatr Child Health* 2010;15:150-2.
 48. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 international clinical practice guidelines from the Infectious Diseases Society of America. *Clin Infect Dis* 2010;50:625-63.

49. Hooton TM, Scholes D, Gupta K, et al. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women. *JAMA* 2005;293:949-55.
50. Hooton TM, Scholes D, Stapleton AE, et al. A prospective study of asymptomatic bacteriuria in sexually active young women. *N Engl J Med* 2000;343:992-7.
51. Hooton TM, Stamm WE. Diagnosis and treatment of uncomplicated urinary tract infection. *Infect Dis Clin N Amer* 1997;11:551-81.
52. Hooton TM, Stamm WE. Management of acute uncomplicated urinary tract infection in adults. *Med Clin N Amer* 1991;75:339-57.
53. Hooton TM, Winter C, Tiu F, et al. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. *JAMA* 1995;273:41-5.
54. Horcajada JP, Shaw E, Padilla B, et al. Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. *Clin Microbiol Infect* 2013;19:962-8.
55. Iravani A. Advances in the understanding and treatment of urinary tract infections in young women. *Urology* 1991;37:503-11.
56. Jacobsen SM, Stickler DJ, Mobley HLT, et al. Complicated catheter-associated urinary tract infections due to *Escherichia coli* and *Proteus mirabilis*. *Clin Microbiol Rev* 2008;21:26-59.
57. Jepson RG, Williams G, Craig JC. Cranberries for preventing urinary tract infections (Review). *Cochrane Database Systematic Reviews* 2012, Issue 10. Art. No.:CD001321.
58. Johnson JR, Stamm WE. Urinary tract infections in women: diagnosis and treatment. *Ann Intern Med* 1989;111:906-17.
59. Keren R, Carpenter MA, Hoberman A, et al. Rationale and design issues of the randomized intervention for children with vesicoureteral reflux (RIVUR) study. *Pediatrics* 2008;122:S240-50.
60. Khan AJ, Kumar K, Evans HE. Single-dose gentamicin therapy of recurrent urinary tract infection in patients with normal urinary tracts. *J Pediatr* 1987;110:131-5.
61. Kunin CM. Urinary tract infections in females. *Clin Infect Dis* 1994;18:1-12.
62. Le TP, Miller LG. Empirical therapy for uncomplicated urinary tract infections in an era of increasing antimicrobial resistance: a decision and cost analysis. *Clin Infect Dis* 2001;33:615-21.

63. Leisure MK, Dudley SM, Donowitz LG. Does a clean-catch urine sample reduce bacterial contamination? *N Engl J Med* 1993;328:289-90.
64. Lin K, Fajardo K. Screening for asymptomatic bacteriuria in adults: evidence for the U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med* 2008;149:W20-4.
65. Lipsky BA. Urinary tract infections in men: epidemiology, pathophysiology, diagnosis, and treatment. *Ann Intern Med* 1989;110:138-50.
66. Lo E, Nicolle LE, Coffin SE, et al. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals: 2014 update. *Infect Control Hosp Epidemiol* 2014;35:464-79.
67. Lohr JA, Donowitz LG, Sadler JE. Hospital-acquired urinary tract infection. *Pediatrics* 1989;83:193-9.
68. Luchsinger IS. Urinary tract infections: management update. *Can J CME* 1994;Apr:87-94.
69. Maki DG. Review: antibiotic prophylaxis on removal of urinary catheters reduces symptomatic urinary tract infections. *ACP* 2013;159:JC9.
70. Marschall J, Carpenter CR, Fowler S, et al. Antibiotic prophylaxis for urinary tract infections after removal of urinary catheter: meta-analysis. *BMJ* 2013;346:f3147.
71. Masson P, Matheson S, Webster AC, et al. Meta-analyses in prevention and treatment of urinary tract infections. *Infect Dis Clin N Am* 2009;23:355-85.
72. Mehnert-Kay SA. Diagnosis and management of uncomplicated urinary tract infections. *Am Fam Physician* 2005;72:451-6, 458.
73. Micali S, Isgro G, Bianchi G, et al. Cranberry and recurrent cystitis: more than marketing? *Crit Rev Food Science Nutrition* 2014;54:1063-75.
74. Millar LK, Cox SM. Urinary tract infections complicating pregnancy. *Infect Dis Clin North Am* 1997;11:13-26.
75. Miller O, Hemphill RR. Urinary tract infection and pyelonephritis. *Emerg Med Clin North Am* 2001;19:655-74.
76. Mody L, Juthani-Mehta M. Urinary tract infections in older women. A clinical review. *JAMA* 2014;311:844-54.
77. Montini G, Tullus K, Hewitt I. Febrile urinary tract infections in children. *N Engl J Med* 2011;365:239-50.

78. Mori R, Fitzgerald A, Williams C, et al. Antibiotic prophylaxis for children at risk of developing urinary tract infection: a systematic review. *Acta Paediatrica* 2009;98:1781-6.
79. Mori R, Lakhanpaul M, Verrier-Jones K. Diagnosis and management of urinary tract infection in children: summary of NICE guidance. *BMJ* 2007;335:395-7.
80. Neu HC. Trimethoprim alone for treatment of urinary tract infection. *Rev Infect Dis* 1982;4:366-71.
81. Nicolle LE. A practical guide to antimicrobial management of complicated urinary tract infection. *Drugs & Aging* 2001;18:243-54.
82. Nicolle LE. Asymptomatic bacteriuria – Important or not? *N Engl J Med* 2000;343:1037-9.
83. Nicolle LE. Asymptomatic bacteriuria. *Curr Opin Infect Dis* 2014;27:90-6.
84. Nicolle LE. Complicated urinary tract infection in adults. *Can J Infect Dis Med Microbiol* 2005;16:349-60.
85. Nicolle LE. Epidemiology of urinary tract infections. *Clin Microbiol Newsletter* 2002;24:135-40.
86. Nicolle LE. Urinary tract infection in long term-care facility residents. *Clin Infect Dis* 2000;31:757-61.
87. Nicolle LE. Urinary infection in the elderly. *Mod Med* 1990;45:556-63.
88. Nicolle LE, Bradley S, Colgan R, et al. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. *Clin Infect Dis* 2005;40:643-54.
89. Nigrin J. Laboratory diagnosis of urinary tract infections. *Capital Health/DKML Laboratory Bulletin* 1995;1:1-6.
90. Norrby SR. Short-term treatment of uncomplicated lower urinary tract infections in women. *Rev Infect Dis* 1990;12:458-67.
91. Ooi ST, Frazee LA, Gardner WG. Management of asymptomatic bacteriuria in patients with diabetes mellitus. *Ann Pharmacother* 2004;38:490-3.
92. Oreskovic NM, Sembrano EU. Repeat urine cultures in children who are admitted with urinary tract infections. *Pediatrics* 2007;119:e325-9.
93. Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum β -lactamase producing *Escherichia coli*: changing epidemiology and clinical impact. *Curr Opin Infect Dis* 2010;23:320-6.
94. Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. *J Antimicrob Chemother* 2010;65(suppl 3):iii25-33.

95. Pappas PG. Laboratory in the diagnosis and management of urinary tract infections. *Med Clin North Am* 1991;75:313-25.
96. Platt R. Quantitative definition of bacteriuria. *Am J Med* 1983;44-51.
97. Preiksaitis J. Capital Health Protocol: UTI kidney transplant recipients. *Clin Infect Dis* 1992;15.
98. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. *N Engl J Med* 1993;329:753-6.
99. Robinson JL, Finlay JC, Lang ME, et al. Prophylactic antibiotics for children with recurrent urinary tract infections. *Paediatr Child Health* 2015;20:45-7.
100. Robinson JL, Finlay JC, Lang ME, et al. Urinary tract infection in infants and children: Diagnosis and management. *Paediatr Child Health* 2014;19:315-9.
101. Rodriguez-Bano J, Navarro MD. Extended-spectrum β -lactamases in ambulatory care: a clinical perspective. *Clin Microbial Infect* 2008;14(suppl 1):104-10.
102. Rogers BA, Sidjabat HE, Paterson DL. *Escherichia coli* O25b-ST131: a pandemic, multiresistant, community-associated strain. *J Antimicrob Chemother* 2011;66:1-14.
103. Ronald AR, Conway B. An approach to urinary tract infections in ambulatory women. *Curr Clin Topics Infect Dis* 1988;76-125.
104. Ronald AR. Current concepts in the management of urinary tract infections in adults. *Med Clin N Amer* 1984;68:335-49.
105. Rowe TA, Juthani-Mehta M. Diagnosis and management of urinary tract infection in older adults. *Infect Dis Clin North Am* 2014;28:75-89.
106. Saadeh SA, Mattoo TK. Managing urinary tract infections. *Pediatr Nephrol* 2011;26:1967-76.
107. Shapiro ED. Infections of the urinary tract. *Pediatr Inf Dis J* 1992;11:165-8.
108. Shuman EK, Chenoweth CE. Recognition and prevention of healthcare-associated urinary tract infections in the intensive care unit. *Crit Care Med* 2010;38:S373-9.
109. Silver SA, Baillie L, Simor AE. Positive urine cultures: a major cause of inappropriate antimicrobial use in hospitals? *Can J Infect Dis Med Microbiol* 2009;20:107-11.
110. Smellie JM, Gruneberg RN, Bantock HM, et al. Prophylactic co-trimoxazole and trimethoprim in the management of urinary tract infection in children. *Pediatr Nephrol* 1988;2:12-17.

111. Smellie JM, Gruneberg RN, Leakey A, et al. Long-term low-dose co-trimoxazole in prophylaxis of childhood urinary tract infection: clinical aspects. *Brit Med J* 1976;2:203-6.
112. Smellie JM, Gruneberg RN, Normand ICS, et al. Trimethoprim-sulfamethoxazole and trimethoprim alone in the prophylaxis of childhood urinary tract infection. *Rev Infect Dis* 1982;4:461-6.
113. Sousa R, Munoz-Mahamud E, Quayle J, et al. Is asymptomatic bacteriuria a risk factor for prosthetic joint infection? *Clin Infect Dis* 2014;59:41-7.
114. Spencer JR, Schaeffer AJ. Pediatric urinary tract infections. *Urol Clin North Am* 1986;13:661-72.
115. Stamm WE, Counts GW, Running KR, et al. Diagnosis of coliform infection in acutely dysuric women. *N Engl J Med* 1982;307:463-8.
116. Stamm WE, Hooton TM. Management of urinary tract infections in adults. *N Engl J Med* 1993;329:1328-34.
117. Swerkesson S, Jodal U, Ahren C, et al. Urinary tract infection in infants: the significance of low bacterial count. *Pediatr Nephrol* 2016;31:239-45.
118. Talan DA, Stamm WE, Hooton TM, et al. Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial. *JAMA* 2000;283:1583-90.
119. Tenke P, Koves B, Johansen TEB. An update on prevention and treatment of catheter-associated urinary tract infections. *Curr Opin Infect Dis* 2014;27:102-7.
120. Trautner BW. Asymptomatic bacteriuria: when the treatment is worse than the disease. *Nat Rev Urol* 2012;9:85-93.
121. Trautner BW. Management of catheter-associated urinary tract infection. *Curr Opin Infect Dis* 2010;23:76-82.
122. Trautner BW, Bhimani RD, Amspoker AB, et al. Development and validation of an algorithm to recalibrate mental models and reduce diagnostic errors associated with catheter-associated bacteriuria. *BMC Med Informatics Decision Making* 2013;13:48.
123. U.S. Preventative Services Task Force. Screening for asymptomatic bacteriuria in adults: U.S. Preventive Services Task Force reaffirmation recommendation statement. *Ann Intern Med* 2008;149:43-7.
124. Wang CH, Fang CC, Chen NC, et al. Cranberry-containing products for prevention of urinary tract infections in susceptible populations. *Arch Intern Med* 2012;172:988-96.

125. Warren JW, Abrutyn E, Hebel JR, et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. *Clin Infect Dis* 1999;29:745-58.
126. Widmer M, Gulmezoglu AM, Mignini L, et al. Duration of treatment for asymptomatic bacteriuria during pregnancy (Review). *Cochrane Database Systematic Reviews* 2011, Issue 12. Art. No.:CD000491.
127. Williams G, Craig JC. Prevention of recurrent urinary tract infection in children. *Curr Opin Infect Dis* 2009;22:72-6.
128. Williams GJ, Macaskill P, Chan SF, et al. Absolute and relative accuracy of rapid urine tests for urinary tract infection in children: a meta-analysis. *Lancet Infect Dis* 2010;10:240-50.
129. Winn WR, Silton J, Finegold SM. In vitro sensitivity to nitrofurantoin compared with clinical bacteriological response. *Antimicrob Agents Chemother* 1964;5:82-90.

Central Nervous System

Meningitis

1. Anon. Drugs for bacterial infections. *Treatment Guidelines Med Lett* 2010;8: 43-52.
2. Brackbill ML, Brophy GM. Adjunctive rifampin therapy for central nervous system staphylococcal infections. *Ann Pharmacother* 2001;35:765-9.
3. Brouwer MC, Heckenberg SGB, de Gans J. Nationwide implementation of adjunctive dexamethasone therapy for pneumococcal meningitis. *Neurology* 2010;75:1533-9.
4. Brouwer MC, McIntyre P, de Gans, J, et al. Corticosteroids for acute bacterial meningitis. *Cochrane Database Syst Rev* 2010, Issue 9, Art. No.: CD004405.
5. Brouwer MC, Tunkel AR, van de Beek D. Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. *Clin Microbiol Rev* 2010;23:467-92.
6. Carey RB. Rapid diagnosis of bacterial meningitis by antigen detection. *Infect Dis Newslett*.
7. Davis LE, Guerre J, Gerstein WH. Recurrent Herpes simplex virus type 2 meningitis in elderly persons. *Arch Neurol* 2010; 67:759-60.
8. De Gans J, van de Beek D. Dexamethasone in adults with bacterial meningitis. *N Engl J Med* 2002;347:1549-56.
9. Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults: a review of 493 episodes. *N Engl J Med* 1993;328:21-8.

10. Dworzack DL, Sanders CC, Horowitz EA, et al. Evaluation of single-dose ciprofloxacin in the eradication of *Neisseria meningitidis* from nasopharyngeal carriers. *Antimicrob Agents Chemother* 1988;32:1740-1.
11. Feigin RD, McCracken GH, Klein JO. Diagnosis and management of meningitis. *Pediatr Infect Dis J* 1992;11:785-814.
12. Fitch MT, van de Beek D. Emergency diagnosis and treatment of adult meningitis. *Lancet Infect Dis* 2007;7:191-200.
13. Forward KR. Prospective evaluation of bacterial antigen detection in cerebral spinal fluid in the diagnosis of bacterial meningitis in a predominantly adult hospital. *Diagn Microbiol Infect Dis* 1988;11:61-3.
14. Fox JLR. In children with bacterial meningitis, does the addition of dexamethasone to an antibiotic treatment regimen result in a better clinical outcome than the antibiotic regimen alone? Part A: Evidence-based answer and summary. *Paediatr Child Health* 2006;11:33-4.
15. Gaunt PN, Lambert BE. Single dose ciprofloxacin for the eradication of pharyngeal carriage of *Neisseria meningitidis*. *J Antimicrob Chemother* 1988;21:489-96.
16. Guardado AR, Blanco A, Asensi V, et al. Multidrug-resistant *Acinetobacter* meningitis in neurosurgical patients with intraventricular catheters: assessment of different treatments. *J Antimicrob Chemother* 2008;61:908-13.
17. Hart CA, Cuevas LE, Marzouk O, et al. Management of bacterial meningitis. *J Antimicrob Chemother* 1993;32:49-59.
18. Kallio-Laine K, Seppanen M, Kautiainen H, et al. Recurrent lymphocytic meningitis positive for Herpes simplex virus type 2. *Emerg Infect Dis* 2009;15:1119-22.
19. Karageorgopoulos DE, Valkimadi PE, Kapaskelis A, et al. Short versus long duration of antibiotic therapy for bacterial meningitis: a meta-analysis of randomised controlled trials in children. *Arch Dis Child* 2009;94:607-14.
20. Kellner JD. Response to "Benefits of glucocorticosteroids in the treatment of bacterial meningitis in children: End of the controversy?" *Paediatr Child Health* 2006;11:31-2.
21. Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Intrathecal colistin for drug-resistant *Acinetobacter baumannii* central nervous system infection: a case series and systematic review. *Clin Microbiol Infect* 2010;16:888-94.

22. Kim BN, Peleg AY, Lodise TP, et al. Management of meningitis due to antibiotic-resistant *Acinetobacter* species. *Lancet Infect Dis* 2009;9:245-55.
23. Kim KS. Acute bacterial meningitis in infants and children. *Lancet Infect Dis* 2010;10:32-42.
24. Kiska DL, Jones MC, Mangum ME, et al. Quality assurance study of bacterial antigen testing of cerebrospinal fluid. *J Clin Microbiol* 1995;33:1141-4.
25. Le J, Bookstaver PB, Rudisill CN, et al. Treatment of meningitis caused by vancomycin-resistant *Enterococcus faecium*: high-dose and combination daptomycin therapy. *Ann Pharmacother* 2010;44:2001-6.
26. Lu CH, Chang WN. Adults with meningitis caused by oxacillin-resistant *Staphylococcus aureus*. *Clin Infect Dis* 2000;31:723-7.
27. McCracken GH. New developments in the management of children with bacterial meningitis. *Ped Infect Dis* 1984;S32-4.
28. Mirakhur B, McKenna M. Recurrent Herpes simplex type 2 virus (Mollaret) meningitis. *JABFP* 2004;17:303-5.
29. Molyneux E, Nizami SQ, Saha S, et al. 5 versus 10 days of treatment with ceftriaxone for bacterial meningitis in children: a double-blind randomised equivalence study. *Lancet* 2011;377:1837-45.
30. Mongelluzzo J, Mohamad Z, Ten Have TR, et al. Corticosteroids and mortality in children with bacterial meningitis. *JAMA* 2008;299:2048-55.
31. Paris MM, Ramilo O, McCracken GH. Management of meningitis caused by penicillin-resistant *Streptococcus pneumoniae*. *Antimicrob Agents Chemother* 1995;39:2171-5.
32. Pediatric Red Book 1997. *Haemophilus influenzae* infections. 222-4.
33. Peltola H, Roine I, Fernandez J, et al. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial. *Clin Infect Dis* 2007;45:1277-86.
34. Perkins MD, Mirrett S, Reller LB. Rapid bacterial antigen detection is not clinically useful. *J Clin Microbiol* 1995;33:1486-91.
35. Pettersen G, Ovetchkine P, Tapiero B. Group A streptococcal meningitis in a pediatric patient following cochlear implantation: report of the first case and review of the literature. *J Clin Microbiol* 2005;43:5816-8.
36. Quagliarello VJ, Scheld WM. Bacterial meningitis: pathogenesis, pathophysiology, and progress. *N Engl J Med* 1992;327:864-72.

37. Quagliarello VJ, Scheld WM. New perspectives on bacterial meningitis. *Clin Infect Dis* 1993;17:603-10.
38. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. *N Engl J Med* 1997;336:708-16.
39. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. *N Engl J Med* 1997;337:970-6.
40. Sebire G, Cyr C. Benefits of glucocorticosteroids in the treatment of bacterial meningitis in children: End of the controversy? *Paediatr Child Health* 2006;11:29-31.
41. Sigurdardottir B, Bjornsson OM, Jonsdottir KE, et al. Acute bacterial meningitis in adults: a 20 year overview. *Arch Intern Med* 1997;157:425-30.
42. Snape MD, Kelly D. Fine with five? Shorter antibiotic courses for childhood meningitis. *Lancet* 2011;377:1809-10.
43. Spach DH. New issues in bacterial meningitis in adults. *Postgrad Med* 2003;114:43-50.
44. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and *Neisseria meningitidis*. *Lancet* 2007;369:2196-210.
45. Tebruegge M, Curtis N. Epidemiology, etiology, pathogenesis, and diagnosis of recurrent bacterial meningitis. *Clin Microbiol Rev* 2008;21:519-37.
46. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. *Clin Infect Dis* 2004;39:1267-84.
47. Tunkel AR, Scheld WM. Acute bacterial meningitis. *Lancet* 1995;346:1675-80.
48. van de Beek D, Drake JM, Tunkel AR. Nosocomial bacterial meningitis. *N Engl J Med* 2010;362:146-54.
49. Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. *Clin Infect Dis* 2005;40:1288-97.
50. Vaudry W. Steroids in meningitis Part B: Clinical commentary. *Paediatr Child Health* 2006;11:35-6.
51. Visintin C, Mugglestone MA, Fields EJ, et al. Management of bacterial meningitis and meningococcal septicaemia in children and young people: summary of NICE guidance. *BMJ* 2010;340:92-4.
52. Wispelwey B, Tunkel AR, Scheld WM. Bacterial meningitis in adults. *Infect Dis Clin N Amer* 1990;4:645-59.

53. Wong-Beringer A, Beringer P, Lovett MA. Successful treatment of multidrug-resistant *Pseudomonas aeruginosa* meningitis with high-dose ciprofloxacin. Clin Infect Dis 1997;25:936-7.
54. Zarrouk V, Vassor I, Bert F, et al. Evaluation of the management of postoperative aseptic meningitis. Clin Infect Dis 2007;44:1555-9.

Brain Abscess

1. Bartlett JG. 1997 pocket book of infectious disease therapy. Baltimore, Maryland: Williams & Wilkins; 1997.
2. Boom WH, Tuazon CU. Successful treatment of multiple brain abscesses with antibiotics alone. Rev Infect Dis 1985;7:189-99.
3. Chun CH, Johnson JD, Hofstetter M, et al. Brain abscess: a study of 45 consecutive cases. Medicine 1986;65:415-31.
4. Gorbach SL, Mensa J, Gatell JM. 1997 pocket book of antimicrobial therapy and prevention. Baltimore, Maryland: Williams & Wilkins 1997.
5. Jadavji T, Humphreys RP, Prober CG. Brain abscesses in infants and children. Pediatr Infect Dis 1985;4:394-8.
6. Mampalam TJ, Rosenblum ML. Trends in the management of bacterial brain abscesses: a review of 102 cases over 17 years. Neurosurgery 1988;23:451-8.
7. Mathisen GE, Johnson JP. Brain abscess. Clin Infect Dis 1997;25:763-81.
8. Richards J, Sisson PR, Hickman JE, et al. Microbiology, chemotherapy and mortality of brain abscess in Newcastle - upon-Tyne between 1979 and 1988. Scand J Infect Dis 1990;22:511-18.
9. Gilbert DN, Moellering RC, Eliopoulos GM, eds. The Sanford guide to antimicrobial therapy 2012. Sperryville, VA: Antimicrobial Therapy, Inc. 2012.
10. Sjolín J, Lilja A, Eriksson N, et al. Treatment of brain abscess with cefotaxime and metronidazole: prospective study on 15 consecutive patients. Clin Infect Dis 1993;17:857-63.
11. Warner JF, Perkins RL, Cordero L. Metronidazole therapy of anaerobic bacteremia, meningitis and brain abscess. Arch Intern Med 1979;139:167-9.

Epidural Abscess

1. Auletta JJ, John CC. Spinal epidural abscesses in children: a 15-year experience and review of the literature. Clin Infect Dis 2001;32:9-16.

2. Borum SE, McLeskey CH, Williamson JB, et al. Epidural abscess after obstetric epidural analgesia. *Anesthesiology* 1995;82:1523-6.
3. Darouiche, RO. Spinal epidural abscess. *N Engl J Med* 2006;355:2012-20.
4. Ericsson M, Algers G, Schliamser SE. Spinal epidural abscesses in adults: review and report of iatrogenic cases. *Scand J Infect Dis* 1990;22:249-57.
5. Schweich PJ, Hurt TL. Spinal epidural abscess in children: two illustrative cases. *Pediatr Emerg Care* 1992;8:84-7.

Subdural Empyema

1. Dill SR, Cobb CG, McDouals CK. Subdural empyema: analysis of 32 cases and review. *Clin Infect Dis* 1995;20:372-86.

Encephalitis

1. Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. *Ann Intern Med* 1992;116:33-43.
2. Johnson RT. Acute encephalitis. *Clin Infect Dis* 1996;23:219-26.
3. Kimberlin DW, Lin C-Y, Jacobs RF, et al. Natural history of neonatal herpes simplex virus infections in the acyclovir era. *Pediatrics* 2001;108:223-9.
4. Kimberlin DW, Lin C-Y, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. *Pediatrics* 2001;108:230-8.
5. Kolski H, Ford-Jones EL, Richardson S, et al. Etiology of acute childhood encephalitis at the Hospital for Sick Children, Toronto, 1994-95. *Clin Infect Dis* 1998;26:398-409.
6. Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis* 2008;47:303-27.
7. Whitley RJ. Viral encephalitis. *N Engl J Med* 1990;323:242-50.

Vascular

Bacteremia

S. aureus

1. Bai AD, Showler A, Burry L, et al. Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA

- bacteraemia: results from a large multicenter cohort study. *J Antimicrob Chemother* 2015;70:1539-46.
2. Chong YP, Moon SM, Bang KM, et al. Treatment duration for uncomplicated *Staphylococcus aureus* bacteremia to prevent relapse: analysis of a prospective observational cohort study. *Antimicrob Agents Chemother* 2013;57:1150-6.
 3. Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal β -lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant *Staphylococcus aureus*: role of enhanced daptomycin binding. *Clin Infect Dis* 2011;53:158-63.
 4. Gould IM. Treatment of bacteraemia: methicillin-resistant *Staphylococcus aureus* (MRSA) to vancomycin-resistant *S. aureus* (VRSA). *Internat J Antimicrob Agents* 2013;425:S17-21.
 5. Havey TC, Fowler RA, Daneman N. Duration of antibiotic therapy for bacteremia: a systematic review and meta-analysis. *Crit Care* 2011;15:R267.
 6. Holland TL, Arnold C, Fowler VG. Clinical management of *Staphylococcus aureus* bacteremia – a review. *JAMA* 2014;312:1330-41.
 7. Kalil AC, Van Schooneveld TC, Fey PD, et al. Association between vancomycin minimum inhibitory concentration and mortality among patients with *Staphylococcus aureus* bloodstream infections – a systematic review and meta-analysis. *JAMA* 2014;312:1552-64.
 8. McConeghy KW, Bleasdale SC, Rodvold KA. The empirical combination of vancomycin and a β -lactam for staphylococcal bacteremia. *Clin Infect Dis* 2013;57:1760-5.
 9. McDanel JS, Roghmann MC, Perencevich EN, et al. Comparative effectiveness of cefazolin versus nafcillin or oxacillin for treatment of methicillin-susceptible *Staphylococcus aureus* infections complicated by bacteremia: a nationwide cohort study. *Clin Infect Dis* 2017;65:100-6.
 10. Paul M, Kariv G, Goldberg E, et al. Importance of appropriate empirical antibiotic therapy for methicillin-resistant *Staphylococcus aureus* bacteraemia. *J Antimicrob Chemother* 2010;65:2658-65.
 11. Paul M, Zemer-Wassercug N, Talker O, et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive *Staphylococcus aureus* bacteraemia? *Clin Microbial Infect* 2011;17:1581-6.

12. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, et al. Clinical management of *Staphylococcus aureus* bacteraemia. *Lancet Infect Dis* 2011;11:208-22.
13. Tong SYC, Davis JS, Eichenberger E, et al. *Staphylococcus aureus* infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin Microb Rev* 2015;28:603-60.
14. Van Hal SJ, Jensen SO, Vaska VL, et al. Predictors of mortality in *Staphylococcus aureus* bacteremia. *Clin Microb Rev* 2012;25:362-86.
15. Walraven CJ, North MS, Marr-Lyon L, et al. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant *Staphylococcus aureus* bacteraemia. *J Antimicrob Chemother* 2011;66:2386-92.

Salmonella

1. Benenson S, Raveh D, Schlesinger Y, et al. The risk of vascular infection in adult patients with nontyphi *Salmonella* bacteremia. *Am J Med* 2001;110:60-3.
2. Crump JA, Sjolund-Karlsson M, Gordon MA, et al. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive *Salmonella* infections. *Clin Microbiol Rev* 2015;28:901-20.

Endocarditis

3. Abdulmir AS, Hafidh RR, Bakar FA. The association of *Streptococcus bovis/gallolyticus* with colorectal tumors: the nature and the underlying mechanisms of its etiological role. *J Experimental Clin Cancer Research* 2011;30:11-23.
4. American Heart Association. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. Accessed on-line November 23, 2004.
5. Apstein MD, Schneider T. Whipple's disease. UpToDate 2012. Accessed February 23, 2012.
6. Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. *Circulation* 2010;121:458-77.
7. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. A scientific statement for healthcare professionals from

- the American Heart Association. *Circulation* 2015;132:00-00. DOI: 10.1161/CIR.0000000000000296
8. Baltimore RS. Infective endocarditis in children. *Pediatr Infect Dis J* 1992;11:907-12.
 9. Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update. A scientific statement from the American Heart Association. *Circulation* 2015;132:1487-1515.
 10. Bayer AS. Infective endocarditis. *Clin Infect Dis* 1993;17:313-22.
 11. Boleij A, van Gelder MMHJ, Swinkels DW, et al. Clinical importance of *Streptococcus gallolyticus* infection among colorectal cancer patients: systematic review and meta-analysis. *Clin Infect Dis* 2011;53:870-8.
 12. Cahill TJ, Baddour LM, Habib G, et al. Challenges in infective endocarditis. *J Am Coll Cardiol* 2017;69:325-44.
 13. Chambers HF, Korzeniowski OM, Sande MA. *Staphylococcus aureus* endocarditis: clinical manifestations in addicts and nonaddicts. *Medicine* 1983;62:170-7.
 14. Chambers HF, Miller RT, Newman MD. Right-sided *Staphylococcus aureus* endocarditis in intravenous drug abusers: two-week combination therapy. *Ann Intern Med* 1988;109:619-24.
 15. Choudhri SH, Endocarditis Care Plan Working Group. Consensus guidelines for the treatment of infectious endocarditis with outpatient parenteral antibiotic therapy. *Can J Infect Dis* 2000;11(suppl D):4D-10D.
 16. Cohen PS, Maguire JH. Infective endocarditis caused by gram-negative bacteria: a review of the literature, 1945-1977. *Prog Cardiovasc Dis* 1980;22:205-42.
 17. Cosgrove SE, Vighiani GA, Champion M, et al. Initial low-dose gentamicin for *Staphylococcus aureus* bacteremia and endocarditis is nephrotoxic. *Clin Infect Dis* 2009;48:713-21.
 18. Darras-Joly C, Lortholary O, Mainardi JL, et al. Haemophilus endocarditis: report of 42 cases in adults and review. *Clin Infect Dis* 1997; 24:1087-94.
 19. Dhand A, Bayer AS, Pogliano J, et al. Use of antistaphylococcal β -lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant *Staphylococcus aureus*: role of enhanced daptomycin binding. *Clin Infect Dis* 2011;53:158-63.
 20. Didier R. Q fever endocarditis. UpToDate 2012.
 21. DiNubile MJ. Short-course antibiotic therapy for right-sided endocarditis caused by *Staphylococcus aureus* in injection drug users. *Ann Intern Med* 1994;121:873-6.

22. Drinkovic D, Morris AJ, Pottumarthy S, et al. Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis. *J Antimicrob Chemother* 2003;52:820-5.
23. Falagas ME, Giannopoulou KP, Ntziora F, et al. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence. *J Antimicrob Chemother* 2007;60:7-19.
24. Falagas ME, Manta KG, Ntziora F, et al. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. *J Antimicrob Chemother* 2006;58:273-80.
25. Falagas ME, Matthaiou DK, Bliziotis IA. The role of aminoglycosides in combination with a β -lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. *J Antimicrob Chemother* 2006;57:639-47.
26. Fenollar F, Celard M, Lagier JC, et al. *Tropheryma whipplei* endocarditis. *Emerg Infect Dis* 2013;19:1721-30.
27. Fenollar F, Lagier JC, Raoult D. *Tropheryma whipplei* and Whipple's disease. *J Infect* 2014;69:103-12.
28. Fortun J, Navas E, Martinez-Beltran J, et al. Short-course therapy for right-side endocarditis due to *Staphylococcus aureus* in drug abusers: cloxacillin versus glycopeptides in combination with gentamicin. *Clin Infect Dis* 2001;33:120-5.
29. Fowler VG, Boucher HW, Corey R, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by *Staphylococcus aureus*. *N Engl J Med* 2006;355:653-65.
30. Franco MP, Mulder M, Gilman RH, et al. Human brucellosis. *Lancet Infect Dis* 2007;7 :775-86.
31. Gavalda J, Lopez P, Martin T, et al. Efficacy of ceftriaxone and gentamicin given once a day by using human-like pharmacokinetics in treatment of experimental staphylococcal endocarditis. *Antimicrob Agents Chemother* 2002;46:378-84.
32. Gavalda J, Len O, Miro JM, et al. Brief communication: treatment of *Enterococcus faecalis* endocarditis with ampicillin plus Ceftriaxone. *Ann Intern Med* 2007;146:574-9.
33. Gordon RJ, Quagliarello B, Lowy FD. Ventricular assist device-related infections. *Lancet Infect Dis* 2006;6:426-37.
34. Gould FK, Denning DW, Elliott TSJ, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. *J Antimicrob Chemother* 2012;67:269-89.

35. Gutschik E. New developments in the treatment of infective endocarditis infective cardiovasculitis. *Int J Antimicrob Agents* 1999;13:79-92.
36. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009). *European Heart Journal* 2009;30:2369-2413.
37. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC guidelines for the management of infective endocarditis. *European Heart J* 2015;36:3075-123.
38. Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users: prognostic features in 102 episodes. *Ann Intern Med* 1992;117:560-6.
39. Heldman AW, Hartert TV, Ray SC, et al. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. *Am J Med* 1996;101:68-76.
40. Hoen B, Duval X. Infective endocarditis. *N Engl J Med* 2013;368:1425-33.
41. Kanafani Z, Boucher H, Fowler V, et al. Daptomycin compared to standard therapy for the treatment of native valve endocarditis. *Enferm Infecc Microbiol Clin* 2010;28:498-503.
42. Kaye D. Treatment of infective endocarditis. *Ann Intern Med* 1996;124:606-8.
43. Kern WV. Management of *Staphylococcus aureus* bacteremia and endocarditis: progresses and challenges. *Curr Opin Infect Dis* 2010;23:346-58.
44. Knoll B, Tleyjeh IM, Steckelberg JM, et al. Infective endocarditis due to penicillin-resistant viridans group streptococci. *Clin Infect Dis* 2007;44:1585-92.
45. Koruk ST, Erdem H, Koruk I, et al. Management of *Brucella* endocarditis: results of the Gulhane study. *Int J Antimicrob Agents* 2012;40:145-50.
46. Le T, Bayer AS. Combination antibiotic therapy for infective endocarditis. *Clin Infect Dis* 2003;36:615-21.
47. Lester SJ, Wilansky S. Endocarditis and associated complications. *Crit Care Med* 2007;35:S384-91.
48. Levine DP. Clinical experience with daptomycin: bacteraemia and endocarditis. *J Antimicrob Chemother* 2008;62(suppl 3):iii35-9.

49. Meyer DJ, Gerding DN. Favorable prognosis of patients with prosthetic valve endocarditis caused by gram-negative bacilli of the HACEK group. *Am J Med* 1988;85:104-7.
50. Million M, Thuny F, Richet H, et al. Long-term outcome of Q fever endocarditis: a 26-year personal survey. *Lancet Infect Dis* 2010;10:527-35.
51. Morris AJ, Drinkovic D, Pottumarthy S, et al. Bacteriological outcome after valve surgery for active infective endocarditis: implications for duration of treatment after surgery. *Clin Infect Dis* 2005;41:187-94.
52. Oakley CM. Treatment of prosthetic valve endocarditis. *J Antimicrob Chemother* 1987;20:181-6.
53. Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2016;62:e1-50.
54. Parker RH, Fossieck BE. Intravenous followed by oral antimicrobial therapy for Staphylococcal endocarditis. *Ann Intern Med* 1980;93:832-4.
55. Patterson TF, Thompson GR, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2016.
56. Pearce MM, Theodoropoulos N, Noskin GA, et al. Native valve endocarditis due to a noval strain of *Legionella*. *J Clin Microbiol* 2011;49:3340-2.
57. Pericas JM, Cervera C, del Rio A, et al. Changes in the treatment of *Enterococcus faecalis* infective endocarditis in Spain in the last 15 years: from ampicillin plus gentamicin to ampicillin plus ceftriaxone. *Clin Microbiol Infect* 2014;20:O1075-83.
58. Perry JD, Jones AL, Gould FK. Glycopeptide tolerance in bacteria causing endocarditis. *J Antimicrob Chemother* 1999;44:121-4.
59. Prendergast BD, Tornos P. Surgery for infective endocarditis: who and when? *Circulation* 2010;121:1141-52.
60. Raoult D, Sexton DJ. Culture-negative endocarditis. UpToDate 2012. Accessed February 23, 2012.
61. Raoult D. Q fever endocarditis. UpToDate 2012. Accessed February 23, 2012.
62. Remetz MS, Quagliariello V. Endovascular infections arising from right-sided heart structures. *Cardiology Clinics* 1992;10:137-49.
63. Ribera E, Gomez-Jimenez J, Cortes E, et al. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-

- sided *Staphylococcus aureus* endocarditis: a randomized controlled trial. *Ann Intern Med* 1996;125:969-74.
64. Saiman L, Prince A, Gersony WM. Pediatric infective endocarditis in the modern era. *J Pediatr* 1993;122:847-53.
 65. Sandre RM, Shafran SD. Infective endocarditis: review of 135 cases over 9 years. *Clin Infect Dis* 1996;22:276-86.
 66. Spach DH. Endocarditis caused by Bartonella. UpToDate 2012. Accessed February 23, 2012.
 67. Stamboulian D, Carbone E. Recognition, management and prophylaxis of endocarditis. *Drugs* 1997;54:730-44.
 68. Tacke D, Koehler P, Cornely OA. Fungal endocarditis. *Curr Opin Infect Dis* 2013;26:501-7.
 69. Tattevin P, Revest M, Lefort A, et al. Fungal endocarditis: current challenges. *Int J Antimicrob Agents* 2014;44:290-4.
 70. Tsigrelis C, Singh KV, Coutinho TD, et al. Vancomycin-resistant *Enterococcus faecalis* endocarditis: linezolid failure and strain characterization of virulence factors. *J Clin Microbiol* 2007;45:631-5.
 71. Warren RE. Daptomycin in endocarditis and bacteraemia: a British perspective. *J Antimicrob Chemother* 2008;62(suppl 3):iii25-33.
 72. Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. *JAMA* 1995;274:1706-13.
 73. Yung D, Kottachchi D, Neupane B, et al. Antimicrobials for right-sided endocarditis in intravenous drug users: a systematic review. *J Antimicrob Chemother* 2007;60:921-8.

Pericarditis

1. Imazio M, Spodick DH, Brucato A, et al. Controversial issues in the management of pericardial diseases. *Circulation* 2010;121:916-28.
2. Parikh SV, Memon N, Echols M, et al. Purulent pericarditis: report of 2 cases and review of the literature. *Medicine* 2009;88:52-65.

Sepsis

1. Andrews MM, Parent EM, Barry M, et al. Recurrent nonmenstrual toxic shock syndrome: clinical manifestations, diagnosis, and treatment. *Clin Infect Dis* 2001;32:1470-9.
2. Anon. Systemic antifungal drugs. *Med Lett Drugs Ther* 1997;39:86-8.
3. Baraff LJ, Bass JW, Fleisher GR, et al. Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. *Pediatrics* 1993;92:1-12.

4. Bateman SL, Seed PC. Procession to pediatric bacteremia and sepsis: covert operations and failures in diplomacy. *Pediatrics* 2010;126:137-50.
5. Berrington A, Gould FK. Use of antibiotic locks to treat colonized central venous catheters. *J of Antimicrobial Chemotherapy* 2001;48:597-603.
6. Bone RC. Sepsis syndrome: new insights into its pathogenesis and treatment. *Infect Dis Clin North Am* 1991;5:793-805.
7. Burke A, Dunha MD, MAC. Sepsis and septic shock: selection of empiric antimicrobial therapy. *Crit Care Clin* 2008;24:313-334.
8. Burry LD, Wax RS. Role of corticosteroids in septic shock. *Ann Pharmacother* 2004;38:464-72.
9. Chamberland S, L'Ecuyer J, Lessard C, et al. Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. *Clin Infect Dis* 1992;15:615-28.
10. Chan KE, Warren HS, Thadhani RI, et al. Prevalence and outcomes of antimicrobial treatment for *Staphylococcus aureus* bacteremia in outpatients with ESRD. *J Am Soc Nephrol* 2012;23: doi:10.1681/ASN.2012010050.
11. CPS Infectious Diseases and Immunization Committee. Management of the febrile one-to 36-month-old child with no focus of infection. *Paediatr Child Health* 1996;1:41-50.
12. Cunha BA. Antibiotic treatment of sepsis. *Med Clin N Amer* 1995;79:551-8.
13. Cunha BA. Sepsis and septic shock: selection of empiric antimicrobial therapy. *Crit Care Clin* 2008;24:313-34.
14. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Intensive Care Med* 2008;34:17-60.
15. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2012. *Crit Care Med* 2013;41:580-637.
16. Demajo WA, Guimond JG, Rotstein C, et al. Guidelines for the management of nosocomial *Candida* infections in non-neutropenic intensive care patients. *Can J Infect Dis* 1997;8:3-9.
17. Edwards JE. International conference for the development of a consensus on the management and prevention of severe candidal infections. *Clin Infect Dis* 1997;25:43-59.
18. Ehni WF, Reller LB. Short-course therapy for catheter-associated *Staphylococcus aureus* bacteremia. *Arch Intern Med* 1989;149:533-6.

19. Elting LS, Bodey GP, Keefe BH. Septicemia and shock syndrome due to viridans Streptococci: a case-control study of predisposing factors. *Clin Infect Dis* 1992;14:1201-7.
20. Feldman C, Anderson R. Bacteraemic pneumococcal pneumonia. *Drugs* 2011;71:131-53.
21. Fleisher GR, Rosenberg N, Vinci R, et al. Intramuscular versus oral antibiotic therapy for the prevention of meningitis and other bacterial sequelae in young, febrile children at risk for occult bacteremia. *J Pediatr* 1994;124:504-12.
22. Huppler AR, Eickhoff JC, Wald ER. Performance of low-risk criteria in the evaluation of young infants with fever: review of the literature. *Pediatrics* 2010;125:228-33.
23. Johnson MT, Reichley R, Hoppe-Bauer J, et al. Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis. *Crit Care Med* 2011;39:1859-65.
24. Jones AE, Trzeciak S, Kline JA. The sequential organ failure assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation. *Crit Care Med* 2009;37:1649-54.
25. Kumar A. Optimizing antimicrobial therapy in sepsis and septic shock. *Crit Care Clin* 2009;25:733-51.
26. Kumar A, Safdar N, Kethireddy S, et al. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta-regression study. *Crit Care Med* 2010;38:1651-64.
27. Kumar A, Zarychanski R, Light B, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. *Crit Care Med* 2010;38:1773-85.
28. Laupland KB. Polyclonal intravenous immunoglobulin for the prophylaxis and treatment of infection in critically ill adults. *Can J Infect Dis* 2002;13:100-6.
29. Long SS. Antibiotic therapy in febrile children: "best-laid schemes". *J Pediatr* 1994;124:585-8.
30. Low DE, McGeer A. Streptococcal toxic shock and necrotizing fasciitis: new approaches to therapy. *Infect Dis Microbiol Rounds* 2002:vol 2, issue 1.
31. Lutsar I, Metsvaht T. Understanding pharmacokinetics/ pharmacodynamics in managing neonatal sepsis. *Curr Opin Infect Dis* 2010;23:201-7.

32. Martinez JA, Cobos-Trigueros N, Soriano A, et al. Influence of empiric therapy with a β -lactam alone or combined with an aminoglycoside on prognosis of bacteremia due to Gram-negative microorganisms. *Antimicrob Agents Chemother* 2010;54:3590-6.
33. Mermel LA, Farr BM, Sheretz RJ, et al. Guidelines for the management of intravascular catheter-related infections. *Clin Infect Dis* 2001;32:1249-72.
34. Nguyen MH, Peacock JE, Tanner DC, et al. Therapeutic approaches in patients with candidemia. *Arch Intern Med* 1995;155:2429-35.
35. Paul M, Shani V, Muchtar E, et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. *Antimicrob Agents Chemother* 2010;54:4851-63.
36. Piano S, Bartoletti M, Tonon M, et al. Assessment of Sepsis-3 criteria and quick SOFA in patients with cirrhosis and bacterial infections. *Gut* 2017;31 August. doi: 10.1136/gutjnl-2017-314324.
37. Polin R, and the Committee on Fetus and Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis. *Pediatrics* 2012;129:1006-16.
38. Prowle JR, Heenen S, Singer M. Infection in the critically ill – questions we should be asking. *J Antimicrob Chemother* 2011;66 suppl 2:ii3-10.
39. Puskarich MA, Trzeciak S, Shapiro NI, et al. Association between timing of antibiotic administration and mortality from septic shock in patients treated with a quantitative resuscitation protocol. *Crit Care Med* 2011;39:2066-71.
40. Raad II, Bodey GP. Infectious complications of indwelling vascular catheters. *Clin Infect Dis* 1992;15:197-210.
41. Raad II, Hanna HA. Intravascular catheter-related infections. *Arch Intern Med* 2002;162:871-8.
42. Raith EP, Udy AA, Bailey M, et al. Prognostic accuracy of the SOFA score, SIRS criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. *JAMA* 2017;317:290-300.
43. Reuben AG, Musher DM, Hamill RJ. Polymicrobial bacteremia: clinical and microbiologic patterns. *Rev Infect Dis* 1989;11:161-83.
44. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. *N Engl J Med* 1994;331:1325-30.

45. Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. *Crit Care Med* 2017;45:486-52.
46. Rijinders BJ, Wijngaerden EV, Vandecasteele SJ, et al. Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. *J Antimicrob Chemother* 2005;55;90-4.
47. Sawyer RG, Claridge JA, Nathens AB, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. *N Engl J Med* 2015;372:1996-2005.
48. Saxinger LM, Williams KE, Lyon M, et al. Stability of antibiotics in heparin at 37°C: towards antibiotic locks for central venous catheter related infections. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco CA, 1999.
49. Shankar-Hari M, Phillips GS, Levy ML, et al. Developing a new definition and assessing new clinical criteria for septic shock. *JAMA* 2016;315:775-87.
50. Simonsen KA, Anderson-Berry AL, Delair SF, et al. Early-onset neonatal sepsis. *Clin Microbiol Rev* 2014;27:21-47.
51. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with Gram-negative bacteria. *Clin Microbiol Rev* 2012;25:450-70.
52. Vardakas KZ, Tansarli GS, Bliziotis IA, et al. β -lactam plus aminoglycoside or fluoroquinolone combination versus β -lactam monotherapy for *Pseudomonas aeruginosa* infections: a meta-analysis. *Int J Antimicrob Agents* 2013;41:301-10.
53. Vercaigne LM, Wang GQ, Penner BP, et al. Antibiotic/heparin-lock: in vitro stability when combined with heparin in a central venous catheter. *Pharmacother* 2000;20;394-9.
54. Vercaigne LM, Zhanel GG. Antibiotic-heparin lock: in vitro confirmation of antibacterial activity. *Can J Hosp Pharm* 2000;53;193-8.

Catheter-related Bloodstream Infections

1. Chittick P, Sherertz RJ. Recognition and prevention of nosocomial vascular device and related bloodstream infections in the intensive care unit. *Crit Care Med* 2010;38(suppl):S363-72.
2. Eggimann P. Diagnosis of intravascular catheter infection. *Curr Opin Infect Dis* 2007;20:353-9.

3. Funalleras G, Fernandez-Hidalgo N, Borrego A, et al. Effectiveness of antibiotic-lock therapy for long-term catheter-related bacteremia due to gram-negative bacilli: a prospective observational study. *Clin Infect Dis* 2011;53:e129-32.
4. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009;49:1-45.
5. O'Grady NP, Alexander M, Burns LA, et al. Guidelines for the prevention of intravascular catheter-related infections. *Clin Infect Dis* 2011;52:e162-93.
6. Yahav D, Rozen-Zvi B, Gafer-Gvili A, et al. Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials. *Clin Infect Dis* 2008;47:83-93.

Febrile Neutropenia

1. Bliziotis IA, Michalopoulos A, Kasiakou SK, et al. Ciprofloxacin vs an aminoglycoside in combination with a β -lactam for the treatment of febrile neutropenia: a meta-analysis of randomized trials. *Mayo Clin Proc* 2005;80:1146-56.
2. Bodey GP. Empirical antibiotic therapy for fever in neutropenic patients. *Clin Infect Dis* 1993;17:S378-84.
3. Bodey GP. Evolution of antibiotic therapy for infection in neutropenic patients: studies at M.D. Anderson Hospital. *Rev Infect Dis* 1989;11:S1582-90.
4. Bohme A, Shah PM, Stille W, et al. Piperacillin-tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenia patients: a prospective randomized pilot study. *Eur J Med Res* 1998;3:324-30.
5. Bow EJ. Management of the febrile neutropenic cancer patient: lessons from 40 years of study. *Clin Microbiol Infect* 2005;11(suppl 5):24-9.
6. Bustamante CI. Initial empiric therapy for fever in neutropenia. *Recent Results in Cancer Research* 1993;132:45-56.
7. Cooper MR, Durand CR, Beaulac MT, et al. Single-agent, broad-spectrum fluoroquinolones for the outpatient treatment of low-risk febrile neutropenia. *Ann Pharmacother* 2011;45:1094-102.

8. Del Favero A, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. *Clin Infect Dis* 2001;33:1295-301.
9. EORTC International Antimicrobial Therapy Cooperative Group. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. *Ann Intern Med* 1993;119:584-93.
10. European Organization for Research and Treatment of Cancer (EORTC) International Antimicrobial Therapy Cooperative Group and the National Cancer Institute of Canada - Clinical Trials Group. Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic cancer patients. *J Infect Dis* 1991;163:951-8.
11. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2011;52:e56-93.
12. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. *J Clin Oncology* 1995;13:165-76.
13. Giamarellou H, Bassaris HP, Petrikos G, et al. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever. *Antimicrob Agents Chemother* 2000;44:3264-71.
14. Giamarellou H. Empiric therapy for infections in the febrile, neutropenic, compromised host. *Med Clin North Am* 1995;79:559-80.
15. Glasmacher A, Hahn C, Molitor E, et al. A randomized comparison of piperacillin-tazobactam vs. ceftriaxone and gentamicin in 172 severely neutropenic patients with hematologic malignancies. *Interscience Conference on Antimicrobial Agents and Chemotherapy* 1999; Abstract 1090.
16. Glasmacher A, vonLilienfeld-Toal M, Schultz S, et al. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. *Clin Micro Infection* 2005;11(suppl 5):17-23.
17. Hathorn JW, Rubin M, Pizzo PA. Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy. *Antimicrob Agents Chemother* 1987;31:971-7.

18. Hess U, Bohme C, Rey K, et al. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. *Support Care Cancer* 1998;6:402-9.
19. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. *J Infect Dis* 1990;161:381-96.
20. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. *Clin Infect Dis* 1997;25:551-73.
21. Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. *Clin Infect Dis* 2002;34:730-51.
22. Kern WV. Risk assessment and treatment of low-risk patients with febrile neutropenia. *Clin Infect Dis* 2006;42:533-40.
23. Kinsey SE, Machin SJ, Goldstone AH. Ceftazidime monotherapy is as effective as ceftazidime combined with gentamicin in the treatment of febrile neutropenic patients. *J Hosp Infect* 1990;15:49-53.
24. Liles WC, Dale DC. Current approach to the management of neutropenia. *J Intensive Care Med* 1995;10:283-93.
25. Link H, Maschmeyer G, Meyer P, et al. Interventional antimicrobial therapy in febrile neutropenic patients. *Ann Hematol* 1994;69:231-43.
26. Lortholary O, Lefort A, Tod M, et al. Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia. *Lancet Infect Dis* 2008;8:612-20.
27. Martino P, et al. Single daily dose ceftriaxone plus amikacin treatment of febrile episodes in neutropenic patients attending day hospital for hematologic malignancies. *Oncology* 1992;49:49-52.
28. Mavros MN, Polyzos KA, Rafailidis PI, et al. Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis. *J Antimicrob Chemother* 2011;66:251-9.
29. Palazzi DL. The use of antimicrobial agents in children with fever during chemotherapy-induced neutropenia. *Pediatr Infect Dis J* 2011;30:887-90.
30. Paul M, Borok S, Fraser A, et al. Empirical antibiotics against Gram-positive infections for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother* 2005;55:436-44.

31. Paul M, Soares-Weiser K, Leibovici L. β lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. *BMJ* 2003;326:1111-9.
32. Paul M, Yahav D, Fraser A, et al. Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. *J Antimicrob Chemother* 2006;57:176-89.
33. Peacock Jr. JE, Herrington DA, Wade JC, et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. *Ann Intern Med* 2002;137:77-86.
34. Pizzo PA. Current issues in the antibiotic primary management of the febrile neutropenic cancer patient: a perspective from the National Cancer Institute. *J Hosp Infect* 1990;15:41-8.
35. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. *N Engl J Med* 1993;328:1323-32.
36. Ramphal R, Bolger M, Oblon DJ, et al. Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. *Antimicrob Agents Chemother* 1992;36:1062-7.
37. Rolston KVI. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. *Clin Infect Dis* 2005;40(suppl 4):S246-52.
38. Rotstein C, Bow EJ, et al. Adult patient care plan: management of the febrile neutropenic cancer patient on an outpatient basis. *Can J Infect Dis* 2000;11(suppl D):27D-33D.
39. Rozdzinski E, Kern WV, Reichle A, et al. Once-daily versus thrice-daily dosing of netilmicin in combination with β -lactam antibiotics as empirical therapy for febrile neutropenic patients. *J Antimicrob Chemother* 1993;31:585-98.
40. Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a metaanalysis. *J Infect Dis* 1991;164:907-16.
41. Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. *Clin Infect Dis* 1999;29:490-4.

RECOMMENDED EMPIRIC THERAPY OF SELECTED OPHTHALMIC INFECTIONS

1. Al-Badriyeh D, Leung L, Davies GE, et al. Successful salvage treatment of *Scedosporium apiospermum* keratitis with topical voriconazole after failure of natamycin. *Ann Pharmacother* 2009;43:1139-42.
2. Al-Badriyeh D, Leung L, Davies GE, et al. Successful use of topical voriconazole 1% alone as first-line antifungal therapy against *Candida albicans* keratitis. *Ann Pharmacother* 2009;43:2103-7.
3. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern® Guidelines. Bacterial Keratitis. San Francisco, CA: American Academy of Ophthalmology; 2013. Available at www.aao.org/ppp.
4. Auran JD, Starr MB, Jakobiec FA. Acanthamoeba keratitis: a review of the literature. *Cornea* 1987;6:2-26.
5. Bacon AS, Frazer DG, Dart JKG, et al. A review of 72 consecutive cases of Acanthamoeba keratitis, 1984-1992. *Eye* 1993;7:719-25.
6. Barron BA et al: Herpetic eye disease study group, a controlled trial of oral acyclovir for herpes simplex stromal keratitis. *Ophthalmology* 1994;101:1871-82.
7. Baum J. Infections of the eye. *Clin Infect Dis* 1995;21:479-86.
8. Beers M, Berkow R. The Merck manual of diagnosis and therapy 17th ed. West Point, PA: Merck & Co. Inc;1999:704-19.
9. Berger ST, Mondino BJ, Hoft RH, et al. Successful medical management of *Acanthamoeba* keratitis. *Am J Ophthalmol* 1990;110:395-403.
10. Boruchoff A, Boruchoff S. Infections of the lacrimal system. *Infect Dis Clin N Am* 1992;6:925-32.
11. Callegan MC, Engelbert M, Parke II DW, et al. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. *Clin Micro Rev* 2002;15:111-24.
12. Donahue S, Khoury J, Kowalski R. Common ocular infections. A prescriber's guide. *Drugs* 1996;52:526-40.
13. Elder MJ, Dart JKG. Chemotherapy for Acanthamoeba keratitis. *Lancet* 1995;345:791-3.
14. Fanella S, Singer A, Embree J. Presentation and management of pediatric orbital cellulitis. *Can J Infect Dis Med Microbiol* 2011;22:97-100.
15. Friesen A. Sight for sore eyes. *Pharm Pract* 1997;13:71-78.

16. Gilbert DN, Moellering RC, Eliopoulos GM, eds. The Sanford guide to antimicrobial therapy 2012. Sperryville, VA: Antimicrobial Therapy, Inc. 2012.
17. Haimovici R, Roussel T. Treatment of gonococcal conjunctivitis with single intramuscular ceftriaxone. *Am J Ophthalmol* 1989;107:511-14.
18. Hay J, Kirkness CM, Seal DV, et al. Drug resistance and *Acanthamoeba* keratitis: the quest for alternative antiprotozoal chemotherapy. *Eye* 1994;8:555-63.
19. Hershey B, Roth T. Orbital infections. *Seminars in ultrasound, CT, and MRI* 1997;18:448-59.
20. Illingworth CD, Cook SD, Karabatsas CH, et al. *Acanthamoeba* keratitis: risk factors and outcome. *Brit J Ophthalmol* 1995;79:1078-82.
21. Kumar R, Lloyd D. Recent advances in the treatment of *Acanthamoeba* keratitis. *Clin Infect Dis* 2002;35:434-41.
22. Larkin DFP, Kilvington S, Dart JKG. Treatment of *Acanthamoeba* keratitis with polyhexamethylene biguanide. *Ophthalmol* 1992;99:185-91.
23. Leibowitz HM. Primary care: the red eye. *N Engl J Med* 2000;343:345-51.
24. Lindquist TD. Treatment of *Acanthamoeba* keratitis. *Cornea* 1998;17:11-16.
25. Martinez-Vazquez C, Fernandez-Ulloa J, Bordon J, et al. *Candida albicans* endophthalmitis in brown heroin addicts: response to early vitrectomy preceded and followed by antifungal therapy. *Clin Infect Dis* 1998;27:1130-3.
26. McCulley J, Dougherty J, Deneau D. Classification of chronic blepharitis. *Ophthalmology* 1982;89:1173-80.
27. Mueller JB, McStay CM. Ocular infection and inflammation. *Emerg Med Clin N Am* 2008;26:57-72.
28. Nageswaran S, Woods CR, Benjamin DK, et al. Orbital cellulitis in children. *Pediatr Infect Dis J* 2006;25:695-9.
29. O'Brien T, Green W. Section M. Eye infections. In: Mandell GL, Douglas RG, Bennett JE, eds. *Principles and practice of infectious diseases*. 4th ed. New York, NY: Churchill Livingstone;1995;1103-36.
30. Peek MJ, Bajoria R, et al. Chemotherapy for *acanthamoeba* keratitis. *Lancet* 1995;345:
31. Pettit T, Holland G. Chronic keratoconjunctivitis associated with ocular adenovirus infection. *Am J Ophthalmol* 1979;88:748-51.

32. Peyman G, Bassili S. A practical guideline for management of endophthalmitis. *Ophthalmic Surg* 1995;26:294-303.
33. Pierre-Yves R, Adenis JP. Comparative review of topical ophthalmic antibacterial preparations. *Drugs* 2001;61:175-85.
34. Reese R, Betts R. A practical approach to infectious diseases. 3rd ed. Boston/Toronto/London: Little, Brown and Company 1991;146-65.
35. Riddell J, Comer GM, Kauffman CA. Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. *Clin Infect Dis* 2011;52:648-53.
36. Seal DV, Hay J, Kirkness CM. Chlorhexidine or polyhexamethylene biguanide for *Acanthamoeba* keratitis. *Lancet* 1995;345:136.
37. Seal DV, Hay J, Kirkness CM, et al. Successful medical therapy of *Acanthamoeba* keratitis with topical chlorhexidine and propamidine. *Eye* 1996;10:413-21.
38. Sunaric-Megevand G, Pournaras C. Current approach to postoperative endophthalmitis. *Br J Ophthalmol* 1997;81:1006-15.
39. Tasman W, Jaeger E. Duane's Clinical Ophthalmology. Vol 4. Philadelphia, Pennsylvania: Lippincott Williams & Wilkins;1998.
40. Thomas PA, Geraldine P. Infectious keratitis. *Curr Opin Infect Dis* 2007;20:129-41.
41. Virgil D, Liggett P. Vitreoretinal surgery of the injured eye. Philadelphia, PA: Lippincott-Raven Publishers; 1999.
42. Wilhelmus K, et al: Herpetic eye disease study group, a controlled trial of topical corticosteroids for herpes simplex stromal keratitis. *Ophthalmology* 1994;101:1883-96.

RECOMMENDED EMPIRIC THERAPY OF FUNGAL INFECTIONS

1. Achkar JM, Fries BC. Candida infections of the genitourinary tract. *Clin Microbiol Rev* 2010;23:253.
2. Anon. Wide variety of topical treatments for tinea infections. *Drugs Ther Perspect* 1999;13:10-3.
3. Anon. Antifungal drugs. *Med Lett Treatment Guidelines* 2009;7:95-102.
4. Anon. Drugs for vulvovaginal candidiasis. *Med Lett* 2001;43:3-4.
5. Berker D. Fungal nail disease. *N Engl J Med* 2009;360:2108-16.
6. Boursolond A, Lachapelle JM, Aussems J, et al. Double-blind comparison of itraconazole with griseofulvin in the treatment of tinea corporis and tinea cruris. *Int J Dermatol* 1989;28:410-2.

7. Bow EJ, Evans G, Fuller J, et al. Canadian clinical practice guidelines for invasive candidiasis in adults. *Can J Infect Dis Med Microbiol* 2010;21:122-50.
8. Brautigam M, Nolting S, Schopf RE, et al. German randomized double-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection. *Br J Dermatol* 1996;134:18-21.
9. Brown, SJ. Efficacy of fluconazole for the treatment of onychomycosis. *Ann Pharmacother* 2009;43:1684-91.
10. Chapman SW, Bradsher RW, Campbell, Jr GD, et al. Practice guidelines for the management of patients with blastomycosis. *Clin Infect Dis* 2000;30:679-83.
11. Chapman SW, Dismukes WE, Proia LA, et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2008;46:1801-12.
12. Cox GM, Perfect JR. Fungal rhinosinusitis. Up-to-Date 2010. Accessed May 16, 2012.
13. Crissey JT. Common dermatophyte infections. *Postgrad Med* 1998;103:191-205.
14. De Backer M, De Keyser P, De Vroey P, et al. A 12-week treatment for dermatophyte toe onychomycosis: terbinafine 250mg/day vs. itraconazole 200mg/day – a double blind comparative trial. *Br J Dermatol* 1996;134:16-7.
15. Delescluse J. Itraconazole in tinea versicolor: a review. *J Am Acad Dermatol* 1990;23:551-4.
16. Denning DW. Invasive aspergillosis. *Clin Infect Dis* 1998;26:781-805.
17. Dragos V, Lunder M. Lack of efficacy of 6 week treatment with oral terbinafine for tinea capitis due to *Microsporum canis* in children. *Pediatr Dermatol* 1997;14:46-8.
18. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: tinea corporis, tinea cruris, tinea faciei, tinea manuum, and tinea pedis. *J Am Acad Dermatol* 1996;34:282-6.
19. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. *J Am Acad Dermatol* 1996;34:287-9.
20. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: tinea capitis and tinea barbae. *J Am Acad Dermatol* 1996;34:290-4.

21. Edwards JEJ, Bodey GP, Bowden RA, et al. International conference for the development of a consensus on the management and prevention of severe candidal infections. *Clin Infect Dis* 1997;25:43-59.
22. Filho ST, Cuce LC, Foss NT. Efficacy, safety and tolerability of terbinafine for tinea capitis in children: Brazilian multicentric study with daily oral tablets for 1,2, and 4 weeks. *J Eur Acad Dermatol Venereol* 1998;11:141-6.
23. Fisher JF. Infections - epidemiology, pathogenesis, diagnoses, and treatment: Executive summary. *Clin Infect Dis* 2011;52:429-32.
24. Fisher JF, Sobel JD, Kauffman CA, et al. Candida urinary tract infections - treatment. *Clin Infect Dis* 2011;52:457-66.
25. Galgiani JN, Ampel NM, Blair JE, et al. Coccidioidomycosis. *Clin Infect Dis* 2005;41:1217-23.
26. Galgiani JN, Ampel NM, Catanzaro A, et al. Practice guidelines for the treatment of coccidioidomycosis. *Clin Infect Dis* 2000;30:658-61.
27. Griswold M, Briceland L, Stein D. Is amphotericin B test dosing needed? *Ann Pharmacother* 1998;32:475-77.
28. Gruseck E, Splanemann V, Bleck O, et al. Oral terbinafine in tinea capitis in children. *Mycoses* 1996;39:237-40.
29. Gupta AK, Einarson TR, Summerbell RC, et al. An overview of topical antifungal therapy in dermatomycoses. *Drugs* 1998;55:645-74.
30. Hernanz A, Gomez SL, Lastra FG, et al. A comparative double-blind study of terbinafine (Lamisil) and griseofulvin in tinea corporis and tinea cruris. *Clin Exp Dermatol* 1990;15:210-6.
31. Hickman JG. A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor. *J Am Acad Dermatol* 1996;34:785-7.
32. Hofmann H, Brautigam M, Weidinger G, et al. Treatment of toenail onychomycosis: a randomized, double-blind study with terbinafine and griseofulvin. *Arch Dermatol* 1995;131:919-22.
33. Izumikawa K, Takazono T, Kohno S. Chronic aspergillus infections of the respiratory tract: diagnosis, management and antifungal resistance. *Curr Opin Infect Dis* 2010;28:584-9.
34. Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al. Combination antifungal therapy. *Antimicrob Agents Chemother* 2004;48:693-715.
35. Kauffman CA, Bustamante B, Chapman SW, et al. Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2007;45:1255-65.

36. Kauffman CA, Hajjeh R, Chapman SW. Practice guidelines for the management of patients with sporotrichosis. *Clin Infect Dis* 2000; 30:684-7.
37. Kulberg BJ, Verweij PE, Akova M, et al. European expert opinion on the management of invasive candidiasis in adults. *Clin Microbiol Infect* 2011;17:1-12.
38. Lachapelle JM, DeDoncker P, Tennstedt D, et al. Itraconazole compared with griseofulvin in the treatment of tinea corporis/cruris and tinea pedis/manus: an interpretation of the clinical results of all completed double-blind studies with respect to the pharmacokinetic profile. *Dermatology* 1992;184:45-50.
39. Laupland KB, Gregson DB, Church DL, et al. Invasive *Candida* species infections: a 5 year population-based assessment. *J Antimicrob Chemother* 2005;56:532-7.
40. Legendre R, Esola-Macre J. Itraconazole in the treatment of tinea capitis. *J Am Acad Dermatol* 1990;23:559-60.
41. Lewis RE, Klepser ME. The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy. *Am J Health-Syst Pharm* 1999;56:525-36.
42. Limper AH, Knox KS, Sarosi GA et al. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. *Am J Respir Crit Care Med* 2011;183:96-128.
43. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. *Clin Infect Dis* 2004;39:797-802.
44. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2009;48:503-35.
45. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. *Clin Infect Dis* 2004;38:161-89.
46. Pappas PG, Rotstein CMF, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. *Clin Infect Dis* 2007;45:883-93.
47. Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. *Clin Infect Dis* 2008;46:1813-21.

48. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2010;50:291-322.
49. Restrepo A, Robledo J, Gomez I, et al. Itraconazole therapy in lymphangitic and cutaneous sporotrichosis. *Arch Dermatol* 1986;122:413-7.
50. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. *N Engl J Med* 1994;331:1325-30.
51. Rex JH, Pappas PG, Karchmer AW, et al. A randomized and blinded trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. *Clin Infect Dis* 2003;36:1221-8.
52. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. *Clin Infect Dis* 2000;30:710-8.
53. Schwartz S, Ruhnke M, Ribaud P, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. *Blood* 2005;106:2641-5.
54. Segal BH. Aspergillosis. *N Engl J Med* 2009;360:1870-84.
55. Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. *Am J Respir Crit Care Med* 2006;173:707-17.
56. Sharkey-Mathis PK, Kauffman CA, Graybill JR, et al. Treatment of sporotrichosis with itraconazole. *Am J Med* 1993;95:279-85.
57. Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. *Clin Microbiol Rev* 1999;12:40-79.
58. Sobel JD. Practice guidelines for the treatment of fungal infections. *Clin Infect Dis* 2000;30:652.
59. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by *Aspergillus*. *Clin Infect Dis* 2000;30:696-709.
60. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by *Aspergillus*. *Clin Infect Dis* 2000;30:696-709.
61. Tom CM, Kane MP. Management of toenail onychomycosis. *Am J Health-Syst Pharm* 1999;56:865-71.
62. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. *Clin Infect Dis* 2008;46:327-60.
63. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by

the Infectious Diseases Society of America. Clin Infect Dis 2007;45:807-25.

64. Wheat J, Sarosi G, McKinsey D, et al. Practice guidelines for the management of patients with histoplasmosis. Clin Infect Dis 2000;30:688-95.
65. Yamamura DLR, Rotstein C, Nicolle LE, et al. Candidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994. CMAJ 1999;160:493-9.

RECOMMENDED EMPIRIC THERAPY OF ENTERIC PARASITIC INFECTIONS

1. Anon. Drugs for parasitic infections. Treatment Guidelines Med Lett 2013;:e1-31.
2. Bruckner DA. Amebiasis. Clin Microbiol Rev 1992;5:356-69.
3. Cabada MM, White AC. Treatment of cryptosporidiosis: do we know what we think we know? Curr Opin Infect Dis 2010;23:494-9.
4. Chen TL, Chan CC, Chen HP, et al. Clinical characteristics and endoscopic findings associated with Blastocystis hominis in healthy adults. Am J Trop Med Hyg 2003;69:213-6.
5. Cook GC. Use of benzimidazole chemotherapy in human helminthiases: indications and efficacy. Parasitology Today 1990;6:133-6.
6. Coyle CM, Varughese J, Weiss LM, et al. *Blastocystis*: To treat or not to treat....Clin Infect Dis 2012;54:105-10.
7. Craig P, Ito A. Intestinal cestodes. Curr Opin Infect Dis 2007;20:524-32.
8. Gilbert DN, Moellering RC, Eliopoulos GM, eds. The Sanford guide to antimicrobial therapy 2012. Sperryville, VA: Antimicrobial Therapy, Inc. 2012.
9. Graham CS, Brodie SB, Weller PF. Imported *Fasciola hepatica* infection in the United States and treatment with triclabendazole. Clin Infect Dis 2001;33:1-5.
10. Hamblin J, Connor PD. Pinworms in pregnancy. IABFP 1995;8:321-4.
11. Hareesh K, Suresh K, Khairil Anus A, et al. Isolate resistance of Blastocystis hominis to metronidazole. Trop Med Int Health 1999;4:274-7.
12. Khaw M, Panosian CB. Human antiprotozoal therapy: past, present and future. Clin Microbiol Rev 1995;8:427-39.
13. Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections. JAMA 2008;299:1937-48.

14. Koutsavlis AT, Valiquette L, Allard R, et al. Blastocystis hominis: a new pathogen in daycare centres? *CCDR* 2001;27:1-7.
15. Liu LX, Weller PF. Antiparasitic drugs. *N Engl J Med* 1996;334:1178-84.
16. Mandell GL, Bennett JE, and Dolin R, eds. *Mandell, Douglas and Bennett's principles & practice of infectious diseases*. 7th ed. New York: Churchill Livingstone Inc. 2009.
17. Marshall MM, Naumovitz D, Ortega Y, et al. Waterborne protozoan pathogens. *Clin Microbiol Rev* 1997;10:67-85.
18. Montes M, Sawhney C, Barros N. *Strongyloides stercoralis*: there but not seen. *Curr Opin Infect Dis* 2010;23:500-4.
19. Nash TE, Ohl CA, Thomas E, et al. Treatment of patients with refractory giardiasis. *Clin Infect Dis* 2001;33:22-8.
20. Nigro L, Larocca L, Massarelli L, et al. A placebo-controlled treatment trial of Blastocystis hominis infection with metronidazole. *J Travel Med* 2003;10:128-30.
21. Ok UZ, Girginkardesler N, Balcioglu C, et al. Effect of trimethoprim-sulfamethoxazole in *Blastocystis hominis* infection. *Am J Gastroenterol* 1999;94:3245-7.
22. Okhuysen PC. Traveler's diarrhea due to intestinal protozoa. *Clin Infect Dis* 2001;33:110-4.
23. Ortega YR, Adam RD. Giardia: overview and update. *Clin Infect Dis* 1997;25:545-50.
24. Ravdin JI. Amebiasis. *Clin Infect Dis* 1995;20:1453-66.
25. Rosenblatt JE. Antiparasitic agents. *Mayo Clin Proc* 1992;67:276-87.
26. Segarra-Newnham M. Manifestations, diagnosis, and treatment of *Strongyloides stercoralis* infection. *Ann Pharmacother* 2007;41:1992-2001.
27. Smith JW. Strongyloidiasis. *Clin Microbiol Newslet* 1991;13:33-7.
28. Stark D, Barratt JLN, van Hal S, et al. Clinical significance of enteric protozoa in the immunosuppressed human population. *Clin Microbiol Rev* 2009;22:634-50.
29. Stenzel DJ, Boreham PFL. Blastocystis hominis revisited. *Clin Microbiol Rev* 1996;9:563-84.
30. Tan KSW. New insights on classification, identification, and clinical relevance of *Blastocystis* spp. *Clin Microbiol Rev* 2008;21:639-65.
31. Wang KX, Li CP, Wang J, et al. Epidemiological survey of Blastocystis hominis in Huainan city, Anhui province, China. *World J Gastroenterol* 2002;8:928-32.
32. Wolfe MS. Giardiasis. *Clin Microbiol Rev* 1992;5:93-100.

33. Yereli K, Balcioglu IC, Ertan P, et al. Albendazole as an alternative therapeutic agent for childhood giardiasis in Turkey. *Clin Micro Infect* 2004;10:527-9.
34. Zierdt CH. Blastocystis hominis - past and future. *Clin Microbiol Rev* 1991;4:61-79.

RECOMMENDED DRUG REGIMENS FOR SURGICAL PROPHYLAXIS

General Surgery

1. Anon. Antimicrobial prophylaxis for surgery. *Med Lett Treatment Guidelines* 2012;10:73-8.
2. Bauer T, Vennits B, Holm B, et al. Antibiotic prophylaxis in acute nonperforated appendicitis. *Ann Surg* 1989;209:307-11.
3. Bergamini TM, Polk HC. The importance of tissue antibiotic activity in the prevention of operative wound infection. *J Antimicrob Chemother* 1989;23:301-13.
4. Bode LGM, Kluytmans JAJW, Wertheim HFL, et al. Preventing surgical-site infections in nasal carriers of *Staphylococcus aureus*. *N Engl J Med* 2010;362:9-17.
5. Bohnen JMA. Antimicrobial prophylaxis in general surgery. *Can J Surg* 1991;34:548-50.
6. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Am J Health-Syst Pharm* 2013;70:195-283.
7. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention project. *Clin Infect Dis* 2004;38:1706-15.
8. Burke JF. Timing antibiotics to prevent infection. *Drug Therapy* 1976;Feb:209-19.
9. Clinical and economic considerations in antimicrobial surgical prophylaxis. *Drugs and Therapy Perspectives* 1993;2:12-14.
10. Cranny G, Elliott R, Weatherly H, et al. A systematic review and economic model of switching from non-glycopeptide to glycopeptide antibiotic prophylaxis for surgery. *Health Technology Assessment* 2008;12: no. 1.
11. Dellinger EP, Gross PA, Barrett TL, et al. Quality standard for antimicrobial prophylaxis in surgical procedures. *Clin Infect Dis* 1994;18:422-7.
12. Dellinger EP. Antibiotic prophylaxis in trauma: penetrating abdominal injuries and open fractures. *Rev Infect Dis* 1991;13:S847-57.

13. Devlin TB. Canadian Association of Gastroenterology Practice Guidelines: antibiotic prophylaxis for gastrointestinal endoscopy. *Can J Gastroenterol* 1999;13:819-21.
14. Edmiston CE, Krepel C, Kelly H, et al. Perioperative antibiotic prophylaxis in the gastric bypass patient: do we achieve therapeutic levels? *Surgery* 2004;136:738-47.
15. Farr BM. Mupirocin to prevent *S. aureus* infections. *N Engl J Med* 2002;346:1905-6.
16. Forse RA, Karam B, MacLean LD, et al. Antibiotic prophylaxis for surgery in morbidly obese patients. *Surgery* 1989;106:750-7.
17. Gilbert DN, Moellering RC, Eliopoulos GM, eds. *The Sanford guide to antimicrobial therapy* 2013. Sperryville, VA: Antimicrobial Therapy, Inc. 2013.
18. Gorbach SL. Antimicrobial prophylaxis for appendectomy and colorectal surgery. *Rev Infect Dis* 1991;13:S815-20.
19. Gottrup F, Hunt TK. Antimicrobial prophylaxis in appendectomy patients. *World J Surg* 1982;6:306-11.
20. Higgins A, et al. Prophylactic antibiotics for elective laparoscopic cholecystectomy. Are they necessary? *Arch Surg* 1999;134:611-4.
21. Hirota WK, Petersen K, Baron TH, et al. Guidelines for antibiotic prophylaxis for gastrointestinal (GI) endoscopy. *Gastrointest Endosc* 2003;58:475-82.
22. Ho VP, Nicolau DP, Dakin GF, et al. Cefazolin dosing for surgical prophylaxis in morbidly obese patients. *Surg Infect* 2012;13:33-7.
23. Hopkins CC. Antibiotic prophylaxis in clean surgery: peripheral vascular surgery, noncardiovascular thoracic surgery, herniorrhaphy and mastectomy. *Rev Infect Dis* 1991;13:S869-73.
24. Kanji S, Devlin JW. Antimicrobial prophylaxis in surgery. In: Dipro JT, Talbert RL, Yee GC, eds. *Pharmacotherapy*. 6th ed. McGraw-Hill;2005:2217-29.
25. Kernodle DS, Kaiser AB. Postoperative infections and antimicrobial prophylaxis. In: Mandell GL, Bennett JE, Dolin R, et al, eds. *Principles and practice of infectious diseases*. 5th ed. New York: Churchill Livingstone Inc; 2000;3177-91.
26. Lau WY, Chu KW, Poon GP, et al. Prophylactic antibiotics in elective colorectal surgery. *Br J Surg* 1988;75:782-5.
27. Laupland KB, Conly JM. Treatment of *Staphylococcus aureus* colonization and prophylaxis for infection with topical intranasal mupirocin: an evidence-based review. *Clin Infect Dis* 2003;37:933-8.

28. Mangram AJ, Horan TC, Pearson ML, et al. Guideline for prevention of surgical site infection, 1999. *Am J Infect Control* 1999;27:97-134.
29. Matsen JM. The frequency of bacterial pathogens in infections potentially preventable by antimicrobial prophylaxis. *Scand J Infect Dis Suppl* 1990;70:9-17.
30. Nichols RL, Smith JW, Garcia RY, et al. Current practices of preoperative bowel preparation among North American colorectal surgeons. *Clin Infect Dis* 1997;24:609-19.
31. Nichols RL, Smith JW, Klein DB, et al. Risk of infection after penetrating abdominal trauma. *N Engl J Med* 1984;311:1065-70.
32. Norrby SR. Cost-effective prophylaxis of surgical infections. *PharmacoEconomics* 1996;10:128-40.
33. Oates JA, Wood AJJ. Antimicrobial prophylaxis in surgery. *N Engl J Med* 1986;315:1129-38.
34. Page CP, Bohnen JMA, Fletcher JR, et al. Antimicrobial prophylaxis for surgical wounds: Guidelines for clinical care. *Arch Surg* 1993;128:79-88.
35. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative *Staphylococcus aureus* infections. *N Engl J Med* 2002;346:1871-7.
36. Platt R, Zaleznik DF, Hopkins CC, et al. Perioperative antibiotic prophylaxis for herniorrhaphy and breast surgery. *N Engl J Med* 1990;322:153-60.
37. Roland M. Antimicrobial prophylaxis in elective colorectal surgery and appendicitis. *Scand J Infect Dis* 1990;70:36-44.
60. Sanchez-Manuel FJ, Lozano-Garcia J, Seco-Gil JL. Antibiotic prophylaxis for hernia repair (review). *Cochrane Database Syst Rev* 2012, Issue 2. Art. No.: CD003769. DOI: 10.1002/14651858.CD003769.pub4.
38. Tan E, Hart LL. Metronidazole/neomycin as preoperative bowel preparation. *Ann Pharmacother* 1993;27:1064-6.
39. Toma O, Suntrup P, Stefanescu A, et al. Pharmacokinetics and tissue penetration of cefoxitin in obesity: implications for risk of surgical site infection. *Anesth Analg* 2011;113:730-7.
40. van Rijen M, Bonten M, Wenzel R, et al. Mupirocin ointment for preventing *Staphylococcus aureus* infections in nasal carriers. *Cochrane Database Syst Rev* 2008, Issue 4. Art. No.:CD006216.
41. Von Eiff C, Kipp F, Becker K. Intranasal mupirocin to prevent postoperative infections. *N Engl J Med* 2002;347:1207-8.

42. Waddell TK, Rotstein OD. Antimicrobial prophylaxis in surgery. *Can Med Assoc J* 1994;151:925-31.
43. Weber WP, Marti WR, Zwahlen M, et al. The timing of surgical antimicrobial prophylaxis. *Ann Surg* 2008;247:918-26.
44. Winslow RE, Dean RE, Harley JW. Acute nonperforating appendicitis. *Arch Surg* 1983;118:651-5.
45. Zelenitsky SA, Ariano RE, Harding GKM, et al. Antibiotic pharmacodynamics in surgical prophylaxis: an association between intraoperative antibiotic concentrations and efficacy. *Antimicrob Agents Chemother* 2002;46:3026-30.
46. Zelenitsky SA, Silverman RE, Duckworth H, et al. A prospective, randomized, double-blind study of single high dose versus multiple standard dose gentamicin both in combination with metronidazole for colorectal surgical prophylaxis. *J Hospital Infection* 2000;46:135-40.

Cardiovascular Surgery

1. Cesar de Oliveira J, Martinelli M, D'Orio Nishioka SA. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. *Circ Arrhythm Electrophysiol* 2009;2:29-34.
2. Cimochoowski GE, Harostock MD, Brown R, et al. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. *Ann Thorac Surg* 2001;71:1572-9.
3. Conklin CM, Gray RJ, Neilson D, et al. Determinants of wound infection incidence after isolated coronary artery bypass surgery in patients randomized to receive prophylactic cefuroxime or cefazolin. *Ann Thorac Surg* 1988;46:172-7.
4. Curtis JJ, Boley TM, Walls JT, et al. Randomized prospective comparison of first and second generation cephalosporins as infection prophylaxis for cardiac surgery. *Am J Surg* 1993;166:734-7.
5. Da Costa A, Kirkorian G, Cucherat M, et al. Antibiotic prophylaxis for permanent pacemaker implantation: a meta-analysis. *Circulation* 1998;97:1796-1801.
6. Doebbeling B, et al. Cardiovascular surgery prophylaxis: a randomized controlled comparison of cefazolin and cefuroxime. *J Thorac Cardiovasc Surg* 1990;99:981-9.
7. Edwards W, et al. Cefuroxime versus cefazolin as prophylaxis in vascular surgery. *J Vasc Surg* 1992;15:35-41.

8. Edwards FH, Engelman RM, Houck P, et al. The Society of Thoracic Surgeons practice guideline series: Antibiotic prophylaxis in cardiac surgery, part 1: Duration. *Ann Thorac Surg* 2006;81:397-404.
9. Engelman R, Shahian D, Shemin R, et al. The Society of Thoracic Surgeons practice guideline series: Antibiotic prophylaxis in cardiac surgery, part 2: Antibiotic choice. *Ann Thorac Surg* 2007;83:1569-76.
10. Garey KW, Dao T, Chen H, et al. Timing of vancomycin prophylaxis for cardiac surgery patients and the risk of surgical site infections. *J Antimicrob Chemother* 2006;58:645-50.
11. Gentry LO, Zeluff BJ, Cooley DA. Antibiotic prophylaxis in open-heart surgery: a comparison of cefamandole, cefuroxime and cefazolin. *Ann Thorac Surg* 1988;46:167-71.
12. Geroulanos S, Oxelbark S, Turina M. Perioperative antimicrobial prophylaxis in cardiovascular surgery. A prospective randomized trial comparing two day cefuroxime prophylaxis with four day cefazolin prophylaxis. *J Cardiovasc Surg* 1986;27:300-6.
13. Harbarth S, Samore MH, Lichtenberg D, et al. Prolonged antibiotic prophylaxis after cardiovascular surgery and its effect on surgical site infections and antimicrobial resistance. *Circulation* 2000;101:2916-21.
14. Kluytmans JAJW, Mouton JW, VandenBerg MFQ, et al. Reduction of surgical site infections in cardiothoracic surgery by elimination of nasal carriage of *S. aureus*. *Infect Control Hosp Epidemiol* 1996;17:780-5.
15. Kreter B, Woods M. Antibiotic prophylaxis for cardiothoracic operations-metaanalysis of thirty years of clinical trials. *J Thor Cardiovasc Surg* 1992;104:590-9.
16. Lador A, Nasir H, Mansur N, et al. Antibiotic prophylaxis in cardiac surgery: systematic review and meta-analysis. *J Antimicrob Chemother* 2012;67:541-50.
17. Mertz D, Johnstone J, Loeb M. Does duration of perioperative antibiotic prophylaxis matter in cardiac surgery? A systematic review and meta-analysis. *Ann Surg* 2011;254:48-54.
18. Miedzinski LJ, Callaghan JC, Fanning EA, et al. Antimicrobial prophylaxis for open heart operations. *Ann Thor Surg* 1990;50:800-7.
19. Morales DLS, Oz MC. Mechanical circulatory assist devices in critical care management. *New Horiz* 1999;7:489-503.
20. Peterson CD, Lake KD, Arom KV, et al. Antibiotic prophylaxis in open-heart surgery patients: comparison of cefamandole and cefuroxime. *Drug Intell Clin Pharm* 1987;21:728-32.

21. Slama TG, Sklar SJ, Misinski J, et al. Randomized comparison of cefamandole, cefazolin and cefuroxime prophylaxis in open-heart surgery. *Antimicrob Agents Chemother* 1986;29:744-7.
22. Townsend TR, Reitz BA, Bilker WB, et al. Clinical trial of cefamandole, cefazolin, and cefuroxime for antibiotic prophylaxis in cardiac operations. *J Thor Cardiovasc Surg* 1993;106:664-70.
23. Wellens F, et al. Prophylaxis in cardiac surgery. A controlled randomized comparison between cefazolin and cefuroxime. *Eur J Cardiothorac Surg* 1995;9:325-9.
24. Woods M, Tillman D. Antibiotic prophylaxis in cardiothoracic surgery 1990: results of a third study. *Hosp Pharm* 1992;27:404-7.

Head and Neck Surgery

1. Carroll WR, Rosenstiel D, Fix JR, et al. Three-dose vs extended-course clindamycin prophylaxis for free-flap reconstruction of the head and neck. *Arch Otolaryngol Head Neck Surg* 2003;129:771-4.
2. Johnson JT, Yu VL. Antibiotic use during major head and neck surgery. *Ann Surg* 1987;207:108-11.
3. Velanovich V. A meta-analysis of prophylactic antibiotics in head and neck surgery. *Plast Reconstr Surg* 1990;87:429-35.

Neurosurgery

1. Barker FG II. Efficacy of prophylactic antibiotic therapy in spinal surgery: a meta-analysis. *Neurosurgery* 2002;51:391-401.
2. Brown EM, deLouvois J, Bayston R, et al. Antimicrobial prophylaxis in neurosurgery and after head injury. *Lancet* 1994;344:1547-51.
3. Brown EM, Pople IK, deLouvois J, et al. Spine update. Prevention of postoperative infection in patients undergoing spinal surgery. *Spine* 2004;29:938-45.
4. Korinek AM, Bagnon T, Golmard JL, et al. Risk factors for adult nosocomial meningitis after craniotomy: role of antibiotic prophylaxis. *Neurosurgery* 2008;62 suppl 2:532-9.
5. Langley JM, Leblanc JC, Drake J, et al. Efficacy of antimicrobial prophylaxis in placement of cerebrospinal fluid shunts: meta-analysis. *Clin Infect Dis* 1993;17:98-103.
6. Rhoten RL, Murphy MA, Kalfas IH, et al. Antibiotic penetration into cervical discs. *Neurosurgery* 1995;37:418-21.
7. Rubinstein E, Findler G, Amit P, et al. Perioperative prophylactic cephalosporin in spinal surgery: a double-blind placebo-controlled trial. *J Bone Joint Surg Br* 1994;76:99-102.

8. Shapiro M. Prophylaxis in otolaryngologic surgery and neurosurgery: a critical review. *Rev Infect Dis* 1991;13:S858-68.

Obstetrical/Gynecological Surgery

1. American College of Obstetricians and Gynecologists. Antibiotic prophylaxis for gynecologic procedures. *Obstet Gynecol* 2009;113:1180-9.
2. American College of Obstetricians and Gynecologists. Use of prophylactic antibiotics in labor and delivery. *Obstet Gynecol* 2011;117:1472-83.
3. Campillo F, Rubio JM. Comparative study of single-dose cefotaxime and multiple doses of cefoxitin and cefazolin as prophylaxis in gynecologic surgery. *Am J Surg* 1992; 4A:12S-5S.
4. Carlson C, Duff P. Antibiotic prophylaxis for cesarean delivery: is an extended-spectrum agent necessary? *Obstet Gynecol* 1990;76:343-6.
5. Chelmow D, Hennesy M, Evantash EG. Prophylactic antibiotics for nonlaboring patients with intact membranes undergoing cesarean delivery: an economic analysis. *Am J Obstet Gynecol* 2004;191:1661-5.
6. Chelmow D, Ruehli MS, Huang E. Prophylactic use of antibiotics for nonlaboring patients undergoing cesarean delivery with intact membranes: a meta-analysis. *Am J Obstet Gynecol* 2001;184:656-61.
7. Costantine MM, Rahman M, Ghulmiyah L, et al. Timing of perioperative antibiotics for cesarean delivery: a metaanalysis. *Am J Obstet Gynecol* 2008;199:301.e1-6.
8. Crombleholme WR. Use of prophylactic antibiotics in obstetrics and gynecology. *Clin Obstet Gynecol* 1988;31:466-72.
9. Currier JS, Tosteson TD, Platt R. Cefazolin compared with cefoxitin for cesarean section prophylaxis: the use of a two-stage study design. *J Clin Epidemiol* 1993;46:625-30.
10. Faro S. Antibiotic prophylaxis. *Obstet Gynecol Clin North Am* 1989;16:279-89.
11. Gjonnaess H. Antimicrobial prophylaxis in gynaecological and obstetric surgery. *Scand J Infect Dis Suppl* 1990;70:52-67.
12. Griffiths J, Demianczuk N, Cordoviz M, et al. Surgical site infection following elective caesarean section: a case-control study of postdischarge surveillance. *J Obstet Gynaecol Can* 2005;27:340-4.

13. Hager WD, Rapp RP, Billeter M, et al. Choice of antibiotic in nonelective cesarean section. *Antimicrob Agents Chemother* 1991;35:1782-4.
14. Hemsell DL, Bawdon RE, Hemsell PG, et al. Single-dose cephalosporin for prevention of major pelvic infection after vaginal hysterectomy: cefazolin versus cefoxitin versus cefotaxime. *Am J Obstet Gynecol* 1987;156:1201-5.
15. Hemsell DL, Johnson ER, Hemsell PG, Nobles BJ, et al. Cefazolin is inferior to cefotetan as single-dose prophylaxis for women undergoing elective total abdominal hysterectomy. *Clin Infect Dis* 1995;20:677-84.
16. Hemsell DL. Prophylactic antibiotics in gynecologic and obstetric surgery. *Rev Infect Dis* 1991; 13(suppl 10): S821-41.
17. Houang ET. Antibiotic prophylaxis in hysterectomy and induced abortion. *Drugs* 1991;41:19-37.
18. Jakobi P, Weissman A, Zimmer EZ, et al. Single-dose cefazolin prophylaxis for cesarean section. *Am J Obstet Gynecol* 1988;158:1049-52.
19. Kaimal AJ, Zlatnik MG, Cheng YW, et al. Effect of a change in policy regarding the timing of prophylactic antibiotics on the rate of postcesarean delivery surgical-site infections. *Am J Obstet Gynecol* 2008;199:310.e1-5..
20. Periti P, Mazzei T, Periti E. Prophylaxis in gynaecological and obstetric surgery: a comparative randomized multicentre study of single-dose cefotetan versus two doses of cefazolin. *Chemioterapia* 1988;7:245-52.
21. Probst JR, Benrubi GI, Sanchez-Ramos L, et al. Comparison of one dose cefazolin versus one dose cefotetan for cesarean section prophylaxis. *J Florida Med Assoc* 1989;76:1027-9.
22. Scher KS, Bernstein JM, Arenstein GL, et al. Reducing the cost of surgical prophylaxis. *Am Surg* 1990;56:32-5.
23. Shapiro M, Schoenbaum SC, Tager IB, et al. Benefit-cost analysis of antimicrobial prophylaxis in abdominal and vaginal hysterectomy. *JAMA* 1983;249:1290-4.
24. Smail F, Hofmeyr GJ. Antibiotic prophylaxis for cesarean section [review] revised 14 Apr 2004. *Cochrane Database Syst Rev*. The Cochrane Collaboration; Issue, Oxford: Update Software;2004.
25. Smail FM, Gyte GM. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. *Cochrane Database Syst Rev* 2010 Jan 20;(1):CD007482.

26. Society of Family Planning. Prevention of infection after induced abortion. *Contraception* 2011;83:295-309.
27. Sonnichsen DS, Nakagawa RS. A drug utilization review of surgical prophylaxis in obstetrics and gynecology. *Can J Hosp Pharm* 1990;43:281-7.
28. Sullivan SA, Smith T, Chang E, et al. Administration of cefazolin prior to skin incision is superior to cefazolin at cord clamping in preventing postcesarean infectious morbidity: a randomized, controlled trial. *Am J Obstet Gynecol* 2007;196:455.e1-5.
29. Tita ATN, Rouse DJ, Blackwell S, et al. Emerging concepts in antibiotic prophylaxis for cesarean delivery. *Obstet Gynecol* 2009;113:675-82.
30. Van Eyk N, van Schalkwyk J. Antibiotic prophylaxis in gynaecologic procedures. *J Obstet Gynaecol Can* 2012;34:382-91.
31. Van Schalkwyk J, van Eyk N. Antibiotic prophylaxis in obstetric procedures. *J Obstet Gynaecol Can* 2010;247:879-85.

Ophthalmic Surgery

1. Baum JL. Antibiotic use in ophthalmology. In: Tasman W, Jaeger EA, eds. *Duane's clinical ophthalmology*. Philadelphia, Pennsylvania: Lippincott-Raven Publishers; 1995: 4(26): 1-26.
2. Grimes SR, Mein CE, Trevino S. Preoperative antibiotic and povidone-iodine preparation of the eye. *Ann Ophthalmol* 1991;23:263-6.
3. Hurley LD, Westfall CT, Shore JW. Prophylactic use of antibiotics in oculoplastic surgery. *Int Ophthalmol Clin* 1992;32:165-178.
4. Ing MR. Infection following strabismus surgery. *Ophthalmic Surg* 1991;22:41-3.
5. Kolker AE, Freeman MI, Petit TH. Prophylactic antibiotics and postoperative endophthalmitis. *Am J Ophthalmol* 1967;63:434-9.
6. Lean JS, Chignell AH. Infection following retinal detachment surgery. *Br J Ophthalmol* 1977;61:593-4.
7. Masket S, ed. Consultation section. *J Cataract Refract Surg* 1993;19:108-11.
8. McCoy DA, Rains DE. Studies on control of infections at time of intraocular surgery. *Ann Ophthalmol* 1971;3:982-6.
9. McMillan JJ, Mead MD. Prophylactic subconjunctival antibiotics after cataract extraction - evaluation of their desirability and efficacy. *Int Ophthalmol Clin* 1994;34:43-9.
10. Meredith TA. Prevention of postoperative infection. *Arch Ophthalmol* 1991;109:944-5.

11. Ndegwa S, Cimon K, Severn M. Intracameral antibiotics for the prevention of endophthalmitis post-cataract surgery: review of clinical and cost-effectiveness and guidelines. CADTH October 2010.
12. Radda TM, Grasl MM, Gnad HD. Perioperative prevention of infection in ophthalmic surgery. *Antibiot Chemother* 1985;33:184-97.
13. Starr MB, Lally JM. Antimicrobial prophylaxis for ophthalmic surgery. *Surv Ophthalmol* 1995;39:485-501.
14. Walland MJ, Rose GE. Soft tissue infections after open lacrimal surgery. *Ophthalmology* 1994;101:608-11.

Orthopedic Surgery

1. Clarke HJ, Jinnah RH, Byank RP, et al. Clostridium difficile infection in orthopaedic patients. *J Bone Joint Surg* 1990;72A:1056-9.
2. Court-Brown CM. Antibiotic prophylaxis in orthopaedic surgery. *Scand J Infect Dis Suppl* 1990;70:74-9.
3. Cummins JS, Tomek IM, Kantor SR, et al. Cost-effectiveness of antibiotic-impregnated bone cement used in primary total hip arthroplasty. *J Bone Joint Surg Am* 2009;91:634-41.
4. Dellinger EP. Antibiotic prophylaxis in trauma: penetrating abdominal injuries and open fractures. *Rev Infect Dis* 1991;3:S847-57.
5. Gillespie WJ. Prevention and management of infection after total joint replacement. *Clin Infect Dis* 1997;25:1310-7.
6. Hauser CJ, Adams CA, Eachempati SR. Prophylactic antibiotic use of open fractures: an evidence-based guideline. *Surgical Infections* 2006;7:379-405.
7. Hayashi K. Other antibiotics. *Clin Orthopaed Rel Research* 1984;190:109-13.
8. Kalmeijer MD, Coertjens H, van Nieuwland-Bollen PM, et al. Surgical site infections in orthopedic surgery: the effect of mupirocin nasal ointment in a double-blind, randomized, placebo-controlled study. *Clin Infect Dis* 2002;35:353-8.
9. Kim DH, Spencer M, Davidson SM, et al. Institutional prescreening for detection and eradication of methicillin-resistant *Staphylococcus aureus* in patients undergoing elective orthopaedic surgery. *J Bone Joint Surg Am* 2010;92:1820-6.
10. Luer MS, Hatton J. Appropriateness of antibiotic selection and use in laminectomy and microdiscectomy. *Am J Hosp Pharm* 1993;50:667-70.

11. McIntosh J, Earnshaw JJ. Antibiotic prophylaxis for the prevention of infection after major limb amputation. *Eur J Vasc Endovasc Surg* 2009;37:696-703.
12. Norden CW. Antibiotic prophylaxis in orthopedic surgery. *Rev Infect Dis* 1991;13:S842-6.
13. Rao N, Cannella B, Crossett LS, et al. A preoperative decolonization protocol for *Staphylococcus aureus* prevents orthopaedic infections. *Clin Orthop Relat Res* 2008;466:1343-8.
14. Slover J, Haas JP, Quirno M, et al. Cost-effectiveness of a *Staphylococcus aureus* screening and decolonization program for high-risk orthopedic patients. *J Arthroplasty* 2011;26:360-5.
15. Winingar DA, Fass RJ. Antibiotic - impregnated cement and beads for orthopedic infections. *Antimicrob Agents Chemother* 1996;40:2675-9.

Plastics Surgery

1. Aydin N, Uraloglu M, Yilmaz AD, et al. A prospective trial on the use of antibiotics in hand surgery. *Plast Reconstr Surg* 2010;126:1617-23.
2. Bunn F, Cunningham ME, Handscomb K. Prophylactic antibiotics to prevent surgical site infection after breast cancer surgery. *Cochrane Database Syst Rev* 2006, Issue 2. Art No. CD005360.
3. Bykowski MR, Sivak WN, Cray J, et al. Assessing the impact of antibiotic prophylaxis in outpatient elective hand surgery: a single-center, retrospective review of 8,850 cases. *J Hand Surg* 2011;36A:1741-7.
4. Harness NG, Inacio MC, Pfeil FF, et al. Rate of infection after carpal tunnel release surgery and effect of antibiotic prophylaxis. *J Hand Surg Am* 2010;35:189-96.

Spinal Surgery

1. Linam WM, Margolis PA, Staat MA, et al. Risk factors associated with surgical site infection after pediatric posterior spinal fusion procedure. *Infect Control Hosp Epidemiol* 2009;30:109-16.

Thoracic Surgery

1. Bernard A, Pillet M, Goudet P, et al. Antibiotic prophylaxis in pulmonary surgery. A prospective randomized double-blind trial of flash cefuroxime versus forty-eight hour cefuroxime. *J Thor Cardiovasc Surg* 1994;107:896-900.
2. Sharpe DA, Renwick P, Mathews KH, et al. Antibiotic prophylaxis in oesophageal surgery. *Eur J Cardiothorac Surg* 1992;6:561-4.

Urologic Surgery

1. American Urological Association. Best practice policy statement on urologic surgery antimicrobial prophylaxis. Updated Sep 2008. Revised 9/20/2012.
2. Carignan A, Roussy JF, Lapointe V, et al. Increasing risk of infectious complications after transrectal ultrasound-guided prostate biopsies: time to reassess antimicrobial prophylaxis? *Eur Urol* 2012;62:453-9.
3. Gonzalez CM, Averch T, Boyd LA, et al. AUA/SUNA white paper on the incidence, prevention and treatment of complications related to prostate needle biopsy. *Amer Urol Assoc Education and Research* 2012.
4. Larsen EH, Gasser TC, Madsen PO. Antimicrobial prophylaxis in urologic surgery. *Urol Clin North Am* 1986;13:591-602.
5. Mrkobrada M, Ying I, Mokrycke S, et al. CUA guidelines on antibiotic prophylaxis for urologic procedures. *Can Urol Assoc J* 2015;9:13-22.
6. Murdoch DA, Badenoch DF, Gatchalian ER. Oral ciprofloxacin as prophylaxis in transurethral resection of the prostate. *Br J Urol* 1987;60:153-6.
7. Roach MB, Figueroa TE, McBride D, et al. Ciprofloxacin versus gentamicin in prophylaxis against bacteremia in transrectal prostate needle biopsy. *Urology* 1991;38:84-7.
8. Taylor AK, Zembower TR, Nadler RB, et al. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. *J Urology* 2012;187:1275-9.
9. Taylor S, Margolick J, Abughosh Z, et al. Ciprofloxacin resistance in the faecal carriage of patients undergoing transrectal ultrasound guided prostate biopsy. *BJU Int* 2013 Mar 6. doi: 10.1111/j. 1464-410X.2012.11637.x
10. Wolf JS, Bennett CJ, Dmochowski RR, et al. Best practice policy statement on urologic surgery antimicrobial prophylaxis. *J Urology* 2008;179:1379-90.

BLOOD/BODY FLUID EXPOSURE

1. Alberta Health and Wellness. Alberta guidelines for post exposure prophylaxis in non-occupational settings: HIV, Hepatitis B, Hepatitis C,

and sexually transmitted infections. (Alberta nPEP Protocol).
September 2008. Revised January 2010.

2. Centers for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. *Morb Mortal Weekly Rep* 2005;54(RR02):1-20.
3. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. *Morb Mortal Weekly Rep* 2001;50(RR-11):1-52.
4. Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HIV and recommendations for postexposure prophylaxis. *Morb Mortal Weekly Rep* 2005;54(RR-9):1-17.
5. Gerberding JL. Prophylaxis for occupational exposure to HIV. *Ann Intern Med* 1996;125:497-501.
6. Health Canada, HPB-LCDC. An integrated protocol to manage health care workers exposed to bloodborne pathogens. *Can Commun Dis Rep* 1997;23:S2.

Sexual Assault

1. Linden JA. Care of the adult patient after sexual assault. *New Engl J Med* 2011;365:834-41.
2. Public Health Agency of Canada Expert Working Group on the Canadian guidelines on sexually transmitted infections. Canadian guidelines on sexually transmitted infections. Sexual assault in postpubertal adolescents and adults. Available at: <http://www.phac-aspc.gc.ca/std-mts/sti-its/pdf/606sexassault-eng.pdf>. Accessed Feb 2012.

PROPHYLAXIS FOR CONTACTS OF COMMUNICABLE DISEASES

Neisseria meningitidis

1. Alberta Health and Wellness Disease Control and Prevention. Public Health Notifiable Disease Management Guidelines. Invasive meningococcal disease. June 2005.
2. Alberta Health and Wellness. Public Health Notifiable Disease Management Guidelines. Influenza (Seasonal). January 2011.

3. Alberta Health and Wellness. Public Health Notifiable Disease Management Guidelines. Varicella (Chickenpox). January 2012.
4. Deal WB, Sanders E. Efficacy of rifampin in treatment of meningococcal carriers. *N Engl J Med* 1969;281:641-5.
5. Gaunt PN, Lambert BE. Single dose ciprofloxacin for the eradication of pharyngeal carriage of *Neisseria meningitidis*. *J Antimicrob Chemother* 1988;21:489-96.
6. Purcell B, Samuelsson S, Hahne SJM, et al. Effectiveness of antibiotics in preventing meningococcal disease after a case: systematic review. *BMJ* 2004;328:1339-43.
7. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. *N Engl J Med* 2001;344:1378-88.

Haemophilus influenza

1. Alberta Health and Wellness Disease Control and Prevention. Public Health Notifiable Disease Management Guidelines. Invasive *Haemophilus influenzae* disease. June 2005.

Group A Streptococcal Disease

1. Alberta Advisory Committee on Communicable Disease Control, 1996.
2. Allen UD, Moore DL, Canadian Pediatric Society, Infectious Diseases and Immunization Committee. Invasive group A streptococcal disease: management and chemoprophylaxis. *Can J Infect Dis Med Microbiol* 2010;21:115-8.
3. Capital Health Regional Public Health Communicable Disease Corner 1999(Aug);3: 8.
4. Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. *N Engl J Med* 1996;335:547-54.
5. Public Health Agency of Canada. Guidelines for the prevention and control of invasive Group A Streptococcal disease. *CDCR* 2006;32S2:1-26.
6. The Working Group on Prevention of Invasive Group A Streptococcal Infections. Prevention of invasive group A streptococcal disease among household contacts of case-patients. *JAMA* 1998;279:1206-10.

Influenza

1. Anon. Antiviral drugs for prophylaxis and treatment of influenza. *Med Lett Drugs Ther* 2005;47:93-5.

2. Canada Communicable Diseases Report 2005;31(ACS-6):1-32.
<http://www.phac-aspc.gov.ca/publicat/ccdr-rmtc/05> vol 31/asc-dcc-6/index.html.
3. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. *Lancet* 1998;352:1877-81.

Public Health

1. Alberta Health and Wellness Public Health Notifiable Disease Management Guidelines. Pertussis. August 2011.
2. Health Canada. National Consensus Conference on Pertussis. *Can Commun Dis Rep* 2003; 2953.
3. Hewlett EL, Edwards KM. Pertussis – not just for kids. *N Engl J Med* 2005;352:1215-22.

Varicella zoster

1. Capital Health Regional Public Health Communicable Disease Corner 1997(Sep);8: 2-3.
2. Estrada B. What's new in varicella vaccine? *Infect Med* 2000;17:150.
3. Communicable Disease Control – Immunization Program – British Columbia June 2005.

INFECTION PREVENTION AND CONTROL

1. Centers for Disease Control and Prevention. Guidelines for hand hygiene in health-care settings: Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. *Morb Mortal Weekly Rep* 2002;51(RR-16):1-44.
2. Health Canada. Routine practices and additional precautions for preventing the transmission of infection in health care. *Can Commun Dis Rep* 1999;25S4.
<http://www.hc-sc.gc.ca/pphb-dqspsp/publicat/ccdr-rmtc/01pdf/27s2e.pdf>
3. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of *Staphylococcus aureus* and *Enterococcus*. *Infect Control Hosp Epidem* 2003;24(5):362-86.

ANTIMICROBIAL PROPHYLAXIS IN DENTISTRY

1. Addy M, Renton-Harper P. Local and systemic chemotherapy in the management of periodontal disease: an opinion and review of the concept. *J Oral Rehabil* 1996;23:219-31.
2. American Academy of Orthopaedic Surgeons. Antibiotic prophylaxis for bacteremia in patients with joint replacements. AAOS June 2010.
3. American Association of Endodontists. Antibiotic prophylaxis quick reference guide. Oct 1997.
4. American Dental Association; American Academy of Orthopaedic Surgeons. Antibiotic prophylaxis for dental patients with total joint replacements. *J Am Dent Assoc* 2003;134:895-9.
5. American Urological Association and American Academy of Orthopaedic Surgeons. Antibiotic prophylaxis for urological patients with total joint replacements. *J Urology* 2003;169:1796-7.
6. Anon. Antibacterial prophylaxis for dental, GI and GU procedures. *Med Lett* 2005;47:59-60.
7. Antibiotic Subcommittee, The Toronto Hospital. Guidelines for antimicrobial use: surgical prophylaxis: oral and maxillofacial surgery. Toronto, ON. 1997:29.
8. Antolin AB, Garcia MTP, Nasimi A. Infections in implantology: from prophylaxis to treatment. *Med Oral Patol Oral Cir Bucal* 2007;12:E323-30.
9. Berbari EF, Osmon DR, Carr A, et al. Dental procedures as risk factors for prosthetic hip or knee infection: a hospital-based prospective case-control study. *Clin Infect Dis* 2010;50:8-16.
10. Berkey DB, Shay K. General dental care for the elderly. *Clin Geriatr Med* 1992;8:579-97.
11. Canadian Dental Association. Antibiotic prophylaxis for dental patients with total joint replacement. CDA November 2007.
12. Cawson RA. Antibiotic prophylaxis for dental treatment. *Br Med J* 1992;304:933-4.
13. Chenoweth CE, Burket JS. Antimicrobial prophylaxis: principles and practice. *Formulary* 1997;32:692-713.
14. Chiodo G, Tolle SW, Bartley M. Antibiotic prophylaxis for dental treatment. *Ill Dent J* 1990;59:599-602.
15. Cioffi GA, Terezhalmay GT, Taybos GM. Total joint replacement: a consideration for antimicrobial prophylaxis. *Oral Surg Oral Med Oral Pathol* 1988;66:124-9.
16. Clark MM, Album MM, Lloyd RW. Medical care of the dental patient. *Am Fam Physician* 1995;52:1126-32.

17. COA, CDA, AMMI. Consensus statement. patients with total joint replacements having dental procedures. COA, CDA, AMMI 2016.
18. Coco JW, Pankey GA. The use of antimicrobials in dentistry. *Compend Contin Educ Dent* 1989;10:664-72.
19. Dickinson GM, Bisno AL. Antimicrobial prophylaxis of infection. *Infect Dis Clin North Am* 1995;9:783-804.
20. Durack DT. Antibiotics for prevention of endocarditis during dentistry: time to scale back? *Ann Intern Med* 1998;129:829-31.
21. Esposito M, Grusovin MG, Loli V, et al. Does antibiotic prophylaxis at implant placement decrease early implant failures? A Cochrane systematic review. *Eur J Oral Implantol* 2010;3:101-10.
22. Fekete T. Controversies in the prevention of infective endocarditis related to dental procedures. *Dent Clin North Am* 1990;34:79-90.
23. Field EA, Martin MV. Prophylactic antibiotics for patients with artificial joints undergoing oral and dental surgery: necessary or not? *Br J Oral Maxillofac Surg* 1991;29:341-6.
24. Friedlander AH, Yoshikawa TT. Pathogenesis, management, and prevention of infective endocarditis in the elderly dental patient. *Oral Surg Oral Med Oral Pathol* 1990;69:177-81.
25. Grant A, Hoddinott C. Joint replacement, dental surgery, and antibiotic prophylaxis. *Br Med J* 1992;304:959.
26. Hall EH, Sherman RG, Emmons WW, et al. Antibacterial prophylaxis. *Dent Clin North Am* 1994;38:707-18.
27. Hancock EB, Newell DH. Antimicrobials in periodontal practice. *Dent Clin North Am* 1994;38:719-31.
28. Heimdahl A, Nord CE. Antimicrobial prophylaxis in oral surgery. *Scand J Infect Dis* 1990;70:91-101.
29. Hupp JR. Changing methods of preventing infective endocarditis following dental procedures: 1943-1993. *J Oral Maxillofac Surg* 1993;51:616-23.
30. Jacobson JJ, Schweitzer S, DePorter DJ, et al. Antibiotic prophylaxis for dental patients with joint prostheses? A decision analysis. *Int J Technol Assess Health Care* 1990;6:569-87.
31. Jacobson JJ. Is the jaw bone connected to the hip bone? *Oral Surg Oral Med Oral Pathol*: 263.
32. Katoh H, Sasaki J. Clindamycin, its status as an antimicrobial agent in dentistry and oral surgery. *Oral Ther Pharmacol* 1992;11:105-11.
33. Kotze MJ. Antibiotic prophylaxis for preventing endocarditis and infection in joint prosthesis after dental treatment: a review of new trends and recommendations in the literature. *SADJ* 2008;63:440-4.

34. Kotze MJ. Prosthetic joint infection, dental treatment and antibiotic prophylaxis. *Orthopedic Reviews* 2009;1:e7-9.
35. Lancefield M, Conill AM. Antibiotic prophylaxis. *Hosp Pract* 1992;3:126-9.
36. Little JW, Rhodus NL. Dental treatment of the liver transplant patient. *Oral Surg Oral med Oral Pathol* 1992;73:419-26.
37. Little JW. Antibiotic prophylaxis for prevention of bacterial endocarditis and infections of major joint prostheses. *Curr Opin Dent* 1992;2:93-101.
38. Little JW. Managing dental patients with joint prostheses. *JADA* 1994;125:1374-8.
39. Little JW. Preventing bacterial infections: managing the patient with cardiac defects, implants. *Dent Teamwork* 1994;May-June:28-32.
40. Lockhart PB, Loven B, Brennan MT, et al. The evidence base for the efficacy of antibiotic prophylaxis in dental practice. *J Am Dent Assoc* 2007;138:458-74.
41. Lockhart PB, Schmidtke MA. Antibiotic considerations in medically compromised patients. *Dent Clin North Am* 1994;38:381-402.
42. Longman LP, Martin MV. The use of antibiotics in the prevention of post-operative infection: a re-appraisal. *Br Dent J* 1991;170:257-62.
43. Meskin LH. Focal infection: back with a bang! *JADA* 1998;129:8-16.
44. Newman HN. Focal infection. *J Dent Res* 1996; 75: 1912-9.
45. Newman MG. The role of infection and anti-infection treatment in regenerative therapy. *J Periodontol* 1993; 64: 1166-70.
46. Norris LH, Doku HC. Antimicrobial prophylaxis in oral surgery. *Curr Opin Dent* 1992;2:85-92.
47. Olsen I, Snorrason F, Lingaas E. Should patients with hip joint prosthesis receive antibiotic prophylaxis before dental treatment? *J Oral Microbiol* 2010;2:5265-75.
48. Pallasch TJ, Slots J. Antibiotic prophylaxis for medical-risk patients. *J Periodontol* 1991;62:227-31.
49. Pallasch TJ. A critical appraisal of antibiotic prophylaxis. *Int Dent J* 1989;39:183-96.
50. Pallasch TJ. Antibiotic prophylaxis: theory and reality. *J Calif Dent Assoc* 1989;17:27-39.
51. Piecuch JF, Arzadon J, Lieblich SE. Prophylactic antibiotics for third molar surgery: a supportive opinion. *J Oral Maxillofac Surg* 1995;53:53-60.

52. Rethman MP, Watters W, Abt E, et al. Prevention of orthopaedic implant infection in patients undergoing dental procedures. Executive summary on the AAOS/ADA clinical practice guideline.
53. Sancho-Puchades M, Herraiz-Vilas JM, Berini-Ayres L, et al. Antibiotic prophylaxis to prevent local infection in oral surgery: use or abuse? *Med Oral Patol Oral Cir Bucal* 2009;14:E28-33.
54. Schwartz AB, Larson EL. Antibiotic prophylaxis and postoperative complications after tooth extraction and implant placement: a review of the literature. *J Dentistry* 2007;35:881-8.
55. Strom BL, Abrutyn E, Berline JA, et al. Dental and cardiac risk factors for infective endocarditis: a population-based, case-control study. *Ann Intern Med* 1998;129:761-9.
56. Swanson AE. Prevention of dry socket: an overview. *Oral Surg Oral Med Oral Pathol* 1990;70:131-6.
57. Tong D, Theis JC. Antibiotic prophylaxis and invasive dental treatment in prosthetic joint patients. *J New Zealand Med Assoc* 2008;121:1280-5.
58. Uyemura MC. Antibiotic prophylaxis for medical and dental procedures. *Postgrad Med* 1995;98:137-152.
59. Voelker R. Unnecessary antibiotics. *JAMA* 1997;278:620.
60. Wahl MJ. Clinical issues in the prevention of dental-induced endocarditis and prosthetic joint infection. *Pract Periodontics Aesthet Dent* 1995;7:29-37.
61. Wahl MJ. Myths of dental-induced prosthetic joint infections. *Clin Infect Dis* 1995;20:1420-5.
62. Walsh LJ. Serious complications of endodontic infections: some cautionary tales. *Aust Dent J* 1997; 42: 156-9.
63. Watters W, Rethman MP, Hanson NB, et al. AAOS-ADA clinical practice guideline summary. Prevention of orthopaedic implant infection in patients undergoing dental procedures. *J Am Acad Orthop Surg* 2013;21:180-9.
64. Weitekamp MR, Caputo GM. Antibiotic prophylaxis: update on common clinical uses. *Amer Fam Phys* 1993;48:597-604.
65. Yagiela JA. Prophylactic antibiotics: cardiac and prosthetic considerations. *J Calif Dent Assoc* 1995;23:29-40.
66. Young H, Hirsh J, Hammerberg M, et al. Dental disease and periprosthetic joint infection. *J Bone Joint Surg Am* 2014;96:162-8.
67. Zeitler DL. Prophylactic antibiotics for third molar surgery: a dissenting opinion. *J Oral Maxillofac Surg* 1995;53:61-4.

RECOMMENDED EMPIRIC THERAPY OF SELECTED DENTAL INFECTIONS

1. Addy M, Renton-Harper P. Local and systemic chemotherapy in the management of periodontal disease: an opinion and review of the concept. *J Oral Rehabil* 1996;23:219-31.
2. American Academy of Periodontology. Statement on Periostat®; 20 mg doxycycline hyclate capsules for oral administration as an adjunct to scaling and root planning for the treatment of adult periodontitis. <http://www.perio.org/resources-products/periostat.htm>
3. ADA Council on Scientific Affairs. Antibiotic use in dentistry. *JADA* 1997;128:648.
4. Axelsson P. Current role of pharmaceutical in prevention of caries and periodontal disease. *Int Dent J* 1993;43:473-82.
5. Baker KA, Fotos PG. The management of odontogenic infections. *Dent Clin North Am* 1994;38:689-706.
6. Barr CE. Practical considerations in the treatment of the HIV-infected patient. *Dent Clin North Am* 1994;38:403-23.
7. Berge TI. Incidence of large third-molar-associated cystic lesions requiring hospitalization. *Acta Odontol Scand* 1996;54:327-31.
8. Blondel-Hill E, Nigrin J. Guide to antimicrobial susceptibility testing & reporting. 3rd ed. Dynacare Kasper Medical Laboratories/BC Children's Hospital. 2005.
9. Bridgeman A, Wiesenfeld D, Newland S. Anatomical considerations in the diagnosis and management of acute maxillofacial bacterial infections. *Aust Dent J* 1996;41:238-45.
10. Broughton RA. Nonsurgical management of deep neck infections in children. *Pediatr Infect Dis J* 1992;11:14-8.
11. Caton J, Blieden T, Adams D, et al. Subantimicrobial doxycycline therapy for periodontitis. *J Dent Res* 1997;76:177 (Abstract #1307).
12. Caton J, Ciancio S, Crout R, et al. Adjunctive use of subantimicrobial doxycycline therapy for periodontitis. *J Dent Res* 1998;77:1001 (Abstract #2957).
13. Chow AW, Roser SM, Brady FA. Orofacial odontogenic infections. *Ann Intern Med* 1978;88:392-402.
14. Chow AW. Life-threatening infections of the head and neck. *Clin Infect Dis* 1992;14:991-1004.
15. Ciancio S. Expanded and future use of mouthrinses. *JADA* 1994;125:29S-32.
16. Ciancio S. Use and abuse of antibiotics in periodontal therapy. *Dent Econ* 1993;98-100.

17. Douglass CW, Fox CH. The emerging field of oral pharmaceuticals. *JADA* 1994;125:2S-4.
18. Droz D, Koch L, Lenain A, et al. Bacterial endocarditis: results of a survey in a children's hospital in France. *Br Dent J* 1997;183:101-5.
19. Echeverria JJ, Manau GC, Guerrero A. Supportive care after active periodontal treatment. *J Clin Periodontol* 1996;23:898-905.
20. Edlund C, Bjorkman L, Ekstrand J, et al. Resistance of the normal human microflora to mercury and antimicrobials after exposure to mercury from dental amalgam fillings. *Clin Infect Dis* 1996;22:944-50.
21. Ehrenfeld M. Clindamycin in the treatment of dental infections. In: Zambrano D. Clindamycin in the treatment of human infections. Kalamazoo MI: Pharmacia and Upjohn; 1997:12-1-25.
22. Fine D. Evaluation of antimicrobial mouthrinses and their bactericidal effectiveness. *JADA* 1994;125:11S-9.
23. Firatli E, Unal T, Onan U, et al. Antioxidative activities of some chemotherapeutics. A possible mechanism in reducing gingival inflammation. *J Clin Periodontol* 1994;21:680-3.
24. Flemming TF, Millan E, Karch H, et al. Differential clinical treatment outcome after systemic metronidazole and amoxicillin in patients harboring actinobacillus actinomycetemcomitans and/or porphyromonas gingivalis. *J Clin Periodontol* 1998;25:380-7.
25. Genco RJ. Pharmaceutical and periodontal diseases. *JADA* 1994;125:11S-9.
26. Genco RJ. Using antimicrobial agents to manage periodontal diseases. *JADA* 1991;122:31-8.
27. Gibson M, Wilson M, Strahan D, et al. Preliminary evaluation of the use of methylene blue, a redox dye, in the treatment of chronic periodontitis. *Clin Infect Dis* 1993;16:S411-3.
28. Gilmore WC, Jacobus NV, Borbach SL, et al. A prospective double-blind evaluation of penicillin versus clindamycin in the treatment of odontogenic infections. *J Oral Maxillofac Surg* 1988;46:1065-70.
29. Golub LM, Wolff M, Roberts S, et al. Treating periodontal diseases by blocking tissue-destructive enzymes. *JADA* 1994;125:163-71.
30. Greenspan JS. Periodontal complications of HIV infection. *Compend Contin Educ Dent* 18:S694-8.
31. Greenstein G, Berman C, Jaffin R. Chlorhexidine; an adjunct to periodontal therapy. *J Periodontol* 1986;57:370-7.
32. Greenwell H, Bissada NF. Emerging concepts in periodontal therapy. *Drugs* 2002;62:2581-7.

33. Grenby TH. The use of sanguinarine in mouthwashes and toothpaste compared with some other antimicrobial agents. *Br Dent J* 1995;178:254-8.
34. Haas DA, Epstein JB, Eggert FM. Antimicrobial resistance: dentistry's role. *J Can Dent Assoc* 1998;64:496-502.
35. Hammert W. Odontogenic infections-management and treatment. *ODA Journal* 1993;32-4.
36. Hancock EB, Newell DH. Antimicrobials in periodontal practice. *Dent Clin North Am* 1994;38:719-31.
37. Harding AM. Pharmacologic consideration in pediatric dentistry. *Dent Clin North Am* 1994;38:733-53.
38. Har-El G, Aroesty JH, Shaha A, et al. Changing trends in deep neck abscess. *Oral Surg Oral Med Oral Pathol* 1994;77:446-50.
39. Herrera D, Roldan S, Sanz M. The periodontal abscess: a review. *J Clin Periodontol* 2000;27:377-86.
40. Holbrook WP. Bacterial infections of oral soft tissues. *Curr Opin Dent* 1991;1:404-10.
41. Jones JA. Root caries: prevention and chemotherapy. *Am J Dent* 1995;8:352-7.
42. Jousimies-Somer H, Savolainen S, Makitie A, et al. Bacteriologic findings in peritonsillar abscesses in young adults. *Clin Infect Dis* 1993;16:S292-8.
43. Judd PL, Sandor GK. Management of odontogenic orofacial infection in the young child. *Ont Dent* 1997;74:39-43.
44. Karlowsky J, Ferguson J, Zhanel G. A review of commonly prescribed oral antibiotics in general dentistry. *J Can Dent Assoc* 1993;59:292-4, 297-300.
45. Killoy WJ, Polson AM. Controlled local delivery of antimicrobials in the treatment of periodontitis. *Dent Clin North Am* 1998;42:263-83.
46. Koerner KR, Taylor SE. Pharmacologic considerations in the management of oral surgery patients in general dental practice. *Dent Clin North Am* 1994;38:237-54.
47. Kornamn KS. Controlled –release local delivery antimicrobials in periodontics: prospects for the future. *J Periodontol* 1993;64:782-91.
48. Kornman KS, Newman MG, Moore DJ, et al. The influence of supragingival plaque control on clinical and microbial outcomes following the use of antibiotics for the treatment of periodontitis. *J Periodontol* 1994;65:848-54.
49. Kupfer SR. Prevention of dry socket with clindamycin. *NYSMJ* 1995;30-3.

50. Little JW. Preventing bacterial infections, managing the patient with cardiac defects, implants. *Dent Teamwork* 1994;May-June:28-32.
51. Loesche WJ. Bacterial mediators in periodontal disease. *Clin Infect Dis* 1993;16:S203-10.
52. Loesche WJ, Grossman NS. Periodontal disease as a specific, albeit chronic, infection: diagnosis and treatment. *Clin Micro Rev* 2001;14:727-52.
53. Mandel ID. Antimicrobial mouthrinses: overview and update. *JADA* 1994;125:2S-10.
54. Mandel ID. Focal infection. *J Dent Res* 1996;75:1912-9.
55. Marder M, Milgrom P. Chemotherapy and periodontal disease – a review. *Drug Intell Clin Pharm* 1984;18:466-74.
56. Marsh PD, Bradshaw DJ. Microbiological effects of new agents in dentifrices for plaque control. *Int Dent J* 1993;43:399-406.
57. Marsh PD. Microbial ecology of dental plaque and its significance in health and disease. *Adv Dent Res* 1994;8:263-71.
58. Megrant DW, Scheifele DW, Chow AW. Odontogenic infections. *Pediatr Infect Dis* 1984;3:257-65.
59. Meskin LH. Focal infection: back with a bang! *JADA* 1998;129:8-16.
60. Meurman JH. Dental infections and general health. *Quintessence Int* 1997; 28:807-11.
61. Moenning JE, Nelson CL, Kohler RB. The microbiology and chemotherapy odontogenic infections. *J Oral Maxillofac Surg* 1989;47:976-85.
62. Mombelli A. Microbiology of the dental implant. *Adv Dent Res* 1993;7:202-6.
63. Needleman IG, Gerlach RW, Baker RA, et al. Retention, antimicrobial activity, and clinical outcomes following use of a bioerodible tetracycline gel in moderate-to-deep periodontal pockets. *J Periodontol* 1998;69:578-83.
64. Newman HN. Focal infection. *J Dent Res* 1996;75:1912-9.
65. Newman M, Kornman K, eds. *Antibiotic/Antimicrobial use in dental practice*. Quintessence Publishing Co. Inc., 1990.
66. Newman MG. The role of infection and anti-infection treatment in regenerative therapy. *J Periodontol* 1993;64:1166-70.
67. Niessen L. Oral pharmaceutical and adult dental patients. *JADA* 1994;125:54S-62.
68. Olson AK, Edington EM, Kulid JC, et al. Update on antibiotics for the endodontic practice. *Compend Contin Educ Dent* 11:328-32.

69. Olsvik B, Tenover FC. Tetracycline resistance in periodontal pathogens. *Clin Infect Dis* 1993;16:S310-3.
70. Osborn TM, Assael LA, Bell RB. Deep space neck infection: principles of surgical management. *Oral Maxillofacial Surg Clin N Am* 2008;20:353-65.
71. Owens BM, Schuman NJ. Antibiotics and dentistry: a brief review. *J Clin Pediatr Dent* 1994;18:129-34.
72. Pacini N, Zanchi R, Ferara A, et al. Antimicrobial susceptibility tests on anaerobic oral mixed cultures in periodontal diseases. *J Clin Periodontol* 1997;24:401-9.
73. Palcanis KG. The role of antimicrobials in treatment of periodontal diseases. *Gen Dent* 1994;130-7.
74. Pallasch TJ. Antibiotics for acute orofacial infections. *J Calif Dent Assoc* 1993;21:34-44.
75. Pallasch TJ. How to use antibiotics effectively. *J Calif Dent Assoc* 1993;21:46-50.
76. Peterson LJ. Are they still miracle drugs. *Oral Surg Oral Med Oral Pathol* 1994;78:1-2.
77. Petersson LG, Edwardsson S, Arends J. Antimicrobial effect of a dental varnish, in vitro. *Swed Dent J* 1992;16:183-9.
78. Piecuch JF, Arzadon J, Lieblch SE. Prophylactic antibiotics for third molar surgery: a supportive opinion. *J Oral Maxillofac Surg* 1995;53:53-60.
79. Pihlstrom BL, Ammons WF. Treatment of gingivitis and periodontitis. *J Periodontol* 1997;68:1246-53.
80. Pogrel MA. Antibiotics in general practice. *Dent Update* 1994;21:274-80.
81. Pyle MA, Faddoul FF, Terezhalmay GT. Clinical implications of drugs taken by our patients. *Dent Clin North Am* 1993;37:73-90.
82. Pynn BR, Sands T, Pharoah MJ. part one. Odontogenic infections: anatomy and radiology. *Oral Health* 1995;85:7-21.
83. Rams TE, Slots J. Antibiotics in periodontal therapy: an update. *Compend Contin Educ Dent* 13:1130-45.
84. Rethman J, Rethman M, Suzuki J. Controlled-release periodontal chemotherapy: the evolution of antimicrobial delivery systems. 1995;1-8.
85. Rifkin BR, Vernillo AT, Golub LM. Blocking periodontal disease progression by inhibiting tissue-destructive enzymes: a potential therapeutic role for tetracyclines and their chemically-modified analogs. *J Periodontol* 1993;64:819-27.

86. Robinson BW. Update on contemporary management of oral maxillofacial infections. *Ann R Aust Coll Dent Surg* 1994;12:276-8.
87. Rubinstein Devore L. Antimicrobial mouthrinses: impact on dental hygiene. *JADA* 1994;125:23S-8.
88. Sakaguchi M, Sato S, Ishiyama T, et al. Characterization and management of deep neck infections. *Int J Oral Maxillofac Surg* 1997;26:131-4.
89. Sandor GKB, Low DE, Judd PL, et al. Antimicrobial treatment options in the management of odontogenic infections. *J Can Dent Assoc* 1998;64:508-14.
90. Sands T, Pynn BR, Katsikeris N. Odontogenic infections: part two. Microbiology antibiotics and management. *Oral Health* 1995;85:17-21.
91. Sands T, Pynn BR. Odontogenic infections and clindamycin. *UTDJ* 1995;9:32-3.
92. Seymour RA, Heasman PA. Tetracyclines in the management of periodontal diseases-a review. *J Clin Periodontol* 1995;22:22-35.
93. Seymour RA, Steele JG. Is there a link between periodontal disease and coronary heart disease? *Br Dent J* 1998;184:33-8.
94. Slots J. Systemic antibiotics in periodontics. *J Periodontol* 1996;67:831-8.
95. Solomkin JS, Miyagawa CI. Principles of antibiotic therapy. *Surg Clin North Am* 1994;74:497-517.
96. Stoor P, Soderling E, Salonen JI. Antibacterial effects of a bioactive glass paste on oral microorganisms. *Acta Odontol Scand* 1998;56:161-5.
97. Swanson AE. Prevention of dry socket: an overview. *Oral Surg Oral Med Oral Pathol* 1990;70:131-6.
98. Talan DA. The role of new antibiotics for the treatment of infections in the emergency department. *Ann Emerg Med* 1994;24:473-89.
99. Tanner A, Maiden MFJ, Lee K, et al. Dental implant infections. *Clin Infect Dis* 1997;25:S213-7.
100. Tanner A, Stillman N. Oral and dental infections with anaerobic bacteria: clinical features, predominant pathogens, and treatment. *Clin Infect Dis* 1993;16:S304-9.
101. ten Cate JM, Marsh PD. Procedures for establishing efficacy of antimicrobial agents for chemotherapeutic caries prevention. *J Dent Res* 1994;73:695-703.
102. Terpenning M, Bretz W, Lopatin D, et al. Bacterial colonization of saliva and plaque in the elderly. *Clin Infect Dis* 1993;16:S314-6.

103. Topazian RG, Goldberg MH, eds. Oral and maxillofacial infections. Third ed. Philadelphia, Pennsylvania: WB Saunders Company 1994.
104. Vandersall DC. Periodontics in the next millennium. Dent Clin North Am 1998;42:543-60.
105. Villanueva AV, Chandrasekar PH. Emergence of antimicrobial-resistant pathogens: a growing concern. Practical Hygiene 1997;37-41.
106. Wade DN, Kerns DG. Acute necrotizing ulcerative gingivitis-periodontitis: a literature review. Military Med 1998;163:337-42.
107. Walsh LJ. Serious complications of endodontic infections: some cautionary tales. Aust Dent J 1997;42:156-9.
108. Williams RC, Beck JD, Offenbacher SN. The impact of new technologies to diagnose and treat periodontal disease-a look to the future. J Clin Periodontol 1996;23:299-305.
109. Yu VL, Merigan TC, Barriere SL, eds. Antimicrobial therapy and vaccines. Baltimore, Maryland: Williams & Wilkins; 1999.
110. Zeitler DL. Prophylactic antibiotics for third molar surgery: a dissenting opinion. J Oral Maxillofac Surg 1995;53:61-4.

ANTIMICROBIALS IN PREGNANCY

1. Al-Sabbagh A, Moss S, Subhedar N. Neonatal necrotising enterocolitis and perinatal exposure to co-amoxycylav. Arch Dis Child Fetal Neonatal Ed 2004;89:F187.
2. American College of Obstetricians and Gynecologists. Sulfonamides, nitrofurantoin, and risk of birth defects. Committee Opinion No. 494. Obstet Gynecol 2011;117:1484-5.
3. Andersen T, Petersen M, Rasmussen JN, et al. Trimethoprim use prior to pregnancy and risk of congenital malformations: a register based nationwide cohort study. Pharmacoepidemiology and Drug Safety Conference Publication;18(S1):S198.
4. Anon. Antifungal drugs. Med Lett Treatment Guidelines 2005; 3(30):7-14.
5. Bjorn P, Anders H. Atovoquone-proguanil use in early pregnancy and the risk of birth defects. Arch Intern Med 2011;171:259-60.
6. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 9th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins 2011.
7. Burtin P, Taddio A, Ariburnu O, et al. Safety of metronidazole in pregnancy: a meta-analysis. Am J Obstet Gynecol 1995;172:525-9.
8. Caro-Paton T, Carvajal A, de Diego M. Is metronidazole teratogenic? a meta-analysis. Br J Clin Pharmacol 1997;44:179-82.

9. Carter TC, Druschel CM, Romitti PA, et al. Antifungal drugs and the risk of selected birth defects. *Am J Obstet Gynecol* 2008;198:191.e1-e7.
10. Centers for Disease Control and Prevention. 1998 Guidelines for treatment of sexually transmitted diseases. *Morb Mortal Weekly Rep* 1998;47:78.
11. Chow AW, Jewesson PJ. Pharmacokinetics and safety of antimicrobial agents during pregnancy. *Rev Infect Dis* 1985;7:287-313.
12. Connelly RT, Lourwood DL. Pneumocystis carinii pneumonia prophylaxis during pregnancy. *Pharmacother* 1994;14:424-9.
13. Crider KS, Cleves MA, Reefhuis J, et al. Antibacterial medication use during pregnancy and risk of birth defects. *Arch Pediatr Adolesc Med* 2009;163:978-85.
14. Czeizel AE, Rockenbauer M. A population based case-control teratologic study of oral metronidazole. *Br J Obstet Gynaecol* 1998;105:322-7.
15. DeSantis M, Di Gianantonio E, Cesari E, et al. First-trimester itraconazole exposure and pregnancy outcome: a prospective cohort study of women contacting teratology information services in Italy. *Drug Safety* 2009;32:239-44.
16. deSilva N, Sirisena J, Gunasekera D, et al. Effect of mebendazole therapy during pregnancy on birth outcome. *Lancet* 1999;353:1145-49.
17. Diav-Citrin O, Shechtman S, Gotteiner T, et al. Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study. *Teratology* 2001;63:186-92.
18. Donner B, Niranjana V, Hoffman G. Safety of oseltamivir in pregnancy: a review of preclinical and clinical data. *Drug Safety* 2010;33:631-42.
19. Ehsanipoor RM, Chung JH, Clock CA, et al. A retrospective review of ampicillin-sulbactam and amoxicillin + clavulanate vs cefazolin/cephalexin and erythromycin in the setting of preterm premature rupture of membranes: maternal and neonatal outcomes. *Am J Obstet Gynecol* 2008;198:e54-6.
20. Ghidini A, Goldberg L, Locatelli A, et al. Does co-amoxiclav in preterm PROM increase the risk of necrotizing enterocolitis (NEC)? A meta-analysis. *Am J Obstet Gynecol* 2003;189(6 Suppl):S170. Abstract Review Only.
21. Grantham J, McNamee EC, Daly SC. Association between co-amoxiclav used antenatally with necrotising enterocolitis in the neonate. *Am J Obstet Gynecol* 2002; 187(6 Suppl):S90. Abstract

Review Only.

22. Greer LG, Sheffield JS, Rogers VL, et al. Maternal and neonatal outcomes after antepartum treatment of influenza with antiviral medications. *Obstetrical and Gynecological Survey* 2010;115:711-6.
23. Jick S. Pregnancy outcomes after maternal exposure to fluconazole. *Pharmacotherapy* 1999;19:221-2.
24. Kazy Z, Puho E, Czeizel AE. Population-based case-control study of oral ketoconazole treatment for birth outcomes. *Congenital Anomalies* 2005;45:5-8.
25. Kenyon S, Pike K, Jones DR, et al. Childhood outcomes after prescription of antibiotics to pregnant women with preterm rupture of the membranes: 7-year follow-up of the ORACLE 1 trial. *Lancet* 2008;372:1319-27.
26. Kenyon SL, Taylor DJ, Tarnow-Mordi W, ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomized trial. *Lancet* 2001;357:979-88.
27. King C, Rogers PD, Cleary J, et al. Antifungal therapy during pregnancy. *Clin Infect Dis* 1998;27:1151-60.
28. Lewis JS, Terriff CM, Coulston DR, et al. Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. *Clinical Therapeutics* 1997;19:187-214.
29. Loebstein R, Addis A, Ho E, et al. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. *Antimicrob Agents Chemother* 1998;42:1336-39.
30. Martin AC, VanLoo DA. Caspofungin: an overview of its activity and early clinical experience. *J Infect Dis Pharmacother* 2002;5:1-19.
31. Minkoff H, Augenbraun M. Antiretroviral therapy for pregnant women. *Am J Obstet Gynecol* 1997;176:478-89.
32. Motherisk [database on the Internet]. The Hospital for Sick Children (SickKids). c. 1999-Sep 2012. Available from: <http://www.motherisk.org>.
33. Norgaard M, Pederson L, Gislum M, et al. Maternal use of fluconazole and the risk of congenital malformations: a Danish population-based cohort study. *J Antimicrob Chemother* 2008;62:172-6.
34. Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. *JAMA* 2010;304:859-66.
35. Personal communication, Antiretroviral Pregnancy Registry. December 1997.

36. Personal communication, Motherisk [(416) 813-6780]. May 1997.
37. Piper JM, Mitchel EF, Ray WA. Prenatal use of metronidazole and birth defects: no association. *Obstet Gynecol* 1993;82:348-52.
38. Product monographs. Compendium of pharmaceuticals and specialities. 40th ed. Toronto: Webcom Limited; 2005.
39. Quinolones and pregnancy. *Prescrire International* 1999;8:29-31.
40. Reprorisk system. Micromedex Inc. 1997;94 and 1999;100.
41. Rescriptor[®] product monograph, Pharmacia & Upjohn Inc. 1998.
42. Gilbert DN, Moellering RC, Eliopoulos GM, eds. The Sanford guide to antimicrobial therapy 2012. Sperryville, VA: Antimicrobial Therapy, Inc. 2012.
43. Sustiva[®] product monograph, Dupont Pharma 1999.
44. Svensson T, Granath F, Stephansson O, et al. Birth outcomes among women exposed to oseltamivir (Tamiflu) during pregnancy. *Pharmacoepidemiology and Drug Safety Conference: 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management* 2010;19:S211-2.
45. Viracept[®] product monograph, Agouron 1998.
46. Viramune[®] product monograph, Boehringer Ingelheim 1998.
47. White A, Eldridge R, Andrews E. Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry. *Acta Paediatr* 1997;421:86-8.
48. World Health Organization (WHO). Antiviral drugs for pandemic (H1N1) 2009: definitions and use. WHO Global Health Alert and Response. December 2009 (cited Aug 2011). Available from: http://www.who.int/csr/disease/swineflu/frequently_asked_questions/antivirals/definitions_use/en/

ANTIMICROBIALS IN LACTATION

1. American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. *Pediatrics* 2001;108:776-89.
2. Briggs GG, Freeman RK, Yaffe SJ. *Drugs in pregnancy and lactation*. 9th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins 2011.
3. Busser J, Schultz J. *Drugs in breast milk* 2003. BC Children's and Women's Health Clinical Pharmacy Bulletin Fall 2003.
4. Canadian Pediatric Society. Maternal infectious diseases, antimicrobial therapy or immunizations: Very few contraindications to breastfeeding. *Can J Infect Dis Med Microbiol* 2006;17: 270-2.
5. Chung AM, Reed MD, Blumer JL. Antibiotics and breast-feeding: A critical review of the literature. *Pediatr Drugs* 2002;4: 817-37.

6. Dharamsi A, Smith J. Drugs in Breast Milk 2003. Pharmacy, Therapeutics and Nutrition Committee - Children's & Women's Health Centre of British Columbia. Clinical Pharmacy Bulletin; Fall 2003.
7. Drug evaluation monographs. Micromedex Inc. 1997;94 and 1999;100.
8. Ito S. Drug therapy for breast-feeding women. N Engl J Med 2000;343:118-26.
9. Hale TW. Medications and mothers' milk [database on the Internet]. Hale Publishing, LP. c. 1992 – [Aug 2011 – Aug 2012]. Available from: <http://www.medsmilk.com/menu.html>
10. LactMed: A New NLM Database on Drugs and Lactation. U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894, National Institutes of Health, Department of Health & Human Services. Available from: <http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT>
11. Lewis JS, Terriff CM, Coulston DR, et al. Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus. Clinical Therapeutics 1997;19:187-214.
12. MICROMEDEX 2.0(R) Healthcare Series [database on the Internet]. Greenwood Village (COL): Thomson Reuters. c.1974 - [Aug 2011 - Aug 2012]. Available from: <http://www.thomsonhc.com/micromedex2/librarian>
13. Passmore C, McElnay J, Rainey E, et al. Metronidazole excretion in human milk and its effect on the suckling neonate. Br J Clin Pharmacol 1988;26:45-51.
14. Personal communication, MotheRisk [(416) 813-6780]. January 1998 and June 1999.
15. Product monographs and pages L49-L51. Compendium of pharmaceuticals and specialities. 40th ed. Toronto: Webcom Limited; 2005.
16. Rudolph S, Busser J. Drugs in breast milk 1996. CPJ/RPC 1996;Oct:34-41.

EXPOSURE TO SELECTED COMMUNICABLE DISEASES DURING PREGNANCY

1. Beaman MH, McCabe RE, Wong S-Y, et al. Toxoplasma gondii. In: Mandel GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 4th ed. New York, NY: Churchill Livingstone; 1995:2455-75.
2. Capital Health. Communicable disease guidelines for hospital personnel. Edmonton, Alberta 1998.

3. Centers for Disease Control. Epidemiology and prevention of vaccine-preventable diseases. CDC, Department of Health & Human Services. USA.
4. Crane JMG. Prenatal exposure to viral infections. Can J CME; November 1998:61-75.
5. Ford-Jones EL. An approach to the diagnosis of congenital infections. Pediatr Child Health 1999;4:109-12.
6. Heymann DL, ed. Control of communicable diseases manual. 19th ed. Washington DC: American Public Health Association; 2008.
7. Kropp RY, Wong T, Cormier L, et al. Neonatal herpes simplex virus infections in Canada: results of a 3-year national prospective study. Pediatrics 2006;117:1955-62.
8. Money DM. Viral infections in pregnancy. Can J CME; January 1996:93-103.
9. Vaudry W, Lee BE, Rosychuk R, et al. Congenital cytomegalovirus infection in Canada: Cases reported by pediatricians to the Canadian Paediatric Surveillance Program. Canadian Paediatric Society Annual Conference, Victoria, BC, June 2008. (Oral presentation)

PREVENTION OF PERINATAL INFECTION

Intrapartum Antimicrobial Prophylaxis of Group B Streptococcal (GBS) disease

1. AAP Committee on Infectious diseases and Committee on Fetus and Newborn. Revised guidelines for prevention of early-onset Group B Streptococcal (GBS) infection. Pediatrics 1997;99:489-96.
2. Alberta/BC Conjoint Group B Streptococcus CPG Working Group. Recommendations for prevention of neonatal early-onset Group B Streptococcal (GBS) infection.
3. Allen U. Prevention of perinatal group B streptococcal disease in Canada: an update. Paediatr Child Health 1997;2:319-23.
4. American College of Obstetricians and Gynecologists Committee on Obstetric Practice. Prevention of early-onset Group B Streptococcal disease in newborns. ACOG 1996;173:1-8.
5. Capital Health Women's Health Program. Group B streptococcus. Revised May 2004.
6. Centers for Disease Control and Prevention. Prevention of perinatal Group B streptococcal disease. Revised guidelines from CDC. Morb Mortal Weekly Rep 2002; 51(No. RR-11):1-22.
7. Demianczuk NN, Halperin SA, McMillan DD. Prevention of perinatal group B streptococcal infection: management strategies. Can J Infect Dis 1997;8:68-70.

8. Mercer BM, Miodovnik M, Thurnau GR, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. JAMA 1997;278:989-95.
9. Mercer BM, Lewis R. Preterm labor and preterm premature rupture of the membranes. Diagnosis and management. Infect Dis Clin North Am 1997;11:177-201.
10. Prevention of group B streptococcal infection in newborns: recommendation statement from the Canadian Task Force on Preventive Health Care. CMAJ 2002; 166(7):928-30.
11. Society of Obstetricians and Gynaecologists of Canada. Statement on the prevention of early-onset Group B Streptococcal infections in the newborn. SOGC 1997;61:1-9.

Antimicrobial Prophylaxis for Preterm Rupture of Membranes

1. Capital Health Women's Health Program. Preterm Rupture of Membranes. June 2003.
2. Kenyon SL, Taylor DJ, Tarnow-Mordi W, for the ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. Lancet 2001; 357:979-88.
3. Mercer BM, Miodovnik M, Thurnau GR, et al. Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes: a randomized controlled trial. JAMA 1997; 278:989-95.

Perinatal HIV protocol

1. Burdge DR, Money DM, Forbes JC, et al. Canadian consensus guidelines for the care of HIV-positive pregnant women: putting recommendations into practice. CMAJ 2003;168:1683-8.
2. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. July 31, 2012: pp i- J3. Accessed at: <http://aidsinfo.nih.gov>
3. BC Women's Hospital and Health Centre. Clinical Guidelines/HIV Protocols, 2010. Accessed at: <http://www.bcwomens.ca/Services/HealthServices/OakTreeClinic/default.htm>

4. CDC. Revised Recommendations for HIV Testing of Adults, Adolescents and Pregnant Women in Health Care Settings. MMWR 2006; 55(RR14); 1-17
5. AIDS info. HIV and Pregnancy. Health Information for Patients. December 2010. Accessed at: <http://aidsinfo.nih.gov>
6. Canadian HIV Trials Network Working Group on Vertical HIV Transmission. Canadian consensus guidelines for the management of pregnancy, labour and delivery and for postpartum care in HIV-positive pregnant women and their offspring (summary of 2002) guidelines. Commentary. CMAJ 2003; 168(13): 1671-74.
7. Nizova NN, Posokhova SP. Preventing Mother-to-Child Transmission of HIV: A Practical Guide to the Prevention and Treatment of Sexually Transmitted Infections. 2nd edition. American International Health Alliance, Feb 2005.

EMPIRIC THERAPY OF SPECIFIC ORGANISMS

1. Abbo A, Navon-Venezia S, Hammer-Muntz O, et al. Multidrug-resistant *Acinetobacter baumannii*. Emerg Infect Dis 2005;11(1):22-9.
2. Agrawal A, Murphy TF. *Haemophilus influenzae* Infections in the H. influenzae Type b Conjugate Vaccine Era. J Clin Microbiol 2011;49(11):3728-32.
3. Ahamed J, Gangopadhyay J, Kundu M, et al. Mechanisms of quinolone resistance in clinical isolates of *Shigella dysenteriae*. Antimicrob Agents Chemother 1999;43(9):2333-4.
4. Alcaide F, Linares J, Pallares R, et al. In vitro activities of 22 beta-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood. Antimicrob Agents Chemother 1995;39(10):2243-7.
5. Aldridge KE. Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes. Diagn Microbiol Infect Dis 2002;44(2):181-6.
6. Almuzara M, Limansky A, Ballerini V, et al. In vitro susceptibility of *Achromobacter* spp. isolates: comparison of disk diffusion, Etest and agar dilution methods. Int J Antimicrob Agents 2010;35:68-71.
7. Ananthakrishna R, Shankarappa, RK, Jagadeesan N, et al. Infective endocarditis: a rare organism in an uncommon setting. Case Reports Infect Dis 2012; article ID 307852.
8. Arends JE, Stemerding AM, Vorst SP, et al. First report of a brain abscess caused by *Nocardia veterana*. J Clin Microbiol 2011;49(12):4364-65.

9. Arias CA, Contreras GA, Murray BA. Management of multidrug-resistant enterococcal infections. *CMI* 2010;16:555-62.
10. Avison MB, Bennett PM, Walsh TR. Beta-lactamase expression in *Plesiomonas shigelloides*. *J Antimicrob Chemother* 2000;45(6):877-80.
11. Babini GS, Yuan M, Hall LM, et al. Variable susceptibility to piperacillin/tazobactam amongst *Klebsiella* spp. with extended-spectrum beta-lactamases. *J Antimicrob Chemother* 2003;51(3):605-12.
12. Babu E, Oropello J. *Staphylococcus lugdunensis*: the coagulase-negative staphylococcus you don't want to ignore. *Expert Rev Anti Infect Ther* 2011;9(10):901-7
13. Baker C, Byington CL, Polin RA. Policy statement-recommendations for the prevention of perinatal Group B Streptococcal (GBS) disease. *Pediatrics* 2011;128(3):611.
14. Bank S, Jensen A, Hansen TM, et al. *Actinobaculum schaalii*, a common uropathogen in elderly patients, Denmark. *Emerg Infect Dis* 2010;16(1):76.
15. Barnaud G, Benzerara Y, Gravisse J, et al. Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an *Enterobacter aerogenes* clinical isolate. *Antimicrob Agents Chemother* 2004;48(3):1040-2.
16. Basaglia G, Carretto E, Barbarini D, et al. Catheter-related bacteremia due to *Kocuria kristinae* in a patient with ovarian cancer. *J Clin Microbiol* 2002;40(1):311-3.
17. Becker K, Rutsch F, Uekotter A, et al. *Kocuria rhizophila* adds to the emerging spectrum of micrococcal species involved in human infections. *J Clin Microbiol* 2008;46(10):3537-9.
18. Becker K, Wullenweber J, Odenthal HJ, et al. Prosthetic valve endocarditis due to *Kytococcus schroeteri*. *Emerg Infect Dis* 2003;9(11):1493-5.
19. Behera B, Naik V, Mathur P, et al. Identification of *Kocuria rosea* by Vitek 2 GP Card. *The Internet Journal of Medical Informatics* 2008;3(2).
20. Bemis DA, Jones RD, Hiatt LE, et al. Comparison of tests to detect oxacillin resistance in *Staphylococcus intermedius*, *Staphylococcus schleiferi*, and *Staphylococcus aureus* isolates from canine hosts. *J Clin Microbiol* 2006;44(9):3374-6.
21. Bernard K. The genus *Corynebacterium* and other medically relevant coryneform-like bacteria. *J Clin Microbiol* 2012;50(10):3152-8.

22. Binder D, Widmer U, Opravil M, et al. Native and prosthetic valve endocarditis caused by *Rothia dentocariosa*: diagnostic and therapeutic considerations. *Infection* 1997;25(1):22-6.
23. Bittar F, Cassagne C, Bosdure E, et al. Outbreak of *Corynebacterium pseudodiphtheriticum* infection in cystic fibrosis patients, France. *Emerg Infect Dis* 2010;16(8):1231-6.
24. Bizarro MJ, Callan DA, Farrel PA, et al. *Granulicatella adiacens* and early-onset sepsis in neonate. *Emerg Infect Dis* 2011;17(10):1971-3.
25. Blaiotta G, Pennacchia C, Ercolini D, et al. Combining denaturing gradient gel electrophoresis of 16S rDNA V3 region and 16S-23S rDNA spacer region polymorphism analyses for the identification of staphylococci from Italian fermented sausages. *Syst Appl Microbiol* 2003;26(3):423-33.
26. Blaiotta G, Pennacchia C, Villani F, et al. Diversity and dynamics of communities of coagulase-negative staphylococci in traditional fermented sausages. *J Appl Microbiol* 2004;97(2):271-84.
27. Blanc V, Dalle M, Markarian A, et al. *Gordonia terrae*: a difficult-to-diagnose emerging pathogen? *J Clin Microbiol* 2007;45(3):1076-7.
28. Blekher L, Siegman-Igra Y, Schwartz D, et al. Clinical significance and antibiotic resistance patterns of *Leminorella* spp, an emerging nosocomial pathogen. *J Clin Microbiol* 2000;38(8):3036-8.
29. Bloch KC, Nadarajah R, Jacobs R. *Chryseobacterium meningosepticum*: an emerging pathogen among immunocompromised adults. Report of 6 cases and literature review. *Medicine (Baltimore)* 1997;76(1):30-41.
30. Blosser-Middleton R, Sahm DF, Thornsberry C, et al. Antimicrobial susceptibility of 840 clinical isolates of *Haemophilus influenzae* collected in four European countries in 2000-2001. *Clin Microbiol Infect* 2003;9(5):431-6.
31. Boleij A, van Gelder MMHJ, Swinkels DW, et al. Clinical importance of *Streptococcus gallolyticus* infection among colorectal cancer patients: systematic review and meta-analysis. *Clin Infect Dis* 2011;53(9):870-8.
32. Bonacorsi S, Fitoussi F, Lhopital S, et al. Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against *Burkholderia cepacia* isolates from patients with cystic fibrosis. *Antimicrob Agents Chemother* 1999;43(2):213-7.
33. Bonfiglio G, Livermore DM. Behaviour of beta-lactamase-positive and -negative *Staphylococcus aureus* isolates in susceptibility tests with

- piperacillin/tazobactam and other beta-lactam/beta-lactamase inhibitor combinations. *J Antimicrob Chemother* 1993;32(3):431-44.
34. Bonfiglio G, Livermore DM. Beta-lactamase types amongst *Staphylococcus aureus* isolates in relation to susceptibility to beta-lactamase inhibitor combinations. *J Antimicrob Chemother* 1994;33(3):465-81.
 35. Bonomo RA, Szabo D. Mechanisms of multidrug resistance in *Acinetobacter* species and *Pseudomonas aeruginosa*. *Clin Infect Dis* 2006;43 Suppl 2:S49-56.
 36. Bottone EJ. *Bacillus cereus*, a volatile human pathogen. *Clin Microb Rev* 2010;23(2):382-98.
 37. Boyanton B, et al. *Burkholderia gladioli* osteomyelitis in association with chronic granulomatous disease: case report and review. *Pediatr Infect Dis J* 2005;24(9):837.
 38. Brazier J et al. European surveillance study on antimicrobial susceptibility of Gram positive anaerobic cocci. *Int J Antimicrob Agents* 2008;31:316-20.
 39. Brook I. *Veillonella* infections in children. *J Clin Microbiol* 1996;34(5):1283.
 40. Brooke JS. *Stenotrophomonas maltophilia*: an emerging global opportunistic pathogen. *Clin Microbiol Rev* 2012;25(1):2.
 41. Brown WJ, Sautter RL, Crist AE Jr. Susceptibility testing of clinical isolates of *Methylobacterium* species. *Antimicrob Agents Chemother* 1992;36(8):1635-8.
 42. Brown DFJ. Regarding BORSA detection and clinical experience. Chairman, BSAC Susceptibility Testing Working Party. Health Protection Agency, Clinical Microbiology and Public Health Laboratory, Addenbrooke's Hospital. In: Kulkarni S, ed. Cambridge January 2009.
 43. Brown-Elliott BA, et al. Clinical and laboratory features of the *Nocardia* spp. based on current molecular taxonomy. *Clin Microbiol Reviews* 2006;19(2):259-82.
 44. Bruminhent J et al. *Rothia mucilaginosa* prosthetic device infections: a case of prosthetic valve endocarditis. *J Clin Microbiol* 2013;51(5):629.
 45. Buijze GA. Serogroup C meningococcal osteomyelitis. *Pediatric Infect Dis J* 2009;28(10):929.
 46. Burgess DS. Use of pharmacokinetics and pharmacodynamics to optimize antimicrobial treatment of *Pseudomonas aeruginosa* infections. *Clin Infect Dis* 2005 ;40 Suppl 2:S99-104.

47. Cakar M, et al. First report of endocarditis by *Alloioococcus otitidis* spp in a patient with a history of chronic otitis. *J Infect Public Health* 2013;6(6):494.
48. Cargill JS, et al. Granulicatella infection: diagnosis and management. *J Med Microbiol* 2012;61:755-61.
49. Cavallini F. Penicillin resistance in *Streptococcus agalactiae*. Abstractverwaltung AKM AG 18th European Congress of Clinical Microbiology and Infectious Disease (ECCMID) Antibacterial susceptibility studies - III April 4, 2006.
50. Center KJ, Reboli AC, Hubler R, et al. Decreased vancomycin susceptibility of coagulase-negative staphylococci in a neonatal intensive care unit: evidence of spread of *Staphylococcus warneri*. *J Clin Microbiol* 2003;41(10):4660-5.
51. Cerquetti M, Giufre M, Cardines R, et al. First characterization of heterogeneous resistance to imipenem in invasive nontypeable *Haemophilus influenzae* isolates. *Antimicrob Agents Chemother* 2007;51(9):3155-61.
52. Chagla AH, Borczyk AA, Facklam RR, et al. Breast abscess associated with *Helcococcus kunzii*. *J Clin Microbiol* 1998;36(8):2377-9.
53. Chamot E, Boffi El Amari E, Rohner P, et al. Effectiveness of combination antimicrobial therapy for *Pseudomonas aeruginosa* bacteremia. *Antimicrob Agents Chemother* 2003;47(9):2756-64.
54. Chan JFW, Woo PCY, Teng JLL, et al. Primary infective spondylodiscitis caused by *Lactococcus garvieae* and a review of human *L. garvieae* infections. *Infection*. 2011;39:259-64.
55. Chang JC, Hsueh PR, Wu JJ, et al. Antimicrobial susceptibility of flavobacteria as determined by agar dilution and disk diffusion methods. *Antimicrob Agents Chemother* 1997;41(6):1301-6.
56. Chaudhary D, Finkle SN. Peritoneal dialysis-associated peritonitis due to *Kytococcus sedentarius*. *Peritoneal Dialysis International* 2010;30(2):252-3.
57. Chavan R, Pannaraj PS, Luna RA, et al. Significant morbidity and mortality attributable to *Rothia mucilaginosa* infections in children with hematological malignancies or following hematopoietic stem cell transplantation. *Pediatr Hematol Oncol* 2013;30(5):445-54.
58. Chen M, Kemp M, Bruun NE, et al. *Cardiobacterium valvarum* infective endocarditis and phenotypic/molecular characterization of 11 *Cardiobacterium* species strains. *J Med Microbiol* 2001;60:522-8.

59. Cheng AC, Currie BJ. Melioidosis: Epidemiology, pathophysiology, and management. *Clin Microbiol Rev* 2005;18(2):383.
60. Chiquet C, Pechinot A, Creuzot-Garcher C, et al. Acute postoperative endophthalmitis caused by *Staphylococcus lugdunensis*. *J Clin Microbiol* 2007;45(6):1673-8.
61. Chiron R, Marchandin H, Counil F, et al. Clinical and microbiological features of *Inquilinus* sp. isolates from five patients with cystic fibrosis. *J Clin Microbiol* 2005;43(8):3938-43.
62. Cho EJ, Sung H, Park SJ, et al. *Rothia mucilaginosa* pneumonia diagnosed by quantitative cultures and intracellular organisms of bronchoalveolar lavage in a lymphoma patient. *Annals Laboratory Medicine* 2013;33:145-9.
63. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. *Int J Antimicrob Agents* 1999;11(1):7-12.
64. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. *Lancet* 2010;10:853-61.
65. Citro R, Prota C, Greco L, et al. *Kocuria kristinae* endocarditis related to diabetic foot infection. *J Med Microbiol* 2013;62(6):932-4.
66. Citron DM, Warren YA, Fernandez HT, et al. Broth microdilution and disk diffusion tests for susceptibility testing of *Pasteurella* species isolated from human clinical specimens. *J Clin Microbiol* 2005;43(5):2485-8.
67. Clarridge JE, Attori S, Musher DM, et al. *Streptococcus intermedius*, *Streptococcus constellatus*, and *Streptococcus anginosus* ("Streptococcus milleri Group") are of different clinical importance and are not equally associated with abscess. *Clin Infect Dis* 2001;32:1511-5.
68. Cooksey RC, Bannister ER, Farrar WE Jr. Antibiotic resistance patterns of clinical isolates of *Serratia marcescens*. *Antimicrob Agents Chemother* 1975;7(4):396-9.
69. Cortez JMC, Imam AA, Ang JY. *Pasteurella multocoda* urinary tract infection in a pediatric patient with end-stage renal disease. *Pediatric Infect Dis J* 2007;26(2):183-5.
70. Courvalin P, Leclercq R, Rice LB, editors. *Antibiogram*. Portland, Oregon: Eska Publishing; 2010.
71. Crane JK, Hohman DW, Nodzo SR, et al. Antimicrobial susceptibility of *Propionibacterium acnes* isolates from shoulder surgery. *Antimicrob Agents Chemother*. 2013;57(7):3424-6.

72. Currie PF, Codispoti M, Mankad PS, et al. Late aortic homograft valve endocarditis caused by *Cardiobacterium hominis*: a case report and review of the literature. *Heart* 2000;83(5):579-81.
73. Dargere S, Vergnaud M, Verdon R, et al. Enterococcus gallinarum endocarditis occurring on native heart valves. *J Clin Microbiol* 2002;40(6):2308-10.
74. De Backer E, Verhelst R, Verstraelen H, et al. Antibiotic susceptibility of *Atopobium vaginae*. *BMC Infectious Diseases* 2006;51(6):1-6
75. De Champs C, Constantin JM, Bonnet R, et al. Decreased susceptibility to extended-spectrum cephalosporins of a penicillin-susceptible *Streptococcus pneumoniae* in meningitis. *Infection* 2000;28(1):58-9.
76. Decre D, Verdet C, Emirian A, et al. Emerging severe and fatal infections due to *Klebsiella pneumoniae* in two university hospitals in France. *J Clin Microbiol* 2011;49(8):3012-4.
77. De Gheldre Y, Maes N, Rost F, et al. Molecular epidemiology of an outbreak of multidrug-resistant *Enterobacter aerogenes* infections and in vivo emergence of imipenem resistance. *J Clin Microbiol* 1997;35(1):152-60.
78. De Jong MFC, Soetekouw R, Reinier W, et al. *Aerococcus urinae*: severe and fatal bloodstream infections and endocarditis. *J Clin Microbiol* 2010;48(9):3445-7.
79. de la Maza L, Ruoff KL, Ferraro MJ. In vitro activities of daptomycin and other antimicrobial agents against vancomycin-resistant gram-positive bacteria. *Antimicrob Agents Chemother* 1989;33(8):1383-4.
80. den Hollander JG, Horrevorts AM, van Goor ML, et al. Synergism between tobramycin and ceftazidime against a resistant *Pseudomonas aeruginosa* strain, tested in an in vitro pharmacokinetic model. *Antimicrob Agents Chemother* 1997;41(1):95-100.
81. Di Pentima MC, Mason EO Jr., Kaplan SL. In vitro antibiotic synergy against *Flavobacterium meningosepticum*: implications for therapeutic options. *Clin Infect Dis* 1998;26(5):1169-76.
82. Doern GV, Jones RN, Pfaller MA, et al. Bacterial pathogens isolated from patients with skin and soft tissue infections: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). SENTRY Study Group (North America). *Diagn Microbiol Infect Dis* 1999;34(1):65-72.

83. Doern, CD, Burnham CD. It's not easy being green: the Viridans Group Streptococci, with a focus on pediatric clinical manifestations. *J Clin Microbiol* 2010;48(11):3829.
84. Doran TI. The role of *Citrobacter* in clinical disease of children: review. *Clin Infect Dis* 1999;28(2):384-94.
85. Dortet L, Legrand P, Soussy CJ, et al. Bacterial identification, clinical significance, and antimicrobial susceptibilities of *Acinetobacter ursingii* and *Acinetobacter schindleri*, two frequently misidentified opportunistic pathogens. *J Clin Microbiol* 2006;44(12):4471-8.
86. Drago L, De Vecchi E, Nicola L, et al. In vitro selection of resistance in *Pseudomonas aeruginosa* and *Acinetobacter* spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin. *J Antimicrob Chemother* 2005;56(2):353-9.
87. Drobniowski FA. *Bacillus cereus* and related species. *Clin Microbiol Rev* 1993;6(4):324-38.
88. Dunn R, Bares S, David MZ. Central venous catheter-related bacteremia caused by *Kocuria kristinae*: case report and review of the literature. *Annals Clinical Microbiol Antimicrobials* 2011;10:31.
89. Eady EA, Ross JI, Cove JH, et al. Macrolide-lincosamide-streptogramin B (MLS) resistance in cutaneous propionibacteria: definition of phenotypes. *J Antimicrob Chemother* 1989;23(4):493-502.
90. Eady EA, Gloor M, Leyden JJ. Propionibacterium acnes resistance: a worldwide problem. *Dermatology* 2003;206(1):54-6.
91. Edmiston CE, Krepel CJ, Seabrook GR, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. *Antimicrob Agents Chemother* 2004;48(3):1012-6.
92. Edwards R, Greenwood D. Additional characteristics of *Bacteroides fragilis* carbapenemases belonging to group 3a. *Antimicrob Agents Chemother* 1997;41(11):2591-2.
93. Edwards R, Hawkyard CV, Garvey MT, et al. Prevalence and degree of expression of the carbapenemase gene (*cfiA*) among clinical isolates of *Bacteroides fragilis* in Nottingham, UK. *J Antimicrob Chemother* 1999;43(2):273-6.
94. Edwards M, Baker C. Group B streptococcal infections in elderly adults. *Clin Infect Dis* 2005;41:839-47.
95. Elliott JA, Facklam RR. Antimicrobial susceptibilities of *Lactococcus lactis* and *Lactococcus garvieae* and a proposed method to discriminate between them. *J Clin Microbiol* 1996;34(5):1296-8.

96. Elliott TS, Foweraker J, Gould FK, et al. Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy. *J Antimicrob Chemother* 2012;67:269-89.
97. Fass RJ, Barnishan J, Solomon MC, et al. In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli. *Antimicrob Agents Chemother* 1996;40(6):1412-8.
98. Fass RJ, Barnishan J. In vitro susceptibilities of nonfermentative gram-negative bacilli other than *Pseudomonas aeruginosa* to 32 antimicrobial agents. *Rev Infect Dis* 1980;2(6):841-53.
99. Fefer JJ, Ratzan KR, Sharp SE, et al. *Lactococcus garvieae* endocarditis: report of a case and review of the literature. *Diagn Microbiol Infect Dis* 1998;32(2):127-30.
100. Fields MT, Herndon BL, Bamberger DM. Beta-lactamase-mediated inactivation and efficacy of cefazolin and cefmetazole in *Staphylococcus aureus* abscesses. *Antimicrob Agents Chemother* 1993;37(2):203-6.
101. Finegold SM, Jousimies-Somer H. Recently described clinically important anaerobic bacteria: medical aspects. *Clin Infect Dis* 1997;25 Suppl 2:S88-93.
102. Finegold SM. Susceptibility testing of anaerobic bacteria. *J Clin Microbiol* 1988;26(7):1253-6.
103. Fishbain J, Peleg AY. Treatment of *Acinetobacter* infections. *Clin Infect Dis* 2010;51(1):79-84.
104. Fitch L, Johnson AP. Reduced susceptibility to teicoplanin in a methicillin-resistant strain of *Staphylococcus aureus*. *J Antimicrob Chemother* 1998;41(5):578.
105. Florescu D, Hill L, Sudan D, et al. *Leuconostoc* bacteremia in pediatric patients with short bowel syndrome. *Pediatr Infect Dis J* 2008;27(11):1013-9.
106. Fluegge K, Supper S, Siedler A, et al. Antibiotic susceptibility in neonatal invasive isolates of *Streptococcus agalactiae* in a 2-year nationwide surveillance study in Germany. *Antimicrob Agents Chemother* 2004;48(11):4444-6.
107. Fournier B, Lagrange PH, Philippon A. In-vitro susceptibility of *Klebsiella oxytoca* strains to 13 beta-lactams in the presence and absence of beta-lactamase inhibitors. *J Antimicrob Chemother* 1996;37(5):931-42.

108. Frank KL, del Pozo J, Patel R. From clinical microbiology to infection pathogenesis: how daring to be different works for *Staphylococcus lugdunensis*. *Clinical Microbiol Rev* 2008;21(1):111-33.
109. Fraser SL, Jorgensen JH. Reappraisal of the antimicrobial susceptibilities of *Chryseobacterium* and *Flavobacterium* species and methods for reliable susceptibility testing. *Antimicrob Agents Chemother* 1997;41(12):2738-41.
110. Fung, Pui-Man. *Streptococcus bovis* endocarditis with vertebral osteomyelitis, spondylodiscitis, meningitis and colonic carcinoma in 72-year-old man presenting with neck pain. *J Hong Kong Geriatrics Society* 1997;8(1).
111. Funke G, Frodl R, Spommer H. First comprehensively documented case of *Paracoccus yeei* infection in a human. *J Clin Microbiol* 2004;42(7):3366-8.
112. Furuya R, Onoye Y, Kanayama A, et al. Antimicrobial resistance in clinical isolates of *Neisseria subflava* from the oral cavities of a Japanese population. *J Infect Chemother* 2007;13:302-4.
113. Gales AC, Jones RN, Andrade SS, et al. Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002). *Mem Inst Oswaldo Cruz* 2005;100(6):571-7.
114. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. *J Clin Microbiol* 2001;39(1):183-90.
115. Galloway A, Prouzet-Mauleon V, Kempf I, et al. *Campylobacter* antimicrobial drug resistance among humans, broiler chickens, and pigs, France. *Emerg Infect Dis* 2007;13(2):259-66.
116. Gasch O, Fernández N, Armisen A, et al. Community-acquired *Capnocytophaga canimorsus* meningitis in adults: report of one case with a subacute course and deafness, and literature review. *Enferm Infecc Microbiol Clin* 2009;27(1):33-6.
117. Gavalda J, Len O, Miro JM, et al. Brief communication: treatment of *Enterococcus faecalis* endocarditis with ampicillin plus ceftriaxone. *Annals Intern Med* 2007;146:574-9.
118. Gerber J, Glas M, Frank G, et al. *Streptococcus bovis* infection in young infants. *Pediatr Infect Dis J* 2006;25(11):1069-73.
119. Girlich D, Naas T, Bellais S, et al. Biochemical-genetic characterization and regulation of expression of an ACC-1-like

- chromosome-borne cephalosporinase from *Hafnia alvei*. *Antimicrob Agents Chemother* 2000;44(6):1470-8.
120. Gilbert DN, Moellering Jr. RC, Eliopoulos GM, et al. *The Sanford Guide to Antimicrobial Therapy*, 2014. Sperryville, VA.: Antimicrobial Therapy Inc. 2014.
 121. Goldstein EJC, Citron DM. Resistance trends in antimicrobial susceptibility of anaerobic bacteria part I. *CM Newsletter* 2011;33(1):1-8.
 122. Goldstein EJC, Citron DM. Resistance trends in antimicrobial susceptibility of anaerobic bacteria part II. *CM Newsletter* 2011;33(2):9-15.
 123. Goldstein EJ, Citron DM, Merriam CV, et al. In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 *Corynebacterium* clinical isolates. *Antimicrob Agents Chemother* 2003;47(1):337-41.
 124. Gomez E, Gustafson DR, Rosenblatt JE, et al. *Actinobaculum* bacteremia: a report of 12 cases. *J Clin Microbiol* 2011;49(12):4311-3.
 125. Goyache J, Vela AI, Gibello A, et al. *Lactococcus lactis* subsp. *lactis* infection in waterfowl: first confirmation in animals. *Emerg Infect Dis* 2001;7(5):884-6.
 126. Graham JC, Gould FK. Role of aminoglycosides in the treatment of bacterial endocarditis. *J Antimicrob Chemother* 2002;49(3):437-44.
 127. Grayson ML. *Kucers' the use of antibiotics* 6th Edition, Volume 1. Great Britain: Hodder Arnold; 2010.
 128. Guglielmo BJ, Luber AD, Paletta D Jr., et al. Ceftriaxone therapy for staphylococcal osteomyelitis: a review. *Clin Infect Dis* 2000;30(1):205-7.
 129. Han XY, Meltzer MC, Woods JT, et al. Endocarditis with ruptured cerebral aneurysm caused by *Cardiobacterium valvarum* sp. nov. *J Clin Microbiol* 2004;42(4):1590-5.
 130. Hanslik T, Hartig C, Jurand C, et al. Clinical significance of tolerant strains of streptococci in adults with infective endocarditis. *Clin Microbiol Infect* 2003;9(8):852-7.
 131. Harris JB, LaRocque RC, Qadri F, et al. Cholera. *Lancet*. 2012;379:2466-76.
 132. Hassan S, Amer S, Mittal C, et al. *Ewingella americana*: an emerging true pathogen. *Case Reports Infect Dis*; Volume 2012, Article ID 730720, 2 pages.

133. Hatch S, Sree A, Tirrell S, et al. Metastatic complications from *Staphylococcus intermedius*, a zoonotic pathogen. *J Clin Microbiol* 2012;50(3):1099.
134. Hery-Arnaud G, Doloy A, Ansart S, et al. *Globicatella sanguinis* meningitis associated with human carriage. *J Clin Microbiol* 2010;48(4):1491.
135. Hess B, Burtchett A, Huntington MK. *Leclercia adecarboxylata* in an immunocompetent patient. *J Med Microbiol* 2008;57:896-8.
136. Higgins PG, Wisplinghoff H, Stefanik D, et al. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant *Acinetobacter baumannii* strains. *Antimicrob Agents Chemother* 2004;48(5):1586-92.
137. Hilf M, Yu VL, Sharp J, et al. Antibiotic therapy for *Pseudomonas aeruginosa* bacteremia: outcome correlations in a prospective study of 200 patients. *Am J Med* 1989;87(5):540-6.
138. Hilliard NJ, Schelonka RL, Waites KB. *Bacillus cereus* bacteremia in a preterm neonate. *J Clin Microbiol* 2003;41(7):3441-4.
139. Hindler FJ. Non-Enterobacteriaceae: the latest on susceptibility testing (588-971-08). San Francisco, USA: 2008 Teleconference Series APHL, Clinical And Laboratory Standards Institute 2008.
140. Hironaga M, Yamane K, Inaba M, et al. Characterization and antimicrobial susceptibility of *Dysgonomonas capnocytophagoides* isolated from human blood sample. *J Infect Dis* 2008;61:212-3.
141. Banno H, Kimura K, Tanaka Y, et al. Characterization of multidrug-resistant Group B streptococci with reduced penicillin susceptibility forming small non-beta-hemolytic colonies on sheep blood agar plates. *J Clin Microbiol* 2014;52(6):2169-71.
142. Hocqueloux L, Poisson DM, Sunder S, et al. Septic arthritis caused by *Erysipelothrix rhusiopathiae* in a prosthetic knee joint. *J Clin Microbiol* 2010;48(1):333-5.
143. Hoenigl M, Leitner E, Valentin T, et al. Endocarditis caused by *Actinobaculum schaalii*, Austria. *Emerg Infect Dis* 2010;16(7):1170-3.
144. Holt HM, Gahrn-Hansen B, Bruun B. *Shewanella algae* and *Shewanella putrefaciens*: clinical and microbiological characteristics. *Clin Microbiol Infect* 2005;11:347-52.
145. Hsueh PR, Teng LJ, Yang PC, et al. Susceptibilities of *Chryseobacterium indologenes* and *Chryseobacterium*

- meningosepticum to cefepime and ceftazidime. *J Clin Microbiol* 1997;35(12):3323-4.
146. Hsueh PR, Teng LJ, Lee LN, et al. High incidence of erythromycin resistance among clinical isolates of *Streptococcus agalactiae* in Taiwan. *Antimicrob Agents Chemother* 2001;45(11):3205-8.
 147. Humphries RM, Lee C, Hindler JA. *Aerococcus urinae* and trimethoprim-sulfamethoxazole. *J Clin Microbiol* 2011;49(11):3934-5.
 148. Humphries RM, Hindler JA. In vitro antimicrobial susceptibility of *Aerococcus urinae*. *J Clin Microbiol* 2014;52(6):2177.
 149. Hu J, Robinson JL. Systematic review of invasive *Acinetobacter* Infections in children. *Can J Infect Dis Med Microbiol*, 2010;21(2):83.
 150. Hung KH, Wang MC, Huang AH, et al. Heteroresistance to cephalosporins and penicillins in *Acinetobacter baumannii*. *J Clin Microbiol* 2012;50(3):721-6.
 151. Iversen C, Lehner A, Mullane N, et al. Identification of "*Cronobacter*" spp. (*Enterobacter sakazakii*). *J Clin Microbiol* 2007;45(11):3814-6.
 152. Iversen C, Lehner A, Mullane N, et al. The taxonomy of *Enterobacter sakazakii*: proposal of a new genus *Cronobacter* gen. nov. and descriptions of *Cronobacter sakazakii* comb. nov., *Cronobacter sakazakii* subsp. *sakazakii*, comb. nov., *Cronobacter sakazakii* subsp. *malonicus* subsp. nov., *Cronobacter turicensis* sp. nov., *Cronobacter muytjensii* sp. nov., *Cronobacter dublinensis* sp. nov. and *Cronobacter* genomospecies 1. *BMC Evol Biol* 2007;7:64.
 153. Iwen P, Mindru C, Kalil AC, et al. *Pediococcus acidilactici* endocarditis successfully treated with daptomycin. *J Clin Microbiol* 2012;50(3):1106-8.
 154. Janda WM. Update on the HACEK group of fastidious Gram-negative bacilli, part I. *Clin Microbiol Newsletter* 2013;35(11):87-93.
 155. Janda WM. Update on the HACEK group of fastidious Gram-negative bacilli, part II. *Clin Microbiol Newsletter* 2013;35(12):95-101.
 156. Janda J.M, Abbott SL. The genus *Aeromonas*: taxonomy, pathogenicity, and infection. *J Clin Microbiol* 2010;23(1):35-73.
 157. Janda JM, Abbott SL. The genus *Hafnia*: from soup to nuts. *J Clin Microbiol* 2006;19(1):12-28.
 158. Jannat-Khah DP, Halsey ES, Lasker BA, et al. *Gordonia arii* infection associated with an orthopedic device and review of the literature on medical device-associated *Gordonia* infections. *J Clin Microbiol* 2009;47(2):499-502.

159. Johnson DM, Biedenbach DJ, Jones RN. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections. *Diagn Microbiol Infect Dis* 2002;43(1):49-60.
160. Johnson PDR, et al. A sustained hospital outbreak of vancomycin-resistant *Enterococcus faecium* bacteremia due to emergence of vanB E. *faecium* sequence type 203. *J Infect Dis* 2010;202:1278.
161. Jones ME, Karlowsky JA, Draghi DC, et al. Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapy. *Int J Antimicrob Agents* 2004;23(3):240-6.
162. Jones RN, Sader HS, Beach ML. Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains of non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). *Int J Antimicrob Agents* 2003;22(6):551-6.
163. Jones RN, Stilwell MG, Hogan PA, et al. Activity of linezolid against 3,251 strains of uncommonly isolated gram-positive organisms: report from the SENTRY Antimicrobial Surveillance Program. *Antimicrob Agents Chemother* 2007;51(4):1491-3.
164. Jorgensen JH, Crawford SA, Fiebelkorn KR. Susceptibility of *Neisseria meningitidis* to 16 antimicrobial agents and characterization of resistance mechanisms affecting some agents. *J Clin Microbiol* 2005;43(7):3162-71.
165. Jourdain S, Miendje Deyi VY, Musampa K, et al. *Kytococcus schroeteri* infection of a ventriculoperitoneal shunt in a child. *Int J Infect Dis* 2009;13(4):e153-5.
166. Kuo SC, Chen PC, Shiau YR, et al. Levofloxacin-resistant *Haemophilus influenzae*, Taiwan, 2004-2010. *Emerg Infect Dis* 2014;20(8):1386-90.
167. Karlowsky JA, Jones ME, Draghi DC, et al. Clinical isolates of *Streptococcus pneumoniae* with different susceptibilities to ceftriaxone and cefotaxime. *Antimicrob Agents Chemother* 2003;47(10):3155-60.
168. Kati C, Bibashi E, Kokolina E, et al. Case of peritonitis caused by *Ewingella americana* in a patient undergoing continuous ambulatory peritoneal dialysis. *J Clin Microbiol* 1999;37(11):3733-4.

169. Kernodle DS, Classen DC, Stratton CW, et al. Association of borderline oxacillin-susceptible strains of *Staphylococcus aureus* with surgical wound infections. *J Clin Microbiol* 1998;36(1):219-22.
170. Kimura K, Suzuki S, Wachino J, et al. First molecular characterization of group B streptococci with reduced penicillin susceptibility. *Antimicrob Agents Chemother* 2008;52(8):2890-7.
171. Kirby JT, Sader HS, Walsh TR, et al. Antimicrobial susceptibility and epidemiology of a worldwide collection of *Chryseobacterium* spp: report from the SENTRY Antimicrobial Surveillance Program (1997-2001). *J Clin Microbiol* 2004;42(1):445-8.
172. Kitamura Y, Sawabe E, Ohkusu K, et al. First report of sepsis caused by *Rhodococcus corynebacterioides* in a patient with myelodysplastic syndrome. *J Clin Microbiol* 2012;50(3):1089-91.
173. Klotchko A, Wallace MR, Licitra M, et al. *Staphylococcus lugdunensis*: an emerging pathogen. *Southern Med J* 2011;104(7):509.
174. Kovaleva J, Degener JE, van der Mei HC, et al. *Methylobacterium* and its role in health care-associated infection. *J Clin Microbiol* 2014;52(5):1317-20.
175. Frank KL, del Pozo JL, Patel R. From clinical microbiology to infection pathogenesis: how daring to be different works for *Staphylococcus lugdunensis*. *Clin Microbiol Rev* 2008;Jan:111-33.
176. Kuo IC, Lu PL, Lin WR, et al. *Sphingomonas paucimobilis* bacteraemia and septic arthritis in a diabetic patient presenting with septic pulmonary emboli. *J Med Microbiol* 2009;58(9):1259-63.
177. LaClaire L, Facklam R. Antimicrobial susceptibilities and clinical sources of *Facklamia* species. *Antimicrob Agents Chemother* 2000;44(8):2130-2.
178. LaClaire L, Facklam R. Antimicrobial susceptibility and clinical sources of *Dolosigranulum pigrum* cultures. *Antimicrob Agents Chemother* 2000;44(7):2001-3.
179. Lai CC, Wang JY, Lin SH, et al. Catheter-related bacteraemia and infective endocarditis caused by *Kocuria* species. *Clin Microbiol Infect* 2011;17(2):190-2.
180. Lai CC, Cheng A, Liu WL, et al. Infections caused by unusual *Methylobacterium* species. *J Clin Microbiol* 2011;49(9):3329-31.
181. Lawson PA, Malnick H, Collins MD, et al. Description of *Kingella potus* sp. nov., an organism isolated from a wound caused by an animal bite. *J Clin Microbiol* 2005;43(7):3526-9.

182. Lawson PA, Carlson P, Wernersson S, et al. *Dysgonomonas hofstadii* sp. nov., isolated from a human clinical source. *Anaerobe* 2010;16(2):161-4.
183. Le Brun C, Bouet J, Gautier P, et al. *Kytococcus schroeteri* endocarditis. *Emerg Infect Dis* 2005;11(1):179-80.
184. Ledina D, Ivic I, Karanovic J, et al. *Campylobacter fetus* infection presenting with bacteremia and cellulitis in a 72-year-old man with an implanted pacemaker: a case report. *J Med Case Reports* 2012;6:414.
185. Lee CC, Chen PL, Wang LR, et al. Fatal cause of community-acquired bacteremia and necrotizing fasciitis caused by *Chryseobacterium meningosepticum*: case report and review of the literature. *J Clin Microbiol* 2006;44(3):1181-3.
186. Lee MR, Huang YT, Liao CH, et al. Clinical and microbiological characteristics of bacteremia caused by *Eggerthella*, *Paraeggerthella*, and *Eubacterium* species at a university hospital in Taiwan from 2001 to 2010. *J Clin Microbiol* 2012;50(6):2053-5.
187. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. *Antimicrob Agents Chemother* 1997;41(5):1127-33.
188. Leung D, Davis EM, Qian Q, et al. First report of prosthetic joint infection by *Gemella sanguinis* and associated “pseudosatelliting” phenomenon on culture. *J Clin Microbiol* 2011;49(9):3395-7.
189. Levenga H, Donnelly P, Blijlevens N, et al. Fatal hemorrhagic pneumonia caused by infection due to *Kytococcus sedentarius* – a pathogen or passenger? *Ann Hematol* 2004;83(7):447-9.
190. Liassine N, Madec S, Ninet B, et al. Postneurosurgical meningitis due to *Proteus penneri* with selection of a ceftriaxone-resistant isolate: analysis of chromosomal class A beta-lactamase HugA and its LysR-type regulatory protein HugR. *Antimicrob Agents Chemother* 2002;46(1):216-9.
191. Liderot K, Larsson M, Borang S, et al. Polymicrobial bloodstream infection with *Eggerthella lenta* and *Desulfovibrio desulfuricans*. *J Clin Microbiol* 2010;48(10):3810-2.
192. Lin WR, et al. Cellulitis and bacteremia caused by *Bergeyella zoohelcum*. *J Formos Med Assoc* 2007;106(70):573-6.
193. LiPuma J. Update on *Burkholderia* nomenclature and resistance. *Clin Microbiol Newsletter* 2007;29(9):65-9.

194. Livermore DM, Winstanley TG, Shannon KP. Interpretative reading: recognizing the unusual and inferring resistance mechanisms from resistance phenotypes. *J Antimicrob Chemother* 2001;48 Suppl 1:87-102.
195. Looney WJ, Narita M, Muhlemann K, et al. *Stenotrophomonas maltophilia*: an emerging opportunist human pathogen. *Lancet Infect Dis* 2009;9:312-3.
196. Luna VA, King DS, Gullledge J, et al. Susceptibility of *Bacillus anthracis*, *Bacillus cereus*, *Bacillus mycoides*, *Bacillus pseudomycoloides* and *Bacillus thuringiensis* to 24 antimicrobials using sensititre automated microbroth dilution and Etest agar gradient diffusion methods. *J Antimicrob Chemother* 2007;60:555-67.
197. Ma ES, Wong CL, Lai KT, et al. *Kocuria kristinae* infection associated with acute cholecystitis. *BMC Infect Dis* 2005;5(1):60.
198. Maluping RP, Lavilla-Pitogo CR, DePaola A, et al. Antimicrobial susceptibility of *Aeromonas* spp., *Vibrio* spp. and *Plesiomonas shigelloides* isolated in the Philippines and Thailand. *Int J Antimicrob Agents* 2005;25(4):348-50.
199. Manchanda V, Bhalla P. Emergence of non-ceftriaxone-susceptible *Neisseria meningitidis* in India. *J Clin Microbiol* 2006;44(11):4290-1.
200. Maragakis LL, Perl TM. *Acinetobacter baumannii*: epidemiology, antimicrobial resistance, and treatment options. *Clin Infect Dis* 2008;46:1254-63.
201. Marriott D, Stark D, Harkness J, et al. *Veillonella parvula* discitis and secondary bacteremia: a rare infection complicating endoscopy and colonoscopy? *J Clin Microbiol* 2007;45(2):672-4.
202. Martinez E, Miro JM, Almirante B, et al. Effect of penicillin resistance of *Streptococcus pneumoniae* on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults. *Clin Infect Dis* 2002;35(2):130-9.
203. Matar GM, Cuzon G, Araj GF, et al. Oxacillinase-mediated resistance to carbapenems in *Klebsiella pneumoniae* from Lebanon. *Clin Microbiol Infect* 2008;14(9):887-8.
204. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to *Bordetella pertussis* and other *Bordetella* subspecies. *Clin Microbiol Reviews* 2005;18(2):362-82.
205. Matsumoto T, Kawakami Y, Oana K, et al. First isolation of *Dysonomonas mossii* from intestinal juice of a patient with pancreatic cancer. *Arch Med Res* 2006;37(7):914-6.

206. Maurissen W, Eyskens B, Gewillig M, et al. Beta-lactamase-positive *Cardiobacterium hominis* strain causing endocarditis in a pediatric patient with tetralogy of Fallot. *Clin Microbiol Newsletter* 2008;30(17):127-34.
207. McPherson C, Gal P, Ransom JL. Treatment of *Citrobacter koseri* infection with ciprofloxacin and cefotaxime in a preterm infant. *Ann Pharmacother* 2008;42(7):1134-8.
208. Van der Mee-Marquet N, Achard A, Mereghetti L, et al. *Staphylococcus lugdunensis* infections: high frequency of inguinal area carriage. *J Clin Microbiol* 2003;41(4):1404-9.
209. Metzidie E, Manolis EN, Pournaras S, et al. Spread of an unusual penicillin- and imipenem-resistant but ampicillin-susceptible phenotype among *Enterococcus faecalis* clinical isolates. *J Antimicrob Chemother* 2006;57(1):158-60.
210. Mingeot-Leclercq MP, Glupczynski Y, Tulkens PM. Aminoglycosides: activity and resistance. *Antimicrob Agents Chemother* 1999;43(4):727-37.
211. Mnif B, Boujelbene I, Mahjoubi F, et al. Endocarditis due to *Kytococcus schroeteri*: case report and review of the literature. *J Clin Microbiol* 2006;44(3):1187-9.
212. Mortensen JE, Giger O, Rodgers GL. In vitro activity of oral antimicrobial agents against clinical isolates of *Pasteurella multocida*. *Diagn Microbiol Infect Dis* 1998;30(2):99-102.
213. Mory F, Fougnot F, Rabaud C, et al. In vitro activities of cefotaxime, vancomycin, quinupristin/dalfopristin, linezolid and other antibiotics alone and in combination against *Propionibacterium acnes* isolates from central nervous system infections. *J Antimicrob Chemother* 2005;55:265-8.
214. Moubareck C, Gavini F, Vaugien L, et al. Antimicrobial susceptibility of *Bifidobacteria*. *J Antimicrob Chemother* 2005;55(1):38-44.
215. Mouton JW, van Ogtrop ML, Andes D, et al. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. *Antimicrob Agents Chemother* 1999;43(10):2473-8.
216. Mulvey MR, Grant JM, Plewes K, et al. New Delhi metallo- β -lactamase in *Klebsiella pneumoniae* and *Escherichia coli*, Canada. *Emerg Infect Dis* 2011;17(1):103-6.
217. Murphy TF, Parameswaran GI. *Moraxella catarrhalis*, a human respiratory tract pathogen. *Clin Infect Dis* 2009;49:124.

218. Murray CK, Walter EA, Crawford S, et al. Abiotrophia bacteremia in a patient with neutropenic fever and antimicrobial susceptibility testing of Abiotrophia isolates. Clin Infect Dis 2001;32(10):E140-2.
219. Muytjens HL, Eggink CA, Dijkman FCAP, et al. Keratitis due to Shigella flexneri. J Clin Microbiol 2006;44(6):2291-4.
220. Nannini EC, Singh KV, Murray BE. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin Infect Dis 2003;37(9):1194-8.
221. Narchi H. Kluuvera urinary tract infection case report and review of the literature. Pediatric Infect Dis J 2005;24(6):570.
222. Ndon JA. Capnocytophaga canimorsus septicemia caused by a dog bite in a hairy cell leukemia patient. J Clin Microbiol 1992;30(1):211-3.
223. Neuwirth C, Siebor E, Duez JM, et al. Imipenem resistance in clinical isolates of Proteus mirabilis associated with alterations in penicillin-binding proteins. J Antimicrob Chemother 1995;36(2):335-42.
224. Nicolas P. Emergence of non-ceftriaxone-susceptible Neisseria meningitidis in India. J Clin Microbiol 2007;45(4):1378.
225. Niyogi SK. Increasing antimicrobial resistance--an emerging problem in the treatment of shigellosis. Clin Microbiol Infect 2007;13(12):1141-3.
226. Noonan L, et al. Bacillus cereus and other non-anthraxis Bacillus species. UpToDate 2013.
227. O'Connell K, Kelly J, NiRiain U, et al. A rare case of soft-tissue infection caused by Raoultella planticola. Case Reports in Medicine Volume 2010 (2010), Article ID 134086, 2 pages.
228. Olsen DS, Asare K, Lyons M, et al. A novel case of Raoultella planticola urinary tract infection. Infection 2013;41(1):259-61.
229. Oprica C, Nord CE. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes. Clin Microbiol Infect 2005;11:204-13.
230. Otsuka Y, Kawamura Y, Koyama T, et al. Corynebacterium resistens sp. nov., a new multidrug-resistant coryneform bacterium isolated from human infections. J Clin Microbiol 2005;43(8):3713-7.
231. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ 2004;328(7441):668.

232. Peleg AY, Potoski BA, Rea R, et al. *Acinetobacter baumannii* bloodstream infection while receiving tigecycline: a cautionary report. *J Antimicrob Chemother* 2007;59:128-31.
233. Peleg AY, Seifert H, Paterson DL. *Acinetobacter baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev* 2008;21(3):538-82.
234. Perez-Vazquez M, et al. Fluoroquinolone resistance in *Haemophilus influenzae* is associated with hypermutability. *Antimicrob Agents Chemother* 2007;51(4):1566-9.
235. Petti CA, Simmon KE, Miro JM, et al. Genotypic diversity of coagulase-negative staphylococci causing endocarditis: a global perspective. *J Clin Microbiol* 2008;46:1780-4.
236. Poyart C, Pierre C, Quesne G, et al. Emergence of vancomycin resistance in the genus *Streptococcus*: characterization of a vanB transferable determinant in *Streptococcus bovis*. *Antimicrob Agents Chemother* 1997;41(1):24-9.
237. Presterl E, Grisold AJ, Reichmann S, et al. Viridans streptococci in endocarditis and neutropenic sepsis: biofilm formation and effects of antibiotics. *J Antimicrob Chemother* 2005;55(1):45-50.
238. Punpanich W, Srijuntongsiri S. *Pasteurella (Mannheimia) haemolytica* septicemia in an infant: a case report. *J Infect Dev Ctries* 2012;67(7):584-7.
239. Ramana KV. *Kingella kingae* a potentially emerging pathogen: a comprehensive review. *Molecular Pathogens* 2013;4(1):1-8.
240. Ratnayake L, Olver WJ, Fardon T. *Aggregatibacter aphrophilus* in a patient with recurrent empyema: a case report. *J Med Case Reports* 2011;5:448.
241. Raz R, Colodner R, Kunin CM. Who are you – *Staphylococcus saprophyticus*? *Clin Infect Dis* 2005;40:896-8.
242. Reid KC, Cockerill IF, Patel R. Clinical and epidemiological features of *Enterococcus casseliflavus/flavescens* and *Enterococcus gallinarum* bacteremia: a report of 20 cases. *Clin Infect Dis* 2001;32(11):1540-6.
243. Reinhard M, Prag J, Kemp M, et al. Ten cases of *Actinobaculum schaalii* infection: clinical relevance, bacterial identification, and antibiotic susceptibility. *J Clin Microbiol* 2005;43(10):5305-8.
244. Renvoise A, Harle JR, Raoult D, et al. *Gordonia sputi* bacteremia. Centers for Disease Control and Prevention. *Letter Sept* 2009;15(9).
245. Renvoise A, Roux V, Casalta JP, et al. *Kytococcus schroeteri*, a rare agent of endocarditis. *Int J Infect Dis* 2008;12(2):223-7.

246. Risi GF, Spangler CA. Capnocytophaga canimorsus meningitis after routine myelography: a sentinel event identifies multiple opportunities for improvement of standard practices in radiology. AJIC 2006;34(8):540-2.
247. Roberts SA, Lang SDR. Achromobacter (Alcaligenes) species. Antimicrob Therapy Vaccines 1998 First Edition;1.
248. Romero B, Morosini MI, Loza E, et al. Reidentification of Streptococcus bovis isolates causing bacteremia according to the new taxonomy criteria: still an issue? J Clin Microbiol 2011;49(9):3228-33.
249. Ryoo NH, Ha JS, Jeon DS, et al. A case of pneumonia caused by Ewingella americana in a patient with chronic renal failure. J Korean Med Sci 2005;20:143-5.
250. Sabbe LJM, Van De Merwe D, Schouls L, et al. Clinical spectrum of infections due to the newly described Actinomyces species A. turicensis, A. radingae, and A. europaeus. J Clin Microbiol 1999; 37(1):8-13.
251. Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. Int J Antimicrob Agents 2005;25(2):95-109.
252. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004;4(8):519-27.
253. Saito R, Okugawa S, Kumita W, et al. Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients. Clin Microbiol Infect 2007;13(12):1204-6.
254. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004;38(1):62-9.
255. Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, species identification, and antimicrobial susceptibility of 85 blood isolates. Clin Infect Dis 2006;42(5):e35-44.
256. Savini V, Catavittello C, Masciarelli G, et al. Drug sensitivity and clinical impact of members of the genus Kocuria. J Med Microbiol 2010;59:1395-1402.
257. Schett G, Herak P, Graninger W, et al. Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature. J Clin Microbiol 2005;43(5):2537-41.

258. Schlaberg R, Huard RC, Della-Latta P, et al. *Nocardia cyriacigeorgica*, an emerging pathogen in the United States. J Clin Microbiol 2008;46(1):265-73.
259. Seegmuller I, van der Linden M, Heeg C, et al. Globicatella sanguinis is an etiological agent of ventriculoperitoneal shunt-associated meningitis. J Clin Microbiol 2007;666-7.
260. Senn L, Entenza JM, Greub G, et al. Bloodstream and endovascular infections due to Abiotrophia defectiva and Granulicatella species. BCM Infect Dis 2006;6:9.
261. Shah N, Osmon DR, Fadel H, et al. Laboratory and clinical characteristics of Staphylococcal lugdunensis prosthetic joint infections. J Clin Microbiol 2010;48(5):1600-3.
262. Shukla SK, Paustian DL, Stockwell PJ, et al. Isolation of a fastidious *Bergeyella* species associated with cellulitis after a cat bite and a phylogenetic comparison with *Bergeyella zoohelcum* strains. J Clin Microbiol 2004;42(1):290-3.
263. Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008;46:668-74.
264. Slenker AK, Hess BD, Jungkind DL, et al. Fatal case of *Weeksellia virosa* sepsis. J Clin Microbiol 2012;50:4166-7.
265. Slinger R, Desjardins M, McCarthy AE, et al. Suboptimal clinical response to ciprofloxacin in patients with enteric fever due to Salmonella spp. with reduced fluoroquinolone susceptibility: a case series. BMC Infect Dis 2004;4:36.
266. Smego RA Jr., Foglia G. Actinomycosis. Clin Infect Dis 1998;26(6):1255-61.
267. Smith AJ, Hall V, Thakker B, et al. Antimicrobial susceptibility testing of Actinomyces species with 12 antimicrobial agents. J Antimicrob Chemother 2005;56(2):407-9.
268. Song Y, Chengxu L, Finegold SM. Peptoniphilus gorbachii sp. nov., Peptoniphilus olsenii sp. nov., and Anaerococcus murdochii sp. nov. isolated from clinical specimens of human origin. J Clin Microbiol 2007;45(6):1746-52.
269. Soriano F, Tauch A. Microbiological and clinical features of Corynebacterium urealyticum: urinary tract stones and genomics as the Rosetta Stone. CMI 2008;14:632-43.
270. Soriano F, Perez-Trallero E, Pallares R, et al. Streptococcus pneumoniae endophthalmitis: a study of 36 cases with special

- reference to antibiotic resistance and treatment options. Clin Microbiol Infect 2006;12(6):519-26.
271. Spelman D. Microbiology, epidemiology and pathogenesis of nocardiosis. UpToDate 2012.
 272. Spiegel CA. Susceptibility of Mobiluncus species to 23 antimicrobial agents and 15 other compounds. Antimicrob Agents Chemother 1987;31(2):249-52.
 273. Stock I, Burak S, Wiedemann B. Natural antimicrobial susceptibility patterns and biochemical profiles of Leclercia adecarboxylata strains. Clin Microbiol Infect 2004;10(8):724-33.
 274. Stock I, Wiedemann B. Natural antibiotic susceptibility of Enterobacter amnigenus, Enterobacter cancerogenus, Enterobacter gergoviae and Enterobacter sakazakii strains. Clin Microbiol Infect 2002;8(9):564-78.
 275. Stock I. Plesiomonas shigelloides: an emerging pathogen with unusual properties. Reviews in Medical Microbiology 2004;15:129-39.
 276. Sturm PD, Van Eijk J, Veltman S, et al. Urosepsis with Actinobaculum schaalii and Aerococcus urinae. J Clin Microbiol 2006;44(2):652-4.
 277. Swenson JM, Facklam RR, Thornsberry C. Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species. Antimicrob Agents Chemother 1990;34(4):543-9.
 278. Tafe LJ, Ruoff KL. Streptococcus bovis: answers and questions. Clin Microbiol Newsletter 2007;29(7):49-55.
 279. Tee WS, Soh SY, Lin R, et al. Staphylococcus lugdunensis carrying the mecA gene causes catheter-associated bloodstream infection in premature neonate. J Clin Microbiol 2003;41(1):519-20.
 280. Therriault BL, Daniels LM, Carter YL, et al. Severe sepsis caused by Arcanobacterium haemolyticum: a case report and review of the literature. Ann Pharmacother 2008;42:1697.
 281. Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother 2003;51(5):1261-8.
 282. Tinguely R, Seiffert SN, Furrer H, et al. Emergence of extensively drug-resistant Haemophilus parainfluenzae in Switzerland. Antimicrob Agents Chemother 2013;57(6):2867-9.
 283. Toleman MA, Bennett PM, Bennett DM, et al. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas

- maltophilia mediated by acquisition of sul genes. *Emerg Infect Dis* 2007;13(4):559-65.
284. Tomczak H, Bilaska-Stoklosa J, Osmola K, et al. *Rothia mucilaginosa*, rarely isolated pathogen as an etiological factor of infection of soft tissues in young, healthy women. *Postepy Hig Med Dosw (online)* 2013;67:1-5.
285. Topcu Y, Akinci G, Bayram E, et al. Brain abscess caused by *Lactococcus lactis cremoris* in a child. *Eur J Pediatr* 2011;170(12):1603-5.
286. Tripodi MF, Fortunato R, Utili R, et al. Molecular epidemiology of *Streptococcus bovis* causing endocarditis and bacteraemia in Italian patients. *Clin Microbiol Infect* 2005;11(10):814-9.
287. Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in *Haemophilus influenzae*. *Clin Microbiol Rev* 2007;20(2):368-89.
288. Vanden Bempt I, Van Trappen S, Cleenwerck I, et al. *Actinobaculum schaalii* Involved in Fournier's gangrene. *J Clin Microbiol* 2011;49(12):4311-3.
289. Veloo ACM, Welling GW, Degener JE. Antimicrobial susceptibility of clinically relevant Gram-positive anaerobic cocci collected over a three-year period in the Netherlands. *Antimicrobial Agents Chemother* 2011;55(3):1199-203.
290. Verma P, Brown JM, Nunez VH, et al. Native valve endocarditis due to *Gordonia polyisoprenivorans*: case report and review of literature of bloodstream infections caused by *Gordonia* species. *J Clin Microbiol* 2006;44(5):1905-8.
291. Versalovic J, editor in chief. *Manual of Clinical Microbiology* 10th Edition, Volume 1. Washington DC: ASM Press 2011.
292. Villar HE, Danel F, Livermore DM. Permeability to carbapenems of *Proteus mirabilis* mutants selected for resistance to imipenem or other beta-lactams. *J Antimicrob Chemother* 1997;40(3):365-70.
293. Vinh DC, Mubareka S, Fatoye B, et al. *Vibrio vulnificus* septicemia after handling tilapia species fish: a Canadian case report and review. *Can J Dis Med Microbiol* 2006;17(2):129.
294. von Eiff C, Herrmann M, Peters GI. Antimicrobial susceptibilities of *Stomatococcus mucilaginosus* and of *Micrococcus* spp. *Antimicrob Agents Chemother* 1995;39(1):268-70.
295. Vossen M, Gattringer KB, Khalifeh N, et al. *Gemella morbillorum* bacteremia after anti-tumor necrosis factor alpha as acne inversa therapy. *J Clin Microbiol* 2012;50(3):1109.

296. Walkty A. *Cardiobacterium hominis* endocarditis: a case report and review of the literature. *Can J Infect Dis Med Microbiol* 2005;16(5):293
297. Wang CY, Shie HS, Chen SC, et al. *Lactococcus garvieae* infections in humans: possible association with aquaculture outbreaks. *Int J Clin Pract* 2007;61(1):68-73.
298. Wang J-L, Hsueh PR. Therapeutic options for infections due to vancomycin-resistant enterococci. *Expert Opin Pharmacother* 2009;10(5):785-96.
299. Weinbren MJ, Johnson AP, Kaufmann ME, et al. *Acinetobacter* spp. isolates with reduced susceptibilities to carbapenems in a UK burns unit. *J Antimicrob Chemother* 1998;41(5):574-6.
300. Wilson JW. Nocardiosis: updates and clinical overview. *Mayo Clin Proc* 2012;87(4):403-7.
301. Wong DW, Yang W, Vielemeyer O. Catheter-related *Leuconostoc* bacteraemia in a pregnant HIV-infected woman. *J Med Cases* 2012;3(6):331-3.
302. Woo PCY, Tse H, Wong SSY, et al. Life-threatening invasive *Helcococcus kunzii* infections in intravenous-drug users and *ermA*-mediated erythromycin resistance. *J Clin Microbiol* 2005;3(12):6205.
303. Wybo I, Pierard D, Verschraegen I, et al. Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. *J Antimicrob Chemother* 2007;59:132-9.
304. Wybo I, Van den Bossche D, Soetens O, et al. Fourth Belgian Multicentre survey of antibiotic susceptibility of anaerobic bacteria. *J Antimicrob Chemother Advance Access Published Sept 5, 2013.*
305. Zheng X, Freeman AF, Villafranca J, et al. Antimicrobial susceptibilities of invasive pediatric *Abiotrophia* and *Granulicatella* isolates. *J Clin Microbiol* 2004;42(9):4323-6.
306. Yagupsky P, Katz O, Peled N. Antibiotic susceptibility of *Kingella kingae* isolates from respiratory carriers and patients with invasive infections. *J Antimicrob Chemother* 2001;47:191-3.
307. Yamshchikov A, Schuetz A, Lyon GM, et al. *Rhodococcus equi* infection. *Lancet Infect Dis* 2010;10:350-9.
308. Yang K, Guglielmo BJ. Diagnosis and treatment of extended-spectrum and AmpC β -lactamase-producing organisms. *Ann Pharmacother* 2007;41:1427-35.
309. Yildiz O, Alp E, Tokgoz B, et al. Nocardiosis in a teaching hospital in the Central Anatolia region of Turkey: treatment and outcome. *Clin Microbiol Infect* 2005;11(6):495-9.

310. Yokota S, Ohkoshi Y, Sato K, et al. Emergence of fluoroquinolone-resistant *Haemophilus influenzae* strains among elderly patients but not among children. *J Clin Microbiol* 2008;46(1):361-5.
311. Zuberbuhler B, Abedin A, Roudsari A, et al. A novel case of chronic conjunctivitis in a 58-year-old woman caused by *Raoultella* infection. *Infection* 2014;42(5):927-9.

COMMENSAL AND PATHOGENIC ORGANISMS FOR SPECIFIC BODY SITES

1. Isenberg HD, D'Amato RF. Indigenous and pathogenic microorganisms of humans. In: Murray PR, Baron EJ, Pfaller MA, et al, eds. *Manual of clinical microbiology*. 6th ed. American Society of Microbiology 1995:5-18.
2. Koneman EW, Allen SD, Janda WM, et al. *Color atlas and textbook of diagnostic microbiology*. 5th ed. Philadelphia: J.B. Lippincott Company 1997.